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The monoamine hypothesis of depression was born in the 1950s with the 
accidental discovery of the antidepressant effects of compounds initially used to 
treat other disease states. Both iproniazid, a monoamine oxidase inhibitor 
prescribed for the treatment of tuberculosis, and imipramine, a tricyclic 
compound initially used as antipsychotic, appeared to effectively relieve 
depressive symptoms by boosting the levels of the neurotransmitters serotonin 
(5-hydroxytryptamine; 5-HT), noradrenaline (NE) and to a lesser extent 
dopamine (DA; Crane, 1957; Kuhn, 1958). Moreover, the antihypertensive 
reserpine was shown to considerably deplete monoamine stores which was 
thought to be responsible for its apparent depressive-like effects (Pletscher et 
al., 1955; Shore et al., 1955). Based on these early pharmacological observations 
of chemical imbalances, depressive illness was thought to be caused by a 
deficiency in these monoamine levels (France et al., 2007; Schatzberg et al., 
2002). Consequently, experimental monoamine depletion methods have been 
extensively applied for a better understanding of the implication of these 
neurotransmitter systems in the aetiology and treatment of mood disorders.  
 Acute tryptophan depletion (ATD) currently represents the most 
established human challenge test to investigate the involvement of the 5-HT 
system in the pathogenesis and pathophysiology of depression. Since the 
method does not imply the use of neurotoxins it can be used to repeatedly 
manipulate the central 5-HT system in vivo and assess the behavioural effects 
of reduced 5-HT metabolism in the brain. However, the exact mechanism by 
which ATD exerts its neurophysiological effects and to what extent changes in 
5-HT neuronal activity contribute to ATD-induced neurochemical and 
behavioural alterations is not clear. This impedes an adequate interpretation of 
the results arising from application of the method in both clinical and 
preclinical studies. Yet, manipulation of tryptophan (TRP) concentrations in the 
diet is not only a straightforward tool for effectively decreasing brain TRP 
content, it also provides a clue to understanding the mechanism behind the 
regulation of the 5-HT system in general.  
Tryptophan, Serotonin and Depression 
From essential amino acid to modulatory neurotransmitter 
Amino acids are molecules that play a central role in biochemistry as they form 
the basic structural building units of proteins and serve as precursors for 
biosynthesis of other molecules. Due to their pivotal role in metabolism they 
are critical to life and, thus, highly important in nutrition. Of the 20 standard 
amino acids that are used for protein synthesis (Table 1), 12 non-essential 
amino acids can be produced by adults in sufficient quantities out of other 
chemicals (Young, 1994). Tryptophan (TRP), together with phenylalanine 
(PHE), valine (VAL), threonine, (THR) isoleucine (ILE), methionine (MET), 
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leucine (LEU) and lysine (LYS) cannot be synthesized de novo by the body 
itself. Therefore, in order to obtain TRP, its inclusion in the diet is essential 
(Rose et al., 1954) and this is why it is referred to as an essential amino acid. 
This implies that the amount of “dietary 5-HT precursor” eventually available 
to the organism can easily be manipulated, a major point on which the method 
of ATD is based.  
Table 1 Amino acids necessary for protein synthesis, classified into essential and non-essential 
according to the ability of de novo biosynthesis by the adult body. (*) large neutral amino acids 
competing at the blood-brain barrier for transport into the brain 
Essential Non-essential 
Isoleucine* Alanine 
Leucine* Arginine 
Lysine Asparagine 
Methionine Aspartic Acid 
Phenylalanine* Citrulline 
Threonine Cysteine 
Tryptophan* Glutamic Acid 
Valine* Glycine 
 Histidine 
 Proline 
 Serine 
 Tyrosine* 
 
 
By decreasing the availability of TRP in plasma, ATD ultimately aims to 
diminish the amount of 5-HT neurotransmitter in the brain. Yet, the underlying 
assumptions for applying the method as a serotonergic challenge tool eventually 
arise from the specific characteristics of the biosynthesis from TRP to 5-HT. 
Not only is the rate of 5-HT synthesis controlled by the amount of TRP 
available in 5-HT producing neurons, TRP initially needs to compete with other 
amino acids for transport across the blood-brain barrier and is the only amino 
acid that binds to blood albumin in the periphery.  
From tryptophan to serotonin 
TRP taken up into 5-HT producing neurons is synthesized into 5-HT by a two 
step reaction (Figure 1) involving the hydroxylation of TRP into the naturally 
occurring amino acid 5-hydroxytryptophan (5-HTP) followed by the 
decarboxylation of 5-HTP into 5-HT (Boadle-Biber, 1993). The hydroxylation 
of TRP into 5-HTP is catalyzed by the enzyme tryptophan hydroxylase (TPH), 
however, the Michaelis constant (Km) of TPH for TRP is much higher than the 
amount of TRP normally present in the brain. This implies that, under normal 
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physiological conditions (in vivo), the enzyme is not fully saturated and the 
activity of TPH is so-called substrate-driven. In other words, the rate at which 
TRP is hydroxylated by TPH into 5-HTP is limited by substrate concentration 
and therefore considered as the rate-limiting step within the 5-HT biosynthetic 
pathway.  
 After hydroxylation into 5-HTP, decarboxylation by the enzyme aromatic 
L-amino acid decarboxylase (AAAD) finalizes the synthesis of 5-HTP into 
5-HT. The principal metabolite of 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), 
is inactive and formed by oxidative deamination of 5-HT to an aldehyde 
intermediate catalyzed by monoamine oxidase (MAO) with subsequent 
oxidation by aldehyde dehydrogenase (ADH) into 5-HIAA (Boadle-Biber, 
1993). Thus, a decrease in brain TRP levels affects the degree of TPH 
saturation and thereby the amount of TRP converted into 5-HTP and 
subsequent 5-HT formation. This assumption has initially served for using 
ATD as a method to systematically decrease 5-HT synthesis, which is likely to 
result in decreased levels of the inactive metabolite 5-HIAA. However, the 
amount of TRP inside 5-HT producing neurons initially depends upon the 
degree of TRP in plasma that gets into the brain (Fernstrom and Wurtman, 
1971; Fernstrom, 1983). Therefore, 5-HT synthesis is eventually controlled by 
the amount of its dietary precursor TRP available for transport through the 
blood-brain barrier (BBB). Consequently, dietary manipulation of the essential 
amino acid TRP by the method of ATD can interfere with normal brain 5-HT 
synthesis and metabolism. 
 
TPH AAAD
ADH
MAO
Tryptophan 5-Hydroxytryptophan 5-Hydroxytryptamine 5-Hydroxyindoleacetic Acid  
Figure 1 Central serotonin synthesis and metabolism 
In the brain, tryptophan (TRP) is first hydroxylated into 5-hydroxytryptophan (5-HTP) by the 
enzyme tryptophan hydroxylase (TPH). Aromatic L-amino acid decarboxylase (AAAD) 
subsequently catalyzes the decarboxylation of 5-HTP into 5-hydroxytryptamine (5-HT). The 
enzymes monoamine oxidase (MAO) and aldehyde dehydrogenase (ADH) eventually break 
serotonin (5-hydroxytryptamine, 5-HT) down into the inactive metabolite 5-hydroxyindoleacetic 
acid (5-HIAA).  
 
From plasma to brain tryptophan 
The only way amino acids can be transported from the blood through the 
capillary endothelial cells of the BBB into the brain is by carrier-mediated 
transporter systems in the capillary cell plasma membranes (Oldendorf, 1971). 
Given that the surface area of the BBB is much smaller compared to the 
surface area of brain cell membranes, it is this initial transport through the BBB 
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that limits the uptake of plasma TRP into the brain (Pardridge, 1998). The 
brand-chain amino acids (BCAAs; LEU, ILE, VAL) together with the aromatic 
amino acids PHE, tyrosine (TYR) and TRP, are sub-classified as large neutral 
amino acids (LNAAs) according to the specificity of their “large, neutral” side 
chains and subsequent physiological function. Of the nine different amino acid 
transport systems identified at the BBB, the so-called Transport System L is 
only half saturated under normal physiological conditions and mediates high 
affinity, sodium-independent uptake of all LNAAs (Pardridge, 1998; Smith, 
2000). Consequently, for binding to the L-amino acid transport carrier and 
subsequent transport into the brain, TRP has to compete heavily with the other 
LNAAs (Fernstrom and Wurtman, 1971, 1972b; Gessa et al., 1974). This 
implies that the amount of TRP available to 5-HT producing neurons 
additionally depends upon the amount of other LNAAs in plasma. The 
availability of TRP in the brain thus depends upon the ratio of TRP to the sum 
of the other LNAAs (TRP/ΣLNAA) and a decrease in this ratio in plasma is 
normally used as the best predictor of reduced availability of TRP in the brain 
and subsequent synthesis into 5-HT (Fernstrom, 1979b, 1983). 
From bound to free plasma tryptophan; the brain influx parameter 
About 90% of all TRP molecules circulating in blood are bound to serum 
albumin. However, both endogenous ligands, such as non-esterified fatty acids 
(NEFAs; Curzon et al., 1973; Curzon and Knott, 1973), and exogenous ligands, 
such as acetylsalicylic acid (Smith and Lakatos, 1971), can displace TRP from its 
protein binding. Although positive correlations between serum free-TRP and 
whole brain TRP levels have been reported in rats (Biggio et al., 1974; 
Oldendorf and Szabo, 1976), dissociation of TRP from albumin by endogenous 
and exogenous ligands has been shown to increase the entry of TRP into the 
brain, thereby enhancing central 5-HT synthesis (Gessa and Tagliamonte, 1974; 
Tagliamonte et al., 1973). The ratio between TRP-free and TRP-bound levels 
can therefore vary depending on the presence of other circulating substances 
that displace TRP from albumin. This observation, together with the fact that 
TRP is the only amino acid that is bound to serum proteins suggests that only 
free TRP is available for transport into the brain (Biggio et al., 1974). Moreover, 
the changes in TRP-free levels can take place independently of changes in total 
TRP levels (Bender, 1983), which would make a distinction between free and 
bound TRP necessary for estimating its availability in the brain.  
 The free TRP fraction appears to be a very sensitive parameter, not only 
easily influenced by pharmacological modulation, but also by physiological  
aspects such as food intake or deprivation, hormones, exercise and mild 
stressors (Badawy, 2009). Moreover, methodological differences in separating 
and determining free and albumin-bound TRP fractions in blood samples 
interferes considerably with proper interpretation of behavioural and 
biochemical results (Fernstrom, 1979a). Although the fraction of free TRP 
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seems a valuable tool to estimate the amount of TRP in the circulation available 
for uptake into various tissues and organs (Badawy, 2009), accumulating 
evidence supports the fact that total peripheral TRP concentrations (free plus 
bound) better reflect the rate of influx of TRP into the brain. It has been 
shown that TRP is only loosely bound to albumin and although albumin itself 
cannot cross the BBB, it appears to be a highly flexible protein undergoing 
reversible conformational changes (Reed and Burrington, 1989). These 
conformational changes, which occur during transport of TRP from the 
circulating albumin-bound pool, enhance the dissociation of TRP from the 
albumin binding sites within the cerebral microvasculature and appear to be 
highly dependent upon cerebral haemodynamics (Pardridge and Fierer, 1990). 
Low cerebral blood flow is likely to increase the interaction between the 
albumin-bound TRP complex and the glycocalyx of the BBB, thereby causing 
more TRP to dissociate from albumin (Pardridge and Fierer, 1990; Smith et al., 
1987). This implies that temporally dynamic or spatial differences in local 
cerebral blood flow may influence the rate of central TRP uptake in general and 
even within specific brain areas only (Ruddick et al., 2006). Thus, although only 
free TRP can eventually cross the BBB, the amount of albumin-bound TRP in 
plasma must also be taken into account to calculate the availability of TRP in 
the brain, as TRP can easily dissociate from albumin near the BBB thereby 
increasing the TRP-free pool and subsequent uptake into the brain (see also 
Figure 2).  
From tryptophan to kynurenine 
Under normal physiological conditions, only 1-2% of the amount of ingested 
TRP is used by the body for the synthesis of 5-HT (Twarog and Page, 1953). 
The majority of total ingested TRP is catabolyzed into kynurenine (KYN) by 
induction of tryptophan pyrrolase in the liver (Stone and Darlington, 2002). 
Tryptophan pyrrolase is the first rate-limiting enzyme of the kynurenine 
pathway and KYN is the major degradation product of TRP (Moroni, 1999). 
 Induction of pyrrolase by the enzymes indolamine 2,3-dioxygenase (IDO) 
and tryptophan 2,3-dioxygenase (TDO) in the liver reduces TRP availability 
(Botting, 1995) and therefore 5-HT synthesis is also influenced by IDO and 
TDO activity (Moroni, 1999; Smith and Pogson, 1980). Stimulation of these 
enzymes by proinflammatory cytokines, in particular interferon-γ (Hu et al., 
1995), enhances the catabolism of TRP (Botting, 1995), thereby decreasing the 
amount of TRP eventually available for 5-HT synthesis. Moreover, TDO 
activity can also be induced by corticoids (Turner et al., 2006). 
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Figure 2 Overview of tryptophan metabolism from food intake to brain uptake 
In order to obtain the amino acid tryptophan (TRP) its inclusion in the diet is essential. The 
majority of TRP is bound to plasma albumin and only free TRP will eventually cross the blood-
brain barrier (BBB). Albumin-bound TRP easily dissociates from albumin near the 
cerebrovasculature under the influence of haemodynamic changes, thereby increasing the TRP-
free fraction available for uptake into the brain. The amount of TRP in plasma eventually 
crossing the BBB also depends upon the presence of other large neutral amino acids (LNAAs) 
that all compete for the same amino acid transport system L at the BBB. Due to this competition 
of TRP with leucine (LEU), isoleucine (ILE), valine (VAL), phenylalaline (PHE) and tyrosine 
(TYR), the ratio of TRP to the sum of these LNAAs (TRP/ΣLNAA) in plasma better reflects the 
amount of central TRP available for synthesis into 5-HT.  
The modulatory serotonin neurotransmitter 
Although “enteramine” was first discovered by Erspamer in the early 1930s as a 
substance with smooth muscle contracting properties in the enterochromaffin 
cells of the gut (Erspamer and Vialli, 1937; Whitaker-Azmitia, 1999), it was not 
until 1948 that Rapport et al. (1948a) first isolated a factor with “tonic” or 
vasocontrictive actions in serum released from platelets following blood 
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clotting. They first referred to their “serum tonic factor” as serotonin (Page et 
al., 1948; Rapport et al., 1948b) and subsequently identified it as 
5-hydroxytryptamine  (Page, 1954) which later appeared to be the same 
substance as Erspamer’s “enteramine”. In 1953, the same group first detected 
“serotonin” in brain tissue (Page, 1976) which, together with the gut and blood 
serum, completed the key localisations of what later appeared to be a 
multifunctional neurotransmitter (see also: Sjoerdsma and Palfreyman, 1990).  
 Although 90% of all 5-HT is localized in the gastrointestinal tract and the 
amount of 5-HT neurons in the brain is relatively small compared to the total 
numbers of neurons, many neurophysiological processes are known to be 
regulated by the 5-HT system, including mood and cognition, which are most 
prominently impaired in clinical depression (Leonard, 1997; Maes and Meltzer, 
1995; Meltzer, 1990). By means of immunohistochemical methods with a highly 
specific polyclonal antiserum directed against 5-HT  it has been possible to 
precisely map the 5-HT system in detail (Steinbusch et al., 1978; Steinbusch, 
1981). 5-HT cell bodies are clustered in the brainstem raphe nuclei sending out 
projections throughout the entire central nervous system with ascending 
pathways innervating anatomically and functionally diverse regions of the 
cerebral cortex, including the limbic system, the basal ganglia and structures 
within the diencephalon (Steinbusch, 1981). Due to this anatomy, the 
neurotransmitter influences all regions of the neuraxis, thereby modulating an 
extensive range of physiological and behavioural functions. Besides mood and 
cognition, appetite, emesis, endocrine function, gastrointestinal function, motor 
function, neurotrophism, perception, sensory function, pain sensitivity, sex, 
sleep and even vascular function are all under the control of the 5-HT system. 
Consequently, disrupted 5-HT synthesis and subsequent abnormal 5-HT 
function can lead to a diverse range of behavioural disturbances implicated in 
clinical depression (Table 2). 
Table 2 Clinically relevant behaviours modulated by 5-HT and implicated in major depressive 
disorder when disturbed. 
Mood regulation Sexual function 
Fear and anxiety Motivation an reward 
Learning and memory Neuroendocrine regulation 
Cognitive control Circadian rhythm regulation 
Appetite and eating regulation Stress response 
Sleep Impulse control 
5-HT and depression 
Clinical depression is the most prevalent mental illness, symptom clustered 
under mood disorders and specifically classified as major depressive disorder 
(MDD) in the Diagnostic and Statistical Manual of Mental Disorders Text 
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Revision (DSM-IV-TR, 2000) of the American Psychiatric Association. It is 
generally characterized by sadness, loss of interest or pleasure, feelings of guilt 
or low self-esteem, disturbed sleep or appetite, low energy and poor 
concentration. Sustained sadness along with psychological, behavioural and 
physical symptoms can become chronic or recurrent, eventually impairing the 
ability to cope with daily life. Worldwide, depression is one of the leading 
causes of illness-induced disability and at its most severe can lead to suicide, 
which is among the three leading causes of death among those aged 15-44 years 
(Murray and Lopez, 1997). Yet, the underlying genetic and neurobiological 
mechanisms of depressive illness and the controversial responses to different 
treatments are still not fully understood (Nestler et al., 2002).  
 Major depression is a heterogeneous disorder displaying a high prevalence 
of co-morbidity with other neuropathological syndromes such as generalized 
anxiety. Nowadays, besides dysfunctional monoamine systems, disturbances in 
endocrine and immune function and adaptive changes in pre- and postsynaptic 
receptors have taken a prominent position in theories concerning the aetiology 
and pathogenesis of depressive symptoms (Hindmarch, 2002; Leonard, 2007). 
Nevertheless, the pathophysiology of most types of depression, as well as 
genetic vulnerability factors that increase the risk for suffering depressive 
episodes, involve abnormal functioning of the 5-HT system (Meltzer, 1990). 
Therefore, 5-HT dysfunction is widely accepted as one of the main causes 
underlying the development of depressive symptomatology (Asberg et al., 
1976a; Maes and Meltzer, 1995; Meltzer, 1990). Direct evidence supporting the 
central role of 5-HT in depression comes from human studies correlating 
depressive symptoms to decreased physiological parameters, indicative of 
alterations in the 5-HT system (Risch and Nemeroff, 1992). Consistent findings 
specifically include decreased peripheral TRP levels (Cowen et al., 1989) and 
lower levels of the inactive 5-HT metabolite 5-HIAA in cerebral spinal fluid 
(CSF), which all reflect diminished 5-HT metabolism (Asberg et al., 1976b; van 
Praag and de Haan, 1979). The effectiveness of serotonergic drugs used in the 
treatment of depression also confirms the important role of disrupted function 
of specific pre- and postsynaptic receptors underlying impaired 5-HT 
neurotransmission and linked to specific depressive symptoms (Cryan and 
Leonard, 2000; Naughton et al., 2000).  
Acute tryptophan depletion and depression research 
The method of acute tryptophan depletion 
Whereas ATD is based upon decreasing 5-HT synthesis by lowering the 
metabolism of its precursor, other interventions can be used to more directly 
interrupt central 5-HT systems. However, animal studies showed that direct 
manipulations by means of central injections with 5,7-dihydroxytryptamine 
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(5,7-DHT) or peripheral application of TPH inhibitors (parachlorophenyl-
alanine: PCPA; p-ethynylphenylalanine: p-EDH), but also acute and repeated 
treatment with amphetamine derivates such as 3,4-methylenedioxy-
methamphetamine (MDMA; ‘ecstasy’) or 5-HT receptor ligands, cause serious 
side-effects and tend to be neurotoxic, thereby causing irreversible damage with 
long-term behavioural consequences. Moreover, these lesions and 
pharmacological manipulations are not highly specific and normally induce 
almost complete depletion of central 5-HT. This, together with the induced 
neurotoxicity, seems less appropriate for studying behavioural changes linked to 
a dysfunctional 5-HT system, which is characterized by reduced, i.e. not 
completely absent, 5-HT synthesis (Reilly et al., 1997). ATD, on the other hand, 
is non-toxic and nonintrusive, thereby providing the option to repeatedly 
manipulate the central 5-HT system in vivo and assess the behavioural effects 
of reduced 5-HT metabolism in the brain (Fadda et al., 2000). The reduction of 
brain 5-HT in a reversible manner reflects the main methodological advantage 
of the tool, permitting application of the same basic method in both human 
subjects and rodents. This is considered valuable for comparing 
neurophysiological changes linked to behavioural effects across species 
(Blokland et al., 2004).  
 A rather slow reduction in peripheral and central TRP levels and a 
concomitant decrease of brain 5-HT concentrations was observed after long-
term administration of diets low in TRP or completely lacking the essential 
amino acid. However, severe malnutrition, especially in the latter case, 
interferes with appropriate interpretation of the specific behavioural and 
neurological alterations associated with interruption of the 5-HT system after 
chronic depletion of dietary TRP. Therefore, Biggio et al. (1974) provided male 
Wistar rats with a diet devoid of TRP which resulted in a significant decrease of 
total and free TRP levels in serum 2 h after presentation of the diet. While total 
serum TRP levels decreased by 75% compared to baseline levels, free TRP in 
serum decreased by about 90% and additionally correlated highly with the 85% 
decrease of TRP levels in the brain. Highly significant reductions were also 
found in 5-HT (-58%) and 5-HIAA (-76%) concentrations. The same group 
(Gessa et al., 1974) was also the first to demonstrate that peripheral TRP and 
brain TRP, 5-HT and 5-HIAA concentrations were significantly lower in rats 
orally administered (by gavage) a mixture of essential amino acids lacking TRP, 
compared to control rats that were administered an equivalent amount of 
distilled water. Training the rats to eat the same amount of food at a specific 
time point and within a limited time-frame (Biggio et al., 1974) could therefore 
be omitted and the straightforward method of acute tryptophan depletion as a 
serotonergic challenge tool was born. Not long thereafter, changes in the 
mental status of human subjects after the ingestion of an amino acid mixture 
devoid of TRP were evaluated for the first time. 
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Acute tryptophan depletion in humans 
The methodology of ATD as a serotonergic challenge tool, including theories 
regarding its underlying mechanism and its implication for psychiatry in general, 
have been widely explored and extensively reviewed over the past 20 years (Bell 
et al., 2005; Hood et al., 2005; Neumeister, 2003; Reilly et al., 1997; Young, 
1993). Most researchers specifically address its potential as a tool to reveal 
depressive vulnerability and thus to predict the probability of a depressive 
episode (Booij et al., 2002; Booij et al., 2003; Booij et al., 2005b; Moreno et al., 
1999; Moreno et al., 2000a; Neumeister et al., 1999) or a successful treatment 
response (Delgado et al., 1990; Delgado et al., 1991; Delgado et al., 1999). On 
the contrary, others question its validity and criticize its robustness as a tool to 
investigate the pathogenesis of depression (Norra, 2007; Ruhe et al., 2007).  
Acute tryptophan depletion; revealing vulnerability to depression 
Human subjects with genetic pre-existing 5-HT dysfunction may lack 
endogenous compensatory capacity to deal with an acute decrease in 5-HT 
metabolism, thereby exhibiting higher behavioural sensitivity to ATD (Jans et 
al., 2007b; Van der Does, 2001). This implies that a predisposition of so-called 
serotonergic vulnerability only results in direct overt psychiatric symptoms 
when these are triggered, as with ATD, by challenging the already vulnerable 
5-HT system (Jans et al., 2007b) up to a certain threshold (Van der Does, 2001). 
In line with this hypothesis, ATD-induced transient mild mood-lowering 
effects, as reflected by lower mood ratings, have been reported in carriers of the 
“short” allelic polymorphism in the promoter of the 5-HT transporter gene 
5-HTTLPR (SERT; Neumeister et al., 2002; Neumeister et al., 2006) and in 
healthy subjects with a family history of depression (Klaassen et al., 1999b). 
Likewise, a higher behavioural response to ATD has been observed in women 
(Ellenbogen et al., 1996; Smith et al., 1997), who are presumably predisposed to 
a lower 5-HT synthesis rate compared to men (Nishizawa et al., 1997). 
Moreover, ATD provokes a relapse of depressive symptoms in healthy subjects 
with a history of depression (Moreno et al., 1999; Neumeister et al., 2004). 
However, this effect is only in those previously treated successfully with 
selective serotonin re-uptake inhibitors (SSRIs) or MAO inhibiters (MAO-Is). 
Remitted, medication-free depressed patients with a positive treatment 
response history to antidepressants that primarily interact with systems other 
then 5-HT (e.g. tricyclic antidepressants or selective norepinephrine reuptake 
inhibitors) appear not to be affected by ATD (Delgado et al., 1990; Delgado et 
al., 1991; Delgado et al., 1999). The fact that ATD reverses the antidepressant 
response depending upon the specificity of the antidepressant treatment adds 
value to the challenge tool as a predictor of successful drug treatment response 
once serotonergic vulnerability has been revealed.  
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Acute tryptophan depletion in healthy subjects; inducing cognitive deficits 
It is generally believed and accepted that ATD does not induce considerable 
mood-lowering effects in healthy human subjects (Delgado et al., 1989; Moreno 
et al., 1999; Young et al., 1985). Nevertheless, acute decreased peripheral TRP 
levels and diminished 5-HIAA concentrations in CSF are consistently reported 
after ATD and appear to be similar in all subpopulations, i.e. in both healthy 
and so-called serotonergic vulnerable subjects (Carpenter et al., 1998; Evers et 
al., 2006; Klaassen et al., 1999b; Moore et al., 2000; Moreno et al., 2000b; 
Williams et al., 1999). This seems to be in line with the notion that both healthy 
and vulnerable subjects display cognitive dysfunctional behaviour after ATD as 
reported consistently between studies (Booij et al., 2005a; Evers et al., 2005; 
Klaassen et al., 1999a; Mendelsohn et al., 2009; Riedel et al., 1999; Riedel, 2004; 
Sambeth et al., 2007; Sambeth et al., 2009). It might therefore be suggested that 
an acute decrease in peripheral TRP levels directly interferes with mechanisms 
implicated in cognitive processing that depend less upon 5-HT functioning.  
 Altered cognitive processing has been reported with impairments in long 
term memory formation, decision making, reversal-learning and working 
memory. It is possible that an interruption in memory consolidation could 
underlie ATD-induced cognitive dysfunctions, as ATD has been shown to 
selectively impair memory consolidation in human subjects (Riedel et al., 1999). 
Memory consolidation is known to require brain-derived neurotrophic factor 
(BDNF; Lee et al., 2004), which is closely linked to the 5-HT system 
(Mamounas et al., 2000) and is most abundant in the hippocampus (Ernfors et 
al., 1990). Consequently, it has been suggested that ATD-induced impairment 
in memory consolidation is due to decreased 5-HT levels in hippocampal areas 
and linked to alterations in BDNF levels (see Riedel, 2004). Yet, such 
suggestions are likely to remain speculative as it is impossible to directly 
investigate the relationship between cognitive dysfunctional behaviour and 
acute neurochemical changes in the human brain in vivo.   
Acute tryptophan depletion in rats 
Animal models enable direct investigation of the relationships between brain 
and behaviour with the aim of gaining insight into human behaviour and its 
underlying neuronal and neuroendocrinological processes (van der Staay, 2006). 
Therefore, the direct consequences of ATD upon brain parameters like TRP 
and 5-HT in the rat can be used for appropriate interpretation of the alterations 
in behavioural output in accordance with the underlying neurochemical 
mechanism of the method. A large body of preclinical literature provides 
evidence that ATD in rats significantly depletes the levels of TRP in plasma, 
thereby reducing 5-HT metabolism, as is suggested by the lower TRP and 5-HT 
levels in rat brain tissue (Blokland et al., 2002; Cahir et al., 2007; Jans et al., 
2007a; Lieben et al., 2004a; Olivier et al., 2008). ATD in rats consistently 
induces impairment in object memory performance (Jans et al., 2008a; Jans et 
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al., 2007a; Jans and Blokland, 2008; Lieben et al., 2004b; Rutten et al., 2007; van 
Donkelaar et al., 2008) which, in contrast to human subjects, seems even more 
pronounced in rats with pre-existing abnormal 5-HT function (Olivier et al., 
2008). Yet, in line with the ATD effects in healthy human subjects, ATD-
induced alterations in affective behavioural parameters in the rat appear 
inconsistent (Blokland et al., 2002; Brown et al., 1998; Lieben et al., 2004b). 
Table 3 provides an overview of peripheral and central neurochemical effects, 
as well as cognitive and other behavioural alterations after ATD is induced in 
rats through administration of nutritional mixtures completely devoid of TRP.   
Solugel 
Reducing central 5-HT concentrations by lowering the levels of its dietary 
precursor TRP in plasma can be achieved by administration of specific TRP-
free nutritional mixtures. Besides the TRP-free or TRP-low balanced diets and 
pure amino acid mixtures without TRP, a more advanced technique nowadays 
is the oral administration of a gelatin-based protein-carbohydrate mixture 
(Blokland et al., 2004). By adding a specific amount of TRP to the control 
mixture, effects of peripheral TRP suppletion, as often observed with 
traditional AA mixtures in humans (Fusar-Poli et al., 2006; Van der Does, 2001) 
are avoided and thus do not cause misinterpretation of the ATD effects 
(Blokland et al., 2004; Evers et al., 2005; Sambeth et al., 2009). Gelatin is 
derived from the selective hydrolysis of collagen protein, which is easily 
digestible and naturally lacks the essential amino acid TRP (Djagny et al., 2001). 
The gelatin hydrolysate used for the nutritional mixture is gelatin in an 
enzymatic hydrolyzed form, commercially available as Solugel® (PB Gelatins, 
Tessenderlo, Belgium). Solugel no longer consists of a combination of a few 
selective amino acids, but comprises a broad range of amino acids in the form 
of peptides, which makes it comparable to standard diets. Moreover, it is water-
dispensable and unique for its gel-forming ability (Lieben et al., 2004a). In 
addition, a specific amount of carbohydrates are mixed with the Solugel, which 
adds an essential caloric value, thereby making the nutritional mixture even 
more similar to regular food intake. Moreover, mixing proteins with 
carbohydrates avoids any unwanted effects upon amino acid availability in the 
blood (see below and Figure 3) as is normally found with unbalanced diets 
containing high amounts of carbohydrates or proteins only (Benton, 2002; 
Markus et al., 1998; Markus, 2007).  
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Carbohydrates and dietary protein 
Carbohydrates raise blood glucose levels, thereby stimulating the pancreas to 
release insulin, an anabolic hormone. The secretion of insulin stimulates 
glucose to be taken up by the cells for subsequent normalization of glucose 
levels in the blood. Concomitantly with the insulin-induced drop in blood 
glucose levels, plasma TRP levels increase while the concentration of most 
other amino acids in plasma decreases (Fernstrom and Wurtman, 1972a). When 
a carbohydrate-rich meal contains no additional protein, activation of the 
insulin response increases protein synthesis, thereby stimulating the uptake of 
almost all amino acids (mainly the BCAAs) into muscle tissue. Most of the TRP 
in plasma is bound to serum albumin and thus not available for uptake into 
peripheral tissues, hence the effect of insulin upon TRP is much less compared 
to the other LNAAs. Moreover, insulin increases the affinity of serum albumin 
for TRP, thereby decreasing free circulating TRP and thus further increasing 
the ratio of bound to free plasma TRP. The increase in albumin affinity for 
TRP is a result of the rise in insulin which causes more unbound albumin to 
become available due to the stimulation of the uptake by fat cells of free fatty 
acids (NEFAs), which are normally bound to albumin. As TRP is the only 
amino acid bound to albumin, it is the only one highly prevented from being 
taken out of the bloodstream and up into peripheral tissue, specifically when 
the binding to albumin increases due to insulin secretion. Taken together, after 
the ingestion of carbohydrates the plasma ratio of LNAAs changes in favour of 
total TRP, which eventually leads to an increased availability of TRP in the 
brain to be synthesized into 5-HT (Fernstrom and Wurtman, 1972a; Fernstrom 
et al., 1987). Yet, as little as 2.5% of additional protein (by weight) is enough for 
the substantial increase of plasma LNAAs to counteract the effect of 
carbohydrates and the subsequent insulin-induced fall in LNAAs (Benton, 
2002; Teff et al., 1989), as is the case with the TRP-free protein-carbohydrate 
nutritional mixture (see also Figure 3). 
Protein synthesis 
The administration of a TRP-free diet depletes plasma TRP acutely by inducing 
hepatic protein synthesis (Harper et al., 1970). In general, administration of a 
mixture lacking one essential amino acid results in the fall of the plasma level of 
that amino acid, which is rapidly removed from circulation by tissues to allow 
protein synthesis to proceed. Hence, a TRP-free diet induces a decrease of TRP 
levels in plasma due to a rapid removal of extracellular endogenous TRP from 
the circulation. 
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 Figure 3 Differential effects of carbohydrates and protein upon the availability of TRP in plasma 
for uptake into the brain 
Dietary carbohydrates increase the uptake of the large neutral amino acids (LNAAs; tyrosine 
[TYR], leucine [LEU], isoleucine [ILE], valine [VAL], phenylalaline [PHE]) into peripheral tissue, 
thereby decreasing their concentration in plasma. Together with an increase in total tryptophan 
(TRP) levels the ratio TRP to the sum of the LNAAs (TRP/ΣLNAA) changes in favour of TRP 
and increases its availability for transport across the blood-brain barrier (BBB). As little as 2.5% 
of additional proteins counteracts the effects of carbohydrates, as the protein ingestion-induced 
increase in the levels of all amino acids is much higher that the decrease by carbohydrates. When 
a TRP-free diet is administrated (acute tryptophan depletion), all amino acids are elevated except 
for TRP, thereby decreasing the ratio TRP/ΣLNAA and thus TRP uptake into the brain. 
 
 
This extracellular TRP removal is due to an increased incorporation of TRP 
into proteins in liver and other tissue (Biggio et al., 1974; Gessa et al., 1974). 
The ATD-induced depletion of plasma TRP can be dose-dependently blocked 
by administration of the protein synthesis inhibitor cycloheximide together with 
a TRP-free diet (Gessa et al., 1975; Moja et al., 1991). Thus, protein synthesis, 
and not the inhibition of TRP transportation into the brain, seems to be the 
important initial mechanism underlying ATD-induced decreased 5-HT in the 
brain.  
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Challenging the serotonin system 
Since intact 5-HT neurotransmission is necessary for a wide range of 
physiological and functional processes, a disruption in this system can easily 
provoke diverse pathophysiological abnormalities, most of which are reflected 
in dysfunctional behavioural output. As ATD reduces 5-HT synthesis, ATD-
induced behavioural changes in human subjects and laboratory animals are 
normally attributed to decreased 5-HT release, reflecting altered neuronal 
activity. For this reason, ATD has gained its popularity as non-toxic challenge 
to assess the implication of the 5-HT system in the pathogenesis and 
pathophysiology of psychiatric disorders. However, the exact mechanism by 
which ATD exerts its neurophysiological effects, and to what extent changes in 
5-HT neuronal activity contribute to the ATD-induced neurophysiological and 
behavioural alterations, is not fully understood.  
 As previously outlined, brain concentrations of TRP are rate-limiting for 
5-HT synthesis due to the fact that TPH is not saturated by the normal 
intracellular concentrations of TRP. Evidence of enhanced 5-HT synthesis after 
synthetic increases in brain TRP availability corroborate this notion (Fernstrom 
and Wurtman, 1971). Likewise, a variety of antidepressant drugs are thought to 
exert their therapeutic effect by increasing the levels of 5-HT concentration in 
the somatodendritic area, thereby increasing 5-HT neuronal release, i.e. activity. 
The increased 5-HT release promotes interaction with post-synaptic receptors, 
ultimately influencing behaviour. Along similar lines, it is generally believed that 
the mood-lowering and cognitive dysfunctional effects of ATD are mediated by 
decreases in 5-HT neuronal activity since a decrease in brain TRP availability 
reduces 5-HT synthesis.  
The ratio TRP/ΣLNAA in plasma and 5-HIAA levels in cerebrospinal fluid 
Effects of ATD treatment upon 5-HT levels in the brain cannot be directly 
investigated in humans. The ratio TRP/ΣLNAA in plasma indicates the 
amount of peripheral TRP potentially available for crossing the BBB, with a 
decrease in the ratio suggesting that less TRP will be available to the brain for 
synthesis into 5-HT. This has been confirmed by the ATD-induced decrease in 
the uptake of central alpha-methyl-L-tryptophan (α-M-TRP) as measured by 
positron emission tomography (Nishizawa et al., 1997). Although this finding 
supports the concept that ATD exerts central effects, α-MTrp uptake does not 
reveal anything specific about 5-HT release (Moore et al., 2000; Neumeister, 
2003), despite the fact that it is considered a reliable indicator of 5-HT 
synthesis. Similarly, a decrease in the concentration of the inactive 5-HT 
metabolite 5-HIAA in CSF of humans subjected to ATD suggests that less 
5-HT has been catabolyzed, which normally takes place after release, i.e. after 
neuronal firing. Therefore, a decrease in the amount of metabolite is thought to 
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reflect decreased 5-HT metabolism, since lower intracellular 5-HT availability is 
presumed to result in less 5-HT release. However, numerous other peripheral 
factors seem to influence both the amount of 5-HIAA produced and its 
transport into and out of the CSF (see Cryan and Leonard, 2000). Despite the 
fact that both the ratio TRP/ΣLNAA and 5-HIAA concentrations are applied 
in human studies as indicators of altered 5-HT synthesis and metabolism, 
respectively, they do not allow any judgement concerning changes in 5-HT 
release or concomitant adaptations in neuronal activity.  
Central 5-HIAA levels and 5-HT turnover 
Animal studies not only provide the possibility to directly measure 5-HIAA 
levels in the specific brain areas, they also allow the calculation of the ratio of 
5-HIAA to 5-HT concentrations. Alterations in the ratio 5-HIAA/5-HT are 
normally used to estimate changes in endogenous 5-HT turnover, which is 
thought to reflect 5-HT neuronal activity (Shannon et al., 1986). Unfortunately, 
ATD-induced changes in the ratio 5-HIAA/5-HT are controversially reported 
between studies (Ardis et al., 2009; Brown et al., 1998; Cahir et al., 2008; Jans et 
al., 2008a) and a decrease in the 5-HIAA/5-HT ratio after ATD is often 
difficult to directly attribute to a reduction in precursor (i.e. TRP) availability. 
An ATD-induced decrease of the ratio would only occur if significantly less 
5-HIAA is produced compared to the already decreased amount of 5-HT 
synthesised. However, even then, a valid speculation upon changes in 5-HT 
turnover after ATD in rodents at one specific time-point is only possible if 
baseline measurements of central 5-HIAA and 5-HT concentrations are taken 
into account. Although both brain 5-HIAA concentrations and the ratio 
5-HIAA/5-HT have been reported as valid indices of reduced 5-HT 
metabolism (Shannon et al., 1986), 5-HT neuronal activity can still only be 
estimated. 
5-HT neuronal release 
Direct evidence for alterations in neuronal activity comes from in vivo 
microdialysis measurements of changes in extracellular 5-HT concentrations, 
indicative of changes in neuronal release. Actual decreases in extracellular 5-HT 
have only been reported after ATD in combination with blockade of 5-HT 
reuptake (Bel and Artigas, 1996; Fadda et al., 2000; Stancampiano et al., 1997). 
A blockade after 5-HT reuptake seems necessary to raise 5-HT to optimal 
levels for detection (see Moore et al., 2000). Yet, without the initial systemic 
increase in 5-HT concentrations, basal 5-HT release in the prefrontal cortex of 
rats appeared not to be affected by ATD (van der Plasse et al., 2007). In 
addition decreased levels in whole brain 5-HT and 5-HIAA levels 2 h after the 
consumption of a TRP-free diet in cats did not parallel changes in the 
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functional activity of 5-HT containing dorsal raphe cells throughout the 4 h 
after ingestion (Trulson, 1985).  
 
Taken together, there is no direct evidence that brain 5-HT release, reflecting 
neuronal activity, is altered after ATD, whereas behavioural alterations can only 
be attributed to physiological changes in plasma TRP levels if the changes in 
brain 5-HT concentration actually reflect alterations in the functional activity of 
5-HT neurons. Nevertheless, ATD consistently induces cognitive impairment 
in both animals and humans and triggers lowering of mood especially in healthy 
subjects predisposed with a vulnerable 5-HT system. ATD does not directly or 
indirectly affect other monoamine systems in rats (Ardis et al., 2009; Brown et 
al., 1998; Jans et al., 2008a; Lieben et al., 2004a) and no behavioural changes 
have been observed after depletion of other plasma amino acids (Klaassen et 
al., 1999a). Moreover, administration of a TRP-free AA mixture in primates 
decreased TRP and 5-HIAA concentrations in CBF without affecting 
catecholamine metabolites, suggesting that the catecholamine system is not 
influenced by ATD (Young et al., 1989). ATD-induced functional changes thus 
seem specific for the peripheral depletion of the essential amino acid TRP, but, 
are more likely 5-HT-mediated than 5-HT induced. In general, the mood-
lowering effects in human subjects with pre-existing abnormal 5-HT 
functioning, together with the controversial and diverse behavioural and 
biochemical preclinical results, suggest that ATD-induced alterations go beyond 
a straightforward dysfunction of the 5-HT system. Moreover, the effects of 
changes in substrate availability upon 5-HT synthesis rate are generally not 
conditioned under normal physiological circumstances, i.e. in the absence of 
any other regulatory changes. Therefore, changes other than substrate 
availability that interfere with normal 5-HT regulation or disruptions in 
substrate availability itself might act as potential confounding factors for the 
ATD-induced neurochemical effects as expected under normal circumstances 
(Lenard and Dunn, 2005). How then should one interpret the behavioural 
changes after ATD and what are the consequences for speculation upon the 
implication of the 5-HT system in depressive disorders? 
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This thesis 
A mechanistic approach to the method of acute tryptophan depletion in 
rodents  
The method of ATD is non-toxic and reversible and can thus be used safely 
and repeatedly in both human subjects and rodents, thereby offering the ability 
to compare between clinical and preclinical experimental designs and outcomes. 
However, the neurophysiological mechanisms underlying behaviour cannot be 
as directly investigated in humans as they can in laboratory animals. Associating 
acute neurophysiological alterations to behavioural output may provide more 
insight into the extent to which ATD-induced behavioural dysfunction can be 
directly attributed to presumed changes in 5-HT neuronal activity. Not only is 
the 5-HT system involved in the modulation of many important behavioural 
and physiological functions, depression is also a heterogeneous disorder with a 
complex and as yet unresolved underlying pathophysiology. In this sense, 
challenging the serotonergic system by means of ATD and linking 
neurophysiological changes to behavioural output in light of clinical depressive 
symptomatology might seem somewhat challenging itself. Yet, a mechanistic 
approach to the method of ATD in rodents through exploration of its 
underlying neurobiochemical mechanisms will not only improve the 
interpretation of clinical ATD-induced symptoms, but will also provide new 
insights into the implication of the 5-HT system in depressive and other 
neurobiological brain disorders. This thesis covers a comprehensive evaluation 
of the diverse and sometimes controversial neurochemical and behavioural 
effects of ATD in rodents and aims to explore potential mechanisms by which 
ATD exerts its neurophysiological and behavioural effects.  
Outline 
Pre-existing dysfunctional 5-HT systems are nowadays widely modeled in mice 
by manipulating genes implicated in the regulation of the 5-HT system. The 
introduction of these new mouse models of depression appear to be extremely 
important to improve our insight in the underlying neurophysiological 
mechanisms of depressive disorders and the development of new 
pharmacological therapies. Consequently, the use of mice instead of rats for 
studying behaviour and the implication of neurotransmitter systems in 
psychiatric disorders in general has significantly increased. It was, therefore, 
initially aimed to establish the ATD method in the mouse in order to be able to 
apply the method in transgenic mouse models that are predisposed to 
serotonergic dysfunction. Chapter 2 provides an overview of the multiple 
studies in which the pharmacokinetic and behavioural effects of different 
dosing regimes of the TRP-free protein-carbohydrate mixture were explored, 
particularly in the C57BL/6 mouse. 
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In rats, ATD has been extensively used and the TRP-free protein-carbohydrate 
mixture has been proved to successfully lower peripheral TRP levels, thereby 
interfering with 5-HT metabolism and presumably 5-HT neuronal activity in 
the rat brain. Under normal physiological conditions, neuronal activity is related 
to the cerebral metabolic rate of glucose (CMRG), which is in turn closely 
coupled to cerebral blood flow (CBF). As the 5-HT neurotransmitter 
additionally possesses important vasoactive properties, an acute decrease in 
central 5-HT concentration could alter CMRG and CBF and the normal 
relationship between them. Such cerebrovascular alterations may contribute to 
the underlying mechanisms of ATD-induced affective behavioural changes and 
cognitive impairments. Chapter 3 describes the effects of ATD upon local CBF 
and CMRG as measured in 43 distinct brain regions of adult male Wistar rats 
by means of [14C]-iodoantipyrine and [14C]-2-deoxyglucose quantitative 
autoradiographic imaging, respectively.   
 An acute decrease in brain 5-HT is likely to result in disturbed affective 
behaviour only if there is pre-existing vulnerability in the 5-HT system. The 
neurotoxicity of MDMA is known to cause significant 5-HT terminal depletion, 
thereby decreasing 5-HT concentrations in the brain. In Chapter 4, adult male 
Wistar rats are repeatedly pretreated with MDMA in order to apply ATD in an 
animal model of acquired 5-HT dysfunction. By using quantitative 
autoradiographic imaging, the effects of repeated MDMA pretreatment upon 
local CBF and CMRG are measured under an ATD challenged condition, 
thereby investigating the relationship between cerebrovascular function and 
5-HT changes in general and MDMA-induced 5-HT dysfunction as a 
vulnerability factor for depression in general, and cognitive dysfunction in 
particular.  
 BDNF is strongly linked to the 5-HT system and, besides being extremely 
stress-responsive, plays an essential role in mood and memory processes. To 
explore the potential role of BDNF in the underlying mechanisms of ATD-
induced behavioural changes, Chapter 5 examines the effects of ATD upon 
BDNF in serum, hippocampus and prefrontal cortex of adult male Wistar rats, 
while controlling for possible confounding stress effects of the specific 
experimental procedures. 
 Whereas affective behavioural changes after ATD remain controversial, 
ATD-induced memory deficits are consistently reported in humans, but also in 
rats as measured by means of the rat object recognition task. Inhibition of 
phosphodiesterase (PDE) enzymes appears to be a reliable method to improve 
memory processes by increasing the levels of the second messenger molecules 
cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate 
(cGMP) or both. Chapter 6 examines the ability of the PDE inhibitors 
vardenafil and BAY 60-7550, that increase cAMP and both cAMP and cGMP, 
respectively, to reverse an ATD-induced impairment in object recognition 
performance of adult male Wistar rats. Exploring the pro-cognitive effects of 
PDE inhibitors might provide more insight into a potential interaction between 
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second messenger molecules and the 5-HT system as an underlying mechanism 
for ATD-induced cognitive dysfunction.  
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Abstract 
Acute tryptophan depletion (ATD) is extensively used to investigate 
the implication of serotonin (5-hydroxytryptamine; 5-HT) in the 
onset of depressive disorders. In rats, it lowers peripheral tryptophan 
(TRP) and decreases central 5-HT concentrations. We aimed to 
establish the rat model of ATD in the mouse for potential 
application as 5-HT challenge tool in genetic mouse models of 
depression. Pharmacokinetic and behavioural effects of a TRP-free 
diet were examined in Swiss and C57BL/6 mice. Peripheral amino 
acids were measured and central TRP and 5-HT concentrations were 
compared with anxiety and depression-like behaviour in the elevated 
zero-maze (EZM), forced swimming test (FST) or tail suspension 
test (TST). While ATD resulted in a 74% reduction of the plasma 
ratio TRP to the sum of other large neutral amino acids in Swiss 
mice 1h after administration (2x10 ml/kg, 30 min interval), there was 
only a 40% reduction in C57BL/6 mice. The latter did not show 
anxiety in the EZM or increased immobility in the FST or TST. A 
higher dose (2x20 ml/kg) with a longer interval (60 min) reduced the 
ratio with 68% in C57BL/6 mice, lowered hippocampal 5-HT 
turnover and had no functional effect when tested in the EZM and 
FST. These findings have important implications for the use of ATD 
in general and in particular for its application in mice. Although in 
healthy mice no clear central 5-HT or functional effects were 
observed, further research is indicated using mice with pre-existing 
5-HT dysfunction, as they might be more vulnerable to ATD.  
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Introduction 
Although depression is a heterogeneous disorder with complex molecular 
pathophysiological mechanisms, a dysfunctional serotonergic neurotransmitter 
system is widely accepted to be one of the main factors underlying the 
development of depressive symptomatology (Asberg et al., 1976a; Leonard, 
2007; Meltzer, 1990). Direct evidence comes from human studies associating 
depressive symptoms with abnormal physiological parameters related to the 
serotonergic system (Risch and Nemeroff, 1992). Depressed patients often 
display disturbances in 5-HT metabolism (van Praag and de Haan, 1979) as 
indicated by decreased peripheral levels of tryptophan (TRP; Cowen et al., 
1989), the dietary precursor of serotonin (5-hydroxytryptamine, 5-HT), and 
diminished levels of 5-hydroxyindoleacetic acid (5-HIAA; Asberg et al., 1976b), 
an inactive 5-HT degradation product. Drugs successfully used in the treatment 
of depression provide direct evidence for the important role of disrupted 
function of specific pre- and postsynaptic receptors underlying the impaired 
5-HT neurotransmission linked to depressive symptomatology (Naughton et 
al., 2000). Moreover, variations in genes that regulate the 5-HT system appear 
to play an important role in the probability of onset and recurrence of 
depressive episodes and other affective disorders (Caspi et al., 2003; Levinson, 
2006). Therefore, the aetiology of depression is thought to be strongly related 
to specific factors that predispose subjects to a dysfunctional 5-HT system 
(Booij and Van der Does, 2007; Jans et al., 2007b). 
 The implication of the 5-HT system and serotonergic vulnerability in the 
onset of depressive symptomatology is being extensively investigated with tools 
that challenge serotonergic neurotransmission. Most widely applied, clinically 
and pre-clinically, is the method of acute tryptophan depletion (ATD; (Bell et 
al., 2005; Hood et al., 2005; Neumeister, 2003; Young, 1993)). By administering 
a TRP-free nutritional mixture, the dietary intake of TRP is depleted, thereby 
reducing the TRP for uptake into the brain and subsequent synthesis into 5-HT 
(Fadda et al., 2000; Fernstrom, 1983). Brain TRP levels correlate highly with 
brain 5-HT, due to the rate-limiting enzyme tryptophan hydroxylase (TPH), 
which catalyzes the conversion of TRP into 5-hydroxytryptophan (5-HTP) and 
is only half saturated under normal physiological conditions (Boadle-Biber, 
1993). Manipulation of dietary TRP intake is not only a useful tool for 
effectively decreasing brain TRP content and 5-HT synthesis, it also provides a 
clue to understanding the mechanism behind the regulation of the 5-HT system 
in general. Since the method does not require the use of neurotoxins, it can be 
safely and repeatedly used in both human and rodent research and offers the 
ability to compare preclinical and clinical designs and outcomes (Blokland et al., 
2004; Fadda et al., 2000). Likewise, the tool makes it possible to measure both 
physiological and behavioural effects of decreased 5-HT availability in the 
brain. 
Thesis_Donkelaar_v8.pdf   46 30-7-2009   15:07:54
Acute tryptophan depletion in the mouse  
 47 
A large body of preclinical literature provides evidence that ATD in rats 
significantly depletes the levels of TRP in plasma, thereby reducing 5-HT 
metabolism, as is reflected upon by the lower TRP and 5-HT levels in rat brain 
tissue (Biggio et al., 1974; Blokland et al., 2002; Cahir et al., 2007; Jans et al., 
2007a; Lieben et al., 2004a; Olivier et al., 2008). In addition, ATD in rats 
induces profound cognitive deficits (Jans et al., 2008a; Jans et al., 2007a; Jans 
and Blokland, 2008; Lieben et al., 2004b; Olivier et al., 2008; Rutten et al., 2007; 
van Donkelaar et al., 2008) and a wide range of other behavioural changes 
(Blokland et al., 2002; Jans et al., 2008a; Jans et al., 2007a). However, whether 
the ATD-induced functional changes are directly related to a decrease in 5-HT 
neuronal activity remains unclear (Moore et al., 2000; van der Plasse et al., 
2007). Nevertheless, in human subjects, ATD has been proposed as a potential 
tool for identifying subjects at risk of a future depressive episode, as mood-
lowering effects have only been reported in healthy subjects with pre-existing 
abnormal 5-HT functioning (Booij et al., 2002; Booij et al., 2005; Moreno et al., 
2000; Van der Does, 2001). Pre-existing dysfunctional 5-HT systems are 
currently widely modeled in mice by manipulating genes implicated in the 
regulation of the 5-HT system, such as mice with different expression of the 
5-HT transporter (Lesch et al., 1996), 5-HT1A receptor (e.g. Heisler et al., 1998) 
or the tryptophan hydroxylase enzyme (e.g. Zhang et al., 2006).  
 The introduction of new mouse models of depression is extremely 
important in order to improve insight into the underlying neurophysiological 
mechanisms of depressive disorders and for the development of new 
pharmacological therapies (Cryan and Mombereau, 2004). Therefore, we aimed 
to establish the rat model of ATD in the mouse for potential future application 
of the method in transgenic mouse models of serotonergic dysfunction. 
Triggering pre-existing serotonergic dysfunction by challenging the serotonergic 
system might reveal specific phenotypical responses that will provide insights 
into the role of the serotonergic system in depressive symptomatology, in 
particular, and neuropsychiatric disorders in general.  
Experimental procedures 
Animals 
Three-months-old Swiss and C57BL/6 male mice (Charles River, the 
Netherlands) were used for a total of 5 studies in which the effects of ATD 
upon peripheral and central TRP levels and brain 5-HT and 5-HIAA 
concentrations were explored. Some of the studies also included behavioural 
testing. Swiss mice were used in the first study to obtain initial baseline 
measures of the pharmacokinetics of the ATD procedure. Subsequent studies 
were performed on the C57BL/6 mouse strain as this is the primary 
background strain of genetically manipulated mice of specific interest in 
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depression-related research. All of the studies were carried out at Maastricht 
University except study four which was conducted at the University of 
Edinburgh (United Kingdom), using local inbred C57BL/6 mice. 
 Experimental protocols were reviewed and approved by the local ethical 
Committee on Animal Experimentation of the Maastricht University and by the 
University of Edinburgh Ethical Review Process and met Dutch and British 
governmental guidelines, respectively. Throughout all experiments the 
principles of laboratory animal care were carefully followed in accordance with 
the official codes of practice guidelines (Experiments on Animals Act, The 
Netherlands, revised, 1996; Scientific Procedures Act, United Kingdom, 1986). 
All efforts were made to minimize the number of mice used and their suffering. 
 
On arrival mice were individually housed on sawdust bedding in standard 
macrolon cages and maintained on a 12:12-hr light-dark schedule (lights on 
from 18:00 h - 06:00 h), in a temperature-controlled (21 ± 1˚C) and air-
conditioned housing room (relative humidity: 70 ± 10%). To facilitate 
environmental adaptation, mice were not treated or handled until one week 
after arrival. At all times, background noise in the housing room was provided 
by a radio. Food (Hopefarms, The Netherlands) and water were available ad 
libitum throughout the experiments, unless otherwise stated. Animal cages were 
supplied with paper rolls and tissues to enrich environmental conditions. Clean 
cages were provided on a weekly basis.  
 For all studies oral administrations by gavage and blood sampling 
procedures remained constant following an initial period of habituation to the 
reversed day-night cycle (1 week) and the general and specific handling (1 
week), unless otherwise stated. Habituation also included shaving of the hind 
paws and the attendant restraint. In addition to familiarization to the oral 
administrations in general, mice received one administration of the control 
mixture to avoid gastrointestinal effects interfering at time of the actual 
experiment. In most studies, animals were repeatedly used for blood sampling 
and experimental treatment with washout periods of at least 2 days.  
 To avoid TRP uptake from the available standard chow, food deprivation 
always preceded experimental treatment. When deprived overnight, food was 
taken away in the afternoon (6 PM) of the day prior to the experimental day 
(start of experiment 9 AM). The exact time and duration of deprivation varied 
among the different studies. At the time of food removal, animals were 
transferred to clean cages to eliminate TRP uptake resulting from coprophagy 
behaviour (Kenagy and Hoyt, 1980). After all animals completed the 
experimental treatments or behavioural testing, ad libitum food availability was 
continued. On the day of the experiment, prior to treatment, mice were 
weighed to calculate the exact injection volume to be administered. 
 Differences among the studies were mainly based on changes within the 
dosing regime, including administration volume, amount of additional TRP in 
the control mixture, number of dosing administrations and the interval between 
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them. The time of decapitation, an essential time factor for the measurement of 
the ATD effects upon physiological parameters in the brain, was explored in 
more detail in one of the studies. Further, we investigated the role of different 
stressors that were implicated in the treatment procedures (such as blood 
sampling, oral administrations by gavage and food deprivation) as potential 
interfering factors within the 5-HT challenge paradigm. 
Acute tryptophan depletion 
Acute reduction of plasma tryptophan levels was accomplished by using a TRP-
free protein-carbohydrate nutritional mixture (Gelatine hydrolysate, Solugel®; 
PB Gelatins, Tessenderlo, Belgium). This gelatine-based protein mixture 
comprises the entire range of amino acids (see Table 1) in the form of peptides 
and is, therefore, comparable to normal chow (Lieben et al., 2004a). The 
addition of carbohydrates (Glucodry 210; Amylumgroup, Koog aan de Zaan, 
The Netherlands) activates the insulin response, thereby enhancing protein 
synthesis which results in an optimized reduction of plasma TRP levels 
(Fernstrom and Wurtman, 1972; Fernstrom, 1986; Lieben et al., 2004a; Markus 
et al., 1998). Since TRP competes at the blood-brain barrier with other large 
neutral amino acids (LNAAs; leucine [LEU], isoleucine [ILE], phenylalaline 
[PHE], tyrosine [TYR], valine [VAL]) for the same amino acid L-carrier 
transport system (Fernstrom and Wurtman, 1972; Fernstrom, 1983), a decrease 
of the ratio of TRP to the sum of the other LNAAs (TRP/ΣLNAA) in plasma 
is normally used as the best predictor of reduced central availability of TRP 
(Fernstrom, 1979, 1983).  
 Potassium chloride (KCl) and calcium chloride dihydrate (CaCl2.2H2O) were 
obtained from Merck (Darmstadt, Germany). To the control mixture, 
L-Tryptophan (Sigma, Zwijndrecht, The Netherlands) was added, as either 
0.28% or 0.56% of the total protein amount, depending on the experimental 
protocol (see below). Mixtures were dissolved in distilled water and freshly 
prepared in the morning, prior to the start of the experiments.  
 Animals were orally administered by gavage the TRP-free nutritional 
mixture (TRP- group) and compared to a group that received the same mixture 
with additional TRP (TRP+ group). On most occasions, an extra saline group 
was included to control for specific effects of the nutritional mixture in general 
Behavioural testing 
Behavioural testing was conducted in a separate test room, except for the 
elevated-zero maze test, which took place in the same room as were the animals 
were housed. At all times, testing took place in the dark phase of the day-night 
cycle between 10:00 and 16:00 h. Testing was started at specific time-points 
following ATD treatment initiation.  
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Table 1 Composition of the protein-carbohydrate nutritional mixture and determination of the 
amino acid content of the gelatine-based protein (g). 
Substance Amount (g) 
100  Protein (Solugel®) in 100 ml water 
    Alanine 
    Arginine 
    Aspartic Acid 
    Cysteine 
    Glutamic Acid 
    Glycine 
    Histidine 
    Hydroxylysine 
    Hydroxyproline 
    Isoleucine 
    Leucine 
    Lysine 
    Methionine 
    Phenylalanine 
    Proline 
    Serine 
    Threonine 
    Tryptophan 
    Tyrosine 
    Valine 
 8.4 
7.7 
4.5 
0.0 
10.0 
23.3 
0.9 
1.5 
12.3 
1.2 
2.6 
3.3 
0.9 
1.6 
13.7 
3.4 
1.9 
0.0 
0.6 
2.2 
Carbohydrate (Glucodry 210) in 50 ml water 
KCl in 10 ml water 
CaCl2.2H2O in 10 ml water 
L-Tryptophan (TRP+ group) 
L-Tryptophan (TRP-  group) 
50 
  0.095 
  2.318 
 0.28/0.56 
  0 
 
Elevated zero-maze test 
The elevated zero-maze test (EZM) is a modification of the elevated plus-maze 
and models anxiety-like behaviour in rodents (Shepherd et al., 1994). The maze 
consisted of a circular platform (50 cm in diameter), elevated 20 cm above floor 
level, with two opposite enclosed parts (50 cm high side walls) and two open 
parts equally divided along the circular runway (5 cm). This modified design 
allows the animal uninterrupted exploration and avoids undefined time spent in 
the central square as is the case in the traditional elevated plus-maze design 
(Shepherd et al., 1994). Falls from the open parts were prevented by a 5 mm 
high edge. Both the side walls and the maze itself were made of black plastic, 
transparent for infrared light, and connected via an infrared video camera to a 
video tracking system (Ethovision Pro, Noldus Wageningen, The Netherlands). 
For testing, mice were placed in the middle of one of the open parts, facing a 
closed part, and allowed to explore the maze for a total time of 5 min (study 2) 
or 6 min (study 3). Total time spent in closed parts and total distance travelled 
was video tracked under dim light conditions. In between trials, the maze was 
thoroughly cleaned with water and 70% alcohol. 
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Tail suspension test 
The tail suspension test (Steru et al., 1985), is a measure of behavioural despair 
after induction of an inescapable haemodynamic stress situation. The tail 
suspension apparatus consisted of four separate compartments, allowing four 
animals to be tested simultaneously. The apparatus was positioned in front of a 
light box to create specific illumination conditions for optimal video tracking. 
For the test sessions, mice were suspended by their tail for a total time of 6 
min. Tail suspension was achieved by wrapping adhesive tape around the mid-
end of the mouse tail and attaching it to a hook inserted in the middle of the 
roof of the compartment, thereby suspending the mouse head down. The 
sessions were videotaped from the front with a camera connected to a video 
tracking system (Ethovision Pro, Noldus, Wageningen, The Netherlands), 
which allowed automated recording of total immobility time. Settings within 
Ethovision were adjusted based on manually recorded sessions of four 
randomly chosen animals (immobility/mobility threshold: 5.7 %). After 6 min 
testing, mice were immediately transferred back to their home cage and the 
apparatus was thoroughly cleaned with water and 70% alcohol for the following 
session. 
Forced swimming test 
A modified forced swimming test (FST) consisted of exposing the animals to 
an inescapable water stress, using the total time spent in an immobile position a 
measure of their level of behavioural despair (Porsolt et al., 1977a; Porsolt et al., 
1977b). For the swim sessions, transparent Plexiglas cylinders (50 cm in height 
x 19 cm in diameter) were filled with warm water (32 ± 2ºC) up to 20 cm. 
Water height was specifically chosen to prevent the mice from being able to 
touch the cylinder bottom with their hind paws or tail (Detke and Lucki, 1996; 
Lucki, 1997). Four mice were tested in parallel and videotaped from above. 
Mice were not able to see one another due to grey separation panels placed 
between the four cylinders. Swim sessions were initiated by transferring the 
mice from their home cages to one of the cylinders (study 3). In study 2, a 15 
min pre-test session preceded the 6 min test-session 24 hrs before. After the 
swim sessions, mice were immediately removed from the water and transferred 
to a cage filled with paper towels for an initial 2 min recovery. Subsequently, 
mice were dried with paper towels and returned to their home cages. In 
between trials, cylinders were cleaned with 70% alcohol and refilled with clean 
water. 
 The cylinders were positioned on top of a light box to create optimal 
illumination conditions for video tracking. A camera was placed 75 cm above 
the light box and connected to a video tracking system (Ethovision Pro, 
Noldus, Wageningen, The Netherlands), which allowed automated recording of 
individual immobility times and total distance moved. Settings within 
Ethovision were adjusted based on manually recorded sessions of four 
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randomly chosen animals (immobility/mobility threshold: 10 % and 13 % for 
study 2 and 3, respectively).  
Blood samples and brain tissue 
Blood samples (± 50 μl per sample) were taken by means of saphenous vein 
puncture, as this method has been proven to be appropriate for repeated 
sampling in the same animal in a quick and painless manner and without the 
requirement of anesthesia (Hem et al., 1998). Mice had both hind paws shaved 
over the lateral saphenous vein, using a small and almost soundless hair cutting 
system (Kyone, model GT 100, The Netherlands). For shaving and blood 
sampling, the animals were placed in a thick cotton cloth, in such a way that the 
hind paws were freely accessible for the particular procedures. Habituation to 
the specific restraint procedures and hind paw shaving was included in the 
initial and overall habituation period as mentioned above. 
 Blood samples were taken prior to treatment for baseline amino acid (AA) 
determination in plasma. Subsequent blood samplings were carried out at 
specific time points after treatment, depending on the particular experimental 
protocol. At time of decapitation, trunk blood was captured which served for 
final plasma measurement. Brain amino acids and 5-HT and 5-HIAA 
concentrations were measured in bilaterally dissected prefrontal cortex and 
hippocampus. Again, exact time-points depended on the specific protocol used 
and always coincided with final plasma samples for comparison purposes.  
Experimental protocols 
Study 1 Pharmacokinetic effects of different ATD dosing regimes in the Swiss mouse 
Swiss mice (n=16) were used repeatedly to explore the effects of 4 different 
dosing regimes upon peripheral TRP levels. Animals were food deprived 4 h 
prior to experimental treatment. Administrations of the nutritional mixture 
took place in a volume of 10 or 20 ml/kg, as either one single dose or in a 
double dose with a 30 min interval (see overview Table 2).  
 From the total protein amount, the control mixtures contained 0.28% of 
additional TRP. Blood samples were taken approximately 30 min (t-30; 
baseline) prior to the start of the treatment (t0) and at 1 h (t60) and 2 h (t120) 
after the first administration.  
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Table 2 Experimental group overview study 1 
Dosing regime 
(ml/kg) 
saline 
(n) 
TRP+ 
(n) 
TRP- 
(n) 
t-30 
BS1 
t0 
adm 1 
t30 
adm 2 
t60 
BS2 
t120 
BS3 
1x10 5 5 6 x x - x x 
2x10 5 5 6 x x x x x 
1x20 - - 16 x x - x x 
2x20 - 8 8 x x x x x 
TRP+: control nutritional mixture with tryptophan; TRP-: experimental nutritional mixture 
without tryptophan; BS: blood sampling; adm: oral administration by gavage; t: time in min 
Study 2 Pharmacokinetic and behavioural effects of a 2x10 ml ATD dosing regime in the 
C57BL/6 mouse 
C57BL/6 mice (n=36) were used to examine plasma AA concentration and 
behavioural effects of the 2x10 ml/kg dosing regime with a 30 min interval 
between administrations and 0.28% additional TRP in the control mixture 
(same as study 1). After the initial habituation period, experimental treatment 
and blood sampling was carried out over three consecutive days for which 
sampling time of second blood sample differed on each day. Mice were 
deprived of food 3 h prior to experimental treatment and randomly assigned to 
blood sampling time group (n=12 per group/day) and treatment condition 
(saline n=4; TRP+ n=4; TRP- n=4). Blood samples for plasma AA 
determination were taken at baseline (t-30) and either at 1h (t60; day 1), 2 h 
(t120; day 2) or 3 h (t180; day 3) after the first administration. Additionally, this 
ATD dosing regime was tested for its effects upon depression-like (FST and 
TST) and anxiety-related (EZM) behaviour (see overview Table 3). 
 Mice were first exposed to the EZM test (5 min/trial), randomly assigned to 
one of 3 testing days for which each treatment group was equally represented. 
Subsequently, with a one week interval to minimize stress effects of previous 
testing, all mice were exposed to the TST (6 min/trial) within the same day. 
After another week interval, mice underwent a 15 min pretest session of the 
FST, followed 24 hrs later by a 6 min test session. At all times, behavioural 
testing was started 2 h (t120) after the first oral administration.  
Study 3 Pharmacokinetic and behavioural effects of 2x15 ml and 2x20 ml ATD dosing 
regimes in the C57BL/6 mouse 
C57BL/6 mice (n=39) were used to measure the differential effects of 2x15 
ml/kg and 2x20 ml/kg upon peripheral (AAs), central (AAs, 5-HT, 
5-hydroxyindoleacetic acid [5-HIAA]) and behavioural parameters. Mice were 
randomly assigned to one of two dosing groups (n=16 per group), receiving 
either TRP+ (n=8) or TRP- (n=8), in a volume of 15 or 20 ml/kg. In addition, 
7 mice were treated with saline (± 15 ml/kg). Adaptations to the experimental 
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protocol were made based on the results of the previous studies in order to 
intend reaching maximum plasma TRP depletion effects. 
Table 3 Experimental group overview study 2 
Week Day Treatment n t-30 t0 t30 t60 t120 t180 
1 saline, 
TRP+, TRP- 
12 BS1 adm 1 adm 2 BS2   
2 saline,  
TRP+, TRP- 
12 BS1 adm 1 adm 2 - BS2  
4 
3 saline, 
TRP+, TRP- 
12 BS1 adm 1 adm 2 - - BS2 
1 saline,  
TRP+, TRP- 
12 - adm 1 adm 2 - EZM  
2 saline,  
TRP+, TRP- 
12 - adm 1 adm 2 - EZM  
6 
3 saline,  
TRP+, TRP- 
12 - adm 1 adm.2 - EZM  
7 1 saline,  
TRP+, TRP- 
36 - adm 1 adm 2 - TST  
1 saline,  
TRP+, TRP- 
36 - adm 1 adm 2 - FST 
pretest 
 8 
2 saline,  
TRP+, TRP- 
36 - adm 1 adm 2 - FST 
test 
 
1 saline,  
TRP+, TRP- 
18 BS1 adm 1 adm 2 - BS2  10 
2 saline,  
TRP+, TRP- 
18 BS1 adm 1 adm 2 - BS2  
TRP+: control nutritional mixture with tryptophan; TRP-: experimental nutritional mixture 
without tryptophan; BS: blood sampling; adm: oral administration by gavage; t: time in min; 
EZM: elevated zero maze; TST: tail suspension test; FST: forced swimming test 
 
Administrations were given twice, however, this time with a 60 min interval 
compared to a 30 min interval in the previous studies. Moreover, additional 
TRP in the control mixture was doubled from 0.28% to 0.56% of total protein 
amount. Mice were food deprived overnight, the day preceding experimental 
treatment. Behavioural effects of the two dosing regimes were tested 2 h (t120) 
after the first administration, as in the previous studies. Mice were first exposed 
to the EZM (6 min/trial), followed two days later by the FST test (6 min/trial), 
with 2 days separation to minimize stress effects of previous testing and return 
to baseline from any treatment effects. Behavioural testing (both EZM and 
FST) and treatment for brain sampling took place over two consecutive days 
for which the mice were randomized according to dosing regime. Blood 
samples were not taken until after termination of the behavioural testing period. 
Treatment with the 2x15 and 2x20 ml/kg dosing regimes was then repeated for 
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blood sampling (at t-30, t60 and t120) and subsequent decapitation (t120) for 
brain tissue measurements (see overview Table 4). 
Table 4 Experimental group overview study 3 
 Dosing regime 
(ml/kg) 
Treatment 
 
n t-30 t0 t60 t120 
2x15 saline 
TRP+ 
TRP- 
7 
8 
8 
week 4 
day 1+2 
2x20 TRP+ 
TRP- 
8 
8 
 
 
- 
 
 
adm1 
 
 
adm2 
 
 
EZM 
2x15 saline 
TRP+ 
TRP- 
7 
8 
8 
week 4 
day 4+5 
2x20 TRP+ 
TRP- 
8 
8 
 
 
- 
 
 
adm1 
 
 
adm2 
 
 
FST 
2x15 saline 
TRP+ 
TRP- 
7 
8 
8 
week 5 
2x20 TRP+ 
TRP- 
8 
8 
 
 
BS1 
 
 
adm1 
 
 
BS2 + adm2 
 
 
BS3 + decap 
TRP+: control nutritional mixture with tryptophan; TRP-: experimental nutritional mixture 
without tryptophan; BS: blood sampling; adm: oral administration by gavage; t: time in min; 
EZM: elevated zero maze; FST: forced swimming test; decap: decapitation 
Study 4 Time curve of pharmacokinetic effects of ATD  
C57BL/6J mice (n=31) were used to study the effects of the 1x15 ml/kg 
dosing regime upon plasma AAs and brain 5-HT and 5-HIAA at different time 
points after treatment. Treatment and blood sampling was carried out over 
three consecutive days without a preceding habituation period to experimental 
procedures. Mice were food deprived overnight and treated with either TRP- or 
the control mixture (TRP+) which contained 0.56% of additional TRP. 
Decapitations were set at 20 min (t20), 40 min (t40), 60 min (t60) or 240 min 
(t240). All animals were blood sampled for plasma AA measurements prior to 
treatment (BS1; baseline) and at time of decapitation (BS2/BS3). The group 
decapitated at t240 received a double administration dose (2x15 ml/kg) with a 
60 min interval and an extra blood sample (BS2) taken prior to the second 
administration (see overview Table 5).  
Study 5 Interfering effects of application-related stressors upon ATD pharmacokinetics 
C57BL/6 mice (n=50) were used to measure the effects of stressors related to 
the experimental procedures and possibly affecting the ATD-induced 
peripheral and central physiological changes. Food deprivation, oral 
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administration by gavage and blood sampling were identified as factors that 
could affect responses to the ATD treatment. Mice received no oral 
administrations or either saline, TRP+ or TRP- treatment in a single dose of 15 
ml/kg. The group that received no oral treatment was further subdivided in a 
food deprived group and a group that continued normal food intake with or 
without a baseline blood sampling prior to a virtual t0. The other treatment 
conditions that received oral administrations were all food deprived overnight 
and had a blood sample taken at time of decapitation. Only half of these mice 
were also blood sampled at baseline (t-30; see overview Table 6). All 
decapitations were carried out at 20 min from t0. No period of habituation to 
experimental procedures preceded the actual experiment.  
Table 5 Experimental group overview study 4 
Treatment n t-30 t0 t20 t40 t60 t240 
saline 
TRP+ 
TRP- 
4 
4 
4 
 
BS1 
 
adm1 
 
BS2 + 
decap 
   
saline 
TRP+ 
TRP- 
4 
3 
4 
 
BS1 
 
adm1 
 
- 
 
BS2 + 
decap 
  
saline 
TRP+ 
TRP- 
4 
4 
4 
 
BS1 
 
adm1 
 
- 
 
- 
 
BS2 + 
decap 
 
saline 
TRP+ 
TRP- 
4 
4 
4 
 
BS1 
 
adm1 
 
- 
 
- 
 
BS2 + 
adm2 
 
BS3 + 
decap 
TRP+: control nutritional mixture with tryptophan; TRP-: experimental nutritional mixture 
without tryptophan; BS: blood sampling; adm: oral administration by gavage; t: time in min; decap: 
decapitation 
Table 6 Experimental group overview study 5 
Food condition n Baseline blood sample (t-30) Treatment (t0) t20 
Food deprived 5 - saline decap 
Food deprived 5 - TRP+ decap 
Food deprived 5 - TRP- decap 
Food deprived 5 - - decap 
Food 5 - - decap 
Food 5 BS1 - decap 
Food deprived 5 BS1 - decap 
Food deprived 5 BS1 saline decap 
Food deprived 5 BS1 TRP+ decap 
Food deprived 5 BS1 TRP- decap 
TRP+: control nutritional mixture with tryptophan; TRP-: experimental nutritional mixture 
without tryptophan; BS: blood sampling; t: time in min; decap: decapitation 
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Biochemistry 
Sample preparation and analysis were performed as partly described elsewhere 
(Double et al., 2003; Vogel et al., 2003). In detail, blood samples for AA 
determination were collected in heparin coated tubes (Microvette® CB 300, 
Sarstedt, Germany) and kept on ice until centrifuged (for 10 min at 14,000 x g 
in a Hettish EBA 12 centrifuge at 4 ºC) in order to separate approximately 25 
μl of plasma. Plasma samples were subsequently stored at -80ºC until further 
analysis.  
 At time of decapitation, prefrontal cortex and hippocampus were dissected 
out bilaterally and immediately put on dry ice before storage at -80ºC. For 
central amino acid and monoamine determination, the frozen brain structures 
were transferred into pre-weighed 2.0 μl screw-lit cups and exact tissue weight 
was determined with an analytic balance.  Approximately 0.3 g of glass beads 
(1.0 mm diameter) were added to the cup together with ice-cold 150 mΜ 
H3PO4 and 500 μΜ diethylenetriamine pantaacetic acid (volume = 19 x weight 
in μl). Samples were aerated with Argon to minimize monoamine degradation 
and homogenized in a mini-bead beater set at high speed, twice for 30 sec. 
After a subsequent 3 min spin (3000 x g at 4ºC), the homogenate was 
transferred back into an Eppendorf vial and centrifuged for 20 min (35,000 x g 
at 4ºC). The supernatant was filtered through Millipore (Bedford, MA) 
Ultrafree-MC filter cups at 9000 x g for 1-2 h at 4ºC after which they were 
stored at -80ºC until further analysis.  
 Plasma and brain AA concentrations were quantified using a fully 
automated high-performance liquid chromatography (HPLC) system with 
fluorescence detection. The concentrations of total plasma and central amino 
acids were expressed as μmol/l, brain concentrations as ng/mg. The 
concentrations of 5-HT and its metabolite 5-HIAA were quantified by HPLC 
with electrochemical detection.  
Statistical analyses 
Mean concentrations of plasma amino acids were determined for each 
treatment condition and time-point separately. The mean concentrations of all 
absolute plasma LNAAs were determined and TRP/ΣLNAA ratios were 
calculated accordingly. Changes in the ratio TRP/ΣLNAA over time were 
analyzed by means of two-way analysis of variance (ANOVA) with Treatment 
as between-subject factor and Time as within-subject variable. Separate one-
way ANOVAs or appropriate t-tests were performed to analyze differences 
between treatment conditions per time-point and the effects upon behaviour. A 
post hoc LSD test was used to further characterize the treatment effects. Mean 
central amino acid concentrations, 5-HT, 5-HIAA and the ratio 5-HIAA/5-HT 
were analyzed for hippocampus and prefrontal cortex separately.  
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Extreme values in the biochemical data (absolute concentrations) were 
calculated by means of Dixon’s Extremity test (Dixon, 1959) and excluded 
from statistical analysis. In all cases the acceptable level of significance was set 
at P<0.05. All data are represented as mean + standard error of the mean 
(S.E.M.). Analyses were performed using the Statistical Package for Social 
Science (SPSS) for Windows (Rel.12.0.1.2003, Chicago: SPSS Inc.). GraphPad 
Prism, version 4.02 for Windows (GraphPad Software, San Diego California 
USA) was used for preparing the graphs. 
Results 
Study 1 Pharmacokinetic effects of different ATD dosing regimes in the Swiss mouse 
Plasma ratio 1x10 ml/kg 
When administering the nutritional mixture once in a volume of 10 ml/kg, 
ATD decreased the ratio TRP/ΣLNAA over time [F(2, 24) = 11.74; P<0.001] 
and an overall treatment effect [F(2, 12) = 6.69; P<0.05] was found. Post hoc 
analysis showed that the TRP- condition was significantly different from TRP+ 
(LSD; P<0.01). Moreover, the decrease over time was different for the 
treatment groups [F(4, 24) = 7.38; P<0.01]. Separate one-way ANOVAs for 
each treatment per time-point showed that there were no differences between 
treatment conditions at baseline [F(2, 15) = 1.21; n.s.] or 2 hrs after 
administration [F(2, 15) = 3.26; n.s.]. However, the ratio TRP/ΣLNAA was 
significantly different between treatment conditions 1 h (t60) after the oral 
administration [F(2, 15) = 10.64; P<0.01]. Post hoc analyses revealed that at 
this time-point ATD decreased the ratio TRP/ΣLNAA when compared to 
saline and TRP+. In the TRP+ condition the ratio was significantly higher 
when compared to saline. Two hours after administration (t120), the ratio 
TRP/ΣLNAA in the TRP- condition was still significantly reduced when 
compared to baseline (LSD, P<0.01). In the TRP+ condition the ratio was not 
different from baseline values, but was significantly decreased when compared 
to the 1 h time-point (P<0.05; Fig. 1A). 
Plasma ratio 2x10 ml/kg 
ATD with the 2x10 ml/kg dosing regime decreased the ratio TRP/ΣLNAA 
over time [F(2, 24) = 20.86; P<0.001] and an overall treatment effect [F(2, 12) 
= 32.25; P<0.001] was found. Post hoc analyses revealed that the TRP- 
condition was significantly different from both the saline (LSD; P<0.001) and 
the TRP+ condition (LSD; P<0.001) and the decrease over time was different 
for the three treatment groups [F(4, 24) = 39.27; P<0.001]. 
Thesis_Donkelaar_v8.pdf   58 30-7-2009   15:07:55
Acute tryptophan depletion in the mouse  
 59 
Separate one-way ANOVAs for each treatment group per time-point revealed 
significant differences between the treatment conditions at 1 h [F(2, 15) = 
77.75; P<0.001] and 2 h [F(2, 15) = 34.13; P<0.001] after the oral 
administrations. Post hoc analyses showed that at both time points the ratio 
TRP/ΣLNAA was significantly lower after ATD compared to both the saline 
and the TRP+ condition. No differences between treatment conditions were 
found at baseline [F(2, 14) = 0.92; n.s.] and at all times the saline condition did 
not differ from the TRP+ treatment (Fig. 1B). 
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Figure 1 ATD effects of 1x10 ml/kg (A), 2x10 ml/kg (B), 1x20 ml/kg (C) and 2x20 ml/kg (D) 
treatment upon the ratio TRP/ΣLNAA in plasma at different time-points (mean + S.E.M.). % 
indicates percentage change from corresponding baseline values. Significant differences between 
the tryptophan-free experimental mixture (TRP-) and the control mixture with tryptophan 
(TRP+) are denoted with (*), differences between the TRP- and the saline treatment are denoted 
with (+), and differences between the TRP+ and saline treatment are denoted with (#). */+/ # 
P<0.05; **/++/ ## P<0.01; ***/+++/ ### P<0.001.  
Plasma ratio 1x20 ml/kg 
ATD with the 1x20 ml/kg dosing regime also decreased the ratio 
TRP/ΣLNAA over time [F(2, 30) = 43.73; P<0.001] and resulted in an overall 
treatment effect [F(2, 15) = 56.51; P<0.001] with a different decrease over time 
depending on treatment condition [F(4, 30) = 32.31; P<0.001]. Post hoc 
analyses revealed that the TRP- condition was significantly different from both 
the saline (LSD; P<0.001) and the TRP+ condition (LSD; P<0.001) and TRP+ 
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was different from saline treatment (LSD; P<0.05). Separate one-way 
ANOVAs for each treatment group per time-point revealed no differences 
between the treatment conditions at baseline [F(2, 21) = 1.96; n.s.]. Significant 
treatment effects were found 1 h [F(2, 21) = 170.99; P<0.001] and 2 h [F(2, 19) 
= 44.61; P<0.001] after the oral administrations. Post hoc analyses revealed that 
at the 1 h time-point the ratio TRP/ΣLNAA was significantly lower after ATD 
when compared to both the saline and the TRP+ treatment. Moreover, after 
TRP+ treatment, the ratio TRP/ΣLNAA was significantly increased when 
compared to the saline condition. At the 2 h time-point, the ratio 
TRP/ΣLNAA was still significantly lower after ATD when compared to saline 
and TRP+ treatment, however, the difference between TRP+ and saline 
treatment disappeared at this time-point (Fig. 1C). 
Plasma ratio 2x20 ml/kg 
ATD with the 2x20 ml/kg dosing regime decreased the ratio TRP/ΣLNAA 
over time [F(1, 12) = 59.01; P<0.001] and resulted in an overall treatment effect 
[F(1, 12) = 170.70; P<0.001] with a different change over time depending on 
treatment condition  [F(1, 12) = 28.08; P<0.001]. Separate independent samples 
t-tests for the TRP- and TRP+ treatment groups per time-point revealed no 
differences between the treatment conditions at baseline [t(14) = 0.00; n.s.]. A 
highly significant decrease of the ratio TRP/ΣLNAA was found after ATD 1h 
[t(13) = 25.39, P<0.001] and 2 h [t(13) = 11.03, P<0.001] after administration 
of the nutritional mixture (Fig. 1D).   
Study 2 Pharmacokinetic and behavioural effects of ATD in the C57BL/6 mouse 
Plasma ratio 
ATD in the C57BL/6 mouse changed the ratio TRP/ΣLNAA over time [F(3, 
21) = 10.98, P<0.001], however, this pattern did not differ between the 
treatment conditions [F(6,21) = 1.24; n.s.]. An overall treatment effect was 
found [F(2,7) = 13.30, P<0.01]. Post hoc analysis revealed significant 
differences between the saline and TRP+ and the TRP- and TRP+ treatment 
condition. Separate one-way ANOVAs per time-point revealed that there were 
no differences between treatment conditions at baseline [F(2, 34) = 3.157; n.s.] 
and 3 h after the first administration of the 2x10 ml/kg treatment [F(2, 10) = 
0.55; n.s.]. Significant treatment effects were found 1 h [F(2,10) = 11.12, 
P<0.01] and 2 h after the first administration [F(2,11) = 6.76, P<0.05]. At the 
1h time-point the ratio TRP/ΣLNAA was significantly lower after ATD as 
compared to the TRP+ and saline treatment (LSD; P<0.01). The same 
differences between TRP- and TRP+ and TRP- and saline (LSD; P<0.05) were 
found 2 h after the first administration (Fig. 2).  
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Figure 2 ATD effects of 2x10 ml/kg treatment upon the ratio TRP/ΣLNAA in plasma at 
different time-points in the C57BL/6 mouse (mean + S.E.M.). % indicates percentage change 
from corresponding baseline values. Significant differences between the tryptophan-free 
experimental mixture (TRP-) and the control mixture with tryptophan (TRP+) are denoted with 
(*), differences between the TRP- and the saline treatment are denoted with (+). */+ P<0.05; 
**/++ P<0.01.  
Behaviour 
ATD did not produce any anxiety or depression-like behaviour in the C57BL/6 
mouse. In the EZM, no differences were found between treatment conditions 
upon the total time spent in the closed arms [F(2, 28) = 0.56; n.s.] (Fig. 3A) or 
the total distance moved [F(2, 28) = 0.02; n.s.] (Fig. 3B).  
 No ATD effects were found in the TST (Fig. 3C) after 6 min upon total 
immobility time [F(2, 27) = 0.085; n.s.], the amount of time spent hanging 
immobile during the first 3 min [F(2, 27) = 0.16; n.s.] or during the last 3 min 
[F(2, 27) = 1.35; n.s.]. 
 In the 15 min pre-test, no differences were found between the treatment 
conditions for the total amount of time spent immobile in the water [F(2, 35) = 
0.87; n.s.], the mean immobility time during the first 6 min [F(2, 35) = 1.74; 
n.s.] or during the last 5 min of the pre-test [F(2, 35) = 0.35; n.s.] (Fig. 3D). In 
the 6 min test 24 hours later (Fig. 3E), ATD did not have an effect either upon 
the time spent immobile in total [F(2, 35) = 0.55; n.s.] or during the last 3 min 
of the test [F(2, 35) = 1.24; n.s.].  
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Figure 3 The effects (mean + S.E.M.) of ATD in the C57BL/6 mouse 2 h after the first 
administration upon total time spent in the open and closed arms (A) and the total distance 
moved (B) in the elevated zero maze (EZM), the time spent hanging immobile in the tail 
suspension test (TST; C) and the immobility time in the 15 min pre-test swim session (D) and the 
5 min test session of the forced swimming test (FST; E). No differences were found on any of 
the behavioural parameters between the tryptophan-free experimental mixture (TRP-) and the 
control mixture with tryptophan (TRP+). 
 
Study 3 Pharmacokinetic and behavioural effects of two ATD dosing regimes in the 
C57BL/6 mouse 
Plasma ratio 
The ratio TRP/ΣLNAA ratio was decreased over time [F(2, 60) = 229.77, 
P<0.001] and an overall treatment effect was found [F(4, 30) = 40.47, 
P<0.001]. The decrease over time differed for each treatment condition [F(8, 
60) = 17.05, P<0.001]. Post hoc analysis showed that the saline treatment was 
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different from both the 15 and 20 ml/kg TRP- treatment (LSD; P<0.001). For 
both dosing regimes, the TRP- treatment was significantly different from the 
TRP+ treatment (P<0.001). Separate one-way ANOVAs to reveal treatment 
effects per time-point showed that the ratio TRP/ΣLNAA was the same for all 
treatment conditions at baseline [F(4, 36) = 0.63; n.s.].  
 Significant differences between treatment conditions were found at 1 h [F(4, 
37) = 64.37, P<0.001] and 2 h after the first treatment administration [F(4, 37) 
= 45.82, P<0.001]. From post hoc analyses it can be concluded that at the 1 h 
time-point, all the treatment conditions significantly decreased the ratio 
TRP/ΣLNAA when compared to saline and in both dosing regimes the ratio 
TRP/ΣLNAA was significantly lower after TRP- treatment compared to TRP+ 
treatment. At the 2 h time-point the ratio TRP/ΣLNAA was slightly higher 
after TRP+ treatment compared to saline with the 20 ml/kg administration 
(Fig. 4A), whereas no differences were found between these two treatment 
conditions with the 15 ml/kg dosing regime (Fig. 4B). For both dosing regimes, 
the ratio TRP/ΣLNAA was still significantly decreased after the TRP- 
treatment when compared to both the saline and TRP+ condition. 
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Figure 4 ATD effects of 2x15 (A) and 2x20 ml/kg (B) treatment upon the ratio TRP/ΣLNAA in 
plasma, 1 h and 2 h after the first administration (mean + S.E.M.). Percentages indicate 
significant changes from corresponding baseline values. Significant differences between the 
tryptophan-free experimental mixture (TRP-) and the control mixture with tryptophan (TRP+) 
are denoted with (*), differences between the TRP- and the saline treatment are denoted with (+), 
and differences between the TRP+ and saline treatment are denoted with (#). */+/ # P<0.05; 
**/++/ ## P<0.01; ***/+++/ ### P<0.001.  
Brain TRP, 5-HT, 5-HIAA and the ratio 5-HIAA/5-HT 
In the hippocampus, TRP- treatment did not reduce TRP [F(4, 37) = 1.80; n.s.] 
(Fig. 5A), 5-HT [F(4, 37) = 0.98; n.s.] (Fig. 5B) or 5-HIAA concentrations [F(4, 
38) = 1.83; n.s.] (Fig. 5C). However, an overall effect was found upon 5-HT 
turnover (5-HIAA/5-HT) [F(4, 35) = 3.16, P<0.05] in this brain area (Fig. 5D). 
In the prefrontal cortex, an overall treatment effect was also found upon 
5-HIAA concentrations [F(4, 30) = 0.61, P<0.05] (Fig. 5C), however, no effects 
of  ATD were found upon TRP [F(4, 36) = 0.13; n.s.] (Fig. 5A) or 5-HT 
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concentrations [F(4, 32) = 0.59; n.s.] (Fig. 5B) or the 5-HT turnover [F(4, 30) = 
0.61; n.s.] (Fig. 5D). Post hoc analyses revealed that in the hippocampus the 
5-HT turnover ratio was significantly reduced after 20 ml/kg TRP- treatment 
compared to its TRP+ control treatment. Additionally, the 5-HT turnover 
after15 ml/kg TRP- treatment was significantly lower compared to saline (Fig. 
5D). In the frontal cortex, the 5-HIAA levels were significantly reduced after 15 
ml/kg TRP+ treatment compared to saline (Fig. 5C). Moreover, significantly 
lower 5-HIAA levels were found after TRP+ treatment with the 15 ml/kg 
dosing regime when compared to the 20 ml/kg dosing regime (Fig. 5C).  
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Figure 5 ATD effects of 2x15 and 2x20 ml/kg treatment upon central TRP (A), 5-HT (B) and 
5-HIAA (C) concentrations and the ratio 5-HIAA/5-HT (D) in hippocampus and frontal cortex, 
2 h after the first administration (mean + S.E.M.). Significant differences between the 
tryptophan-free experimental mixture (TRP-) and the control mixture with tryptophan (TRP+) 
are denoted with (*), differences between the TRP- and the saline treatment are denoted with (+), 
and differences between the two dosing regimes after TRP+ treatment are denoted with (a). */+/ a 
P<0.05; **/++/ aa P<0.01. 
Behaviour 
In the EZM, no overall treatment effect was found upon the total time spent in 
the closed arms [F(4, 37) = 0.31; n.s.] (Fig. 6A).  However, the total distance 
moved after 6 min (Fig. 6B) was significantly different between the treatment 
conditions [F(4, 38) = 3.36, P<0.05]. Post hoc analyses showed that ATD in a 
volume of 20 ml/kg reduced the total distance moved of the mice compared to 
those treated with saline and the ATD mice of the 15 ml/kg dosing regime. No 
differences were found, however, between ATD and TRP+ control treatment. 
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ATD did not affect the immobility time in the FST (Fig. 6C). No treatment 
effects were found upon total time spent immobile over the 6 min swim session 
[F(4, 38) = 0.86; n.s.]. Analyzing only the first 3 min [F(4, 38) = 1.38; n.s.] or 
the last 3 min of the swim test [F(4, 38) = 0.42; n.s.] did not reveal any ATD 
effects either. 
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Figure 6 The effects (mean + S.E.M.) of 2x15 and 2x20 ml/kg ATD 2 h after the first 
administration upon total time spent in the closed arms (A) and the total distance moved (B) in 
the EZM and the immobility time in a 6 min FST session (C). Significant differences between the 
TRP- and the saline treatment are denoted with (+) and differences between the two dosing 
regimes after TRP- treatment are denoted with (b). +/ b P<0.05; ++/ bb P<0.01. 
Study 4 Time curve of pharmacokinetic effects of ATD 
Plasma ratio 
ATD changed the plasma ratio TRP/ΣLNAA over time [F(4, 20) = 13.03, 
P<0.001] and an overall treatment effect was found [F(1, 5) = 9.44, P<0.05]. 
The changes in the ratio TRP/ΣLNAA over time did not depend on treatment 
condition [F(4, 20) = 2.14; n.s.]. Independent-samples t-tests per time-point 
revealed that baseline values for ratio TRP/ΣLNAA did not differ between the 
TRP+ and TRP- treatment groups [t(37) = 0.144; n.s.]. Significant decreases in 
the ratio TRP/ΣLNAA after ATD were found after 20 min [t(6) = 2.823; 
P<0.05] and after 60 min [t(6) = 2.924; P<0.05], not however after 40 min [t(5) 
= 2.277; n.s.] or 240 min [t(6) = 1.042; n.s.] (Fig. 7). 
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Brain 5-HT, 5-HIAA and the ratio 5-HIAA/5-HT 
ATD did not change the 5-HT concentration in the hippocampus over time 
[F(3, 12) = 1.13; n.s.]. An overall ATD treatment effect was found [F(1, 4) = 
5.93, P< 0.05], however, independent of time [F(3, 12) = 0.08; n.s.]. Separate 
t-tests per time point did not reveal significant ATD effects at any time point 
(Fig. 8A). No time effect [F(3, 9) = 0.79; n.s.] or treatment effect [F(1, 3) = 
1.17; n.s.] was found upon 5-HT concentrations in the prefrontal cortex (Fig. 
8B). 
 
 
Figure 7 ATD effects of 1x15 and 2x15 ml/kg (t240) treatment upon the ratio TRP/ΣLNAA in 
plasma at different time-points (mean + S.E.M.). % indicates percentage change from 
corresponding baseline values. (*) Significant difference between the tryptophan-free 
experimental mixture (TRP-) and the control mixture with tryptophan (TRP+; P<0.05).  
 
No time effect [F(3, 15) = 2.91; n.s.] or treatment effect [F(1, 5) = 0.00; n.s.] 
was found upon the 5-HT metabolite, 5-HIAA, in the hippocampus (Fig. 8C). 
In the prefrontal cortex, ATD changed the concentration 5-HIAA over time 
[F(3, 12) = 3.54, p<0.05, however, independent of treatment [F(3, 12) = 0.45; 
n.s.] and without an overall effect of ATD upon 5-HIAA levels. [F(1, 4) = 1.97; 
n.s.] (Fig. 8D). 
 The turnover rate of 5-HT (5-HIAA/5-HT) did not change over time in the 
hippocampus [F(3,3) = 5.98; n.s.] and no overall treatment effect was found 
[F(1, 1) = 0.28; n.s.] (Fig. 8E). The same was true for the prefrontal cortex, 
where no time effect [F(3, 9) = 0.88; n.s.] and no overall treatment effect [F(1, 
3) = 0.21; n.s.] upon the 5-HT turnover rate was found (Fig. 8F). 
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Figure 8 Brain concentrations (mean + S.E.M.) of 5-HT (hippocampus: A; prefrontal cortex: B), 
5-HIAA (hippocampus: C; prefrontal cortex: D) and the ratio 5-HIAA/5-HT (hippocampus: E; 
prefrontal cortex: F) at different time points (t) after treatment with 1x15 ml/kg (t20, t40, t60) or 
2x15 ml/kg (t240). No differences were found at any of the time points between the tryptophan-
free experimental mixture (TRP-) and the control mixture with tryptophan (TRP+). 
Study 5 Interfering effects of experimental stressors upon ATD pharmacokinetics 
One-way ANOVA revealed a significant overall effect (F(14, 72)=3.58, 
P<0.001) upon the ratio TRP/ΣLNAA in plasma. LSD post hoc testing 
allowed for multiple comparisons between the different experimental 
conditions, effects of which are shown in Fig. 9. 
Application effects  
The ratio TRP/ΣLNAA did not significantly decrease at t20 compared to 
baseline (P=0.23) in the group that was not food deprived overnight or orally 
treated by gavage. Moreover, no effect was observed of the blood sampling 
procedure, as no difference was found in the ratio TRP/ΣLNAA between the 
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group that underwent blood sampling for baseline measurements and the group 
that did not (P=0.32). At baseline, no differences were found between the food 
deprived group and the group that had access to food at all times (P=0.93), 
indicating that food deprivation alone does not directly affect the ratio 
TRP/ΣLNAA. In contrast to the group that was not food deprived, a 
significant decrease of the ratio was found at t20 compared to baseline (P<0.01) 
in the food deprived group without oral treatment, indicating that food 
deprivation and blood sampling together, significantly decreased the ratio 
TRP/ΣLNAA. A significant higher TRP/ΣLNAA ratio was found at t20 after 
blood sampling in the saline treated animals compared to the non-treated group 
(P<0.05), indicating that blood sampling and oral treatment by gavage together 
significantly increased the ratio TRP/ΣLNAA.  
 
 
Figure 9 The effects of oral administration by gavage, blood sampling, food deprivation and 
ATD upon the ratio TRP/ΣLNAA in plasma at baseline and 20 min after administration (mean 
+ S.E.M.). (*) Significant differences in the ratio TRP/ΣLNAA. * P<0.05, ** P<0.01. NO treat:: 
no oral application by gavage; FD: food deprivation; BS: blood sampling; t: time in min. TRP+: 
control mixture with tryptophan; TRP-: the tryptophan-free experimental mixture (TRP-).  
ATD effects 
No differences were found in the ratio TRP/ΣLNAA between baseline 
measurements prior to oral treatment with either saline, TRP+ or TRP-. Saline 
treatment did not affect the ratio TRP/ΣLNAA 20 min after administration 
compared to baseline (P=0.38) and no differences were found at t20 between 
the saline and TRP+ treated animals (P=0.17). A significant increase of the 
ratio TRP/ΣLNAA was found 20 min after administration of the TRP+ 
control mixture compared to baseline levels (P<0.05). The ratio TRP/ΣLNAA 
was significantly lower 20 min after ATD compared to TRP+ treatment 
(P<0.01) in the group that received a baseline blood sample. There was only a 
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tendency for a decrease in the ratio TRP/ΣLNAA (P=0.06) 20 min after ATD 
compared to TRP+ treatment in the group that did not undergo blood 
sampling for baseline measurements. 
Discussion 
Applying ATD in genetic mouse models of anxiety and depression would allow 
vulnerable 5-HT systems to be challenged, paralleling human conditions. The 
present study, therefore, aimed to introduce the established rat model of ATD 
to the mouse, specifically the C57BL/6 mouse since it is the background mouse 
strain used for all behavioural experiments in transgenic and knockout research 
(Gardier and Bourin, 2001). To the best of our knowledge, this is the first study 
to explore the acute pharmacokinetic and behavioural effects of various dosing 
regimes of a TRP-free diet in healthy C57BL/6 mice.  
 Reducing central 5-HT concentrations by lowering the levels of its dietary 
precursor TRP in plasma can be achieved by administration of specific TRP-
free nutritional mixtures. In comparison to the TRP-free or TRP-low balanced 
diets and pure amino acid mixtures without TRP, a more advanced technique 
nowadays is the oral administration of a gelatin-based protein-carbohydrate 
mixture (Blokland et al., 2004). By adding a specific amount of TRP to the 
control mixture, suppletion of peripheral TRP levels as often observed with 
traditional AA mixtures in humans (Fusar-Poli et al., 2006; Van der Does, 2001) 
is avoided, as is the potential misinterpretation of the ATD effects (Blokland et 
al., 2004). A double administration of 10 ml/kg (60 min interval) of this TRP-
free mixture in male adult Wistar rats resulted in a considerable depletion of the 
ratio TRP/ΣLNAA in plasma after the first administration compared to 
baseline levels (71% and 78% at 2 and 4 h, respectively; Lieben et al., 2004a). 
Moreover, with 0.28% (of the total protein amount) of additional TRP in the 
control mixture (TRP+), no differences were found between saline treatment 
and TRP+ treatment (Lieben et al., 2004a).  
 In the present study, the 2x10 ml/kg dosing regime as used in rats was 
initially adapted for application in mice by simply reducing the interval between 
administrations, thereby speculating upon the generally faster metabolism in 
mice compared to rats. Thus, optimal peripheral TRP reductions were expected 
to be within 2 h after the first administration of the TRP-free mixture. In Swiss 
mice, the 74% reduction of the ratio TRP/ΣLNAA found after 1 h (study 1) 
was similar to the amount of depletion observed in Wistar rats after 2 h; in 
contrast, 2 h after the first administration, the ratio TRP/ΣLNAA started to 
recover, corroborating our speculation of a faster metabolism in mice. 
However, only a 40% decrease was found in the C57BL/6 mice with the same 
dosing regime (study 2), although the C57BL/6 mouse recovery after 2h was 
slower which might be indicative of a relatively slower metabolism in these 
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mice compared to the Swiss. In addition, slightly higher baseline levels of 
peripheral TRP can be observed in the C57BL/6 mice, which, together with the 
apparently slower metabolism, could provide an explanation for the lack of 
considerable TRP depletion and the subsequent unaffected behaviour in these 
mice.  
 Although administration with the TRP-free mixture in the C57BL/6 mouse 
resulted in a significantly lower TRP/ΣLNAA ratio compared to the other 
treatments, a reduction of this ratio 2 h after the first administration was also 
observed after treatment with saline (-17%) and the TRP+ control mixture 
(-30%). This suggests that the control mixture contained too many LNAA 
compared to the amount of additional TRP (0.28%) and thus, was not 
appropriately balanced to result in an optimal ATD effect in the C57BL/6 
mouse strain, in contrast to the Swiss mouse. These discrepancies could be 
explained by underlying differences in serotonergic neurochemistry between 
mouse strains which is supported by strain-dependent responses to 
serotonergic antidepressants (Cervo et al., 2005; Crowley et al., 2005; David et 
al., 2003; Lucki et al., 2001). In line with this, higher whole-brain 5-HT 
concentrations have been reported in the C57BL/6 mouse compared to the 
Swiss (David et al., 2003), which might be attributed to strain differences in the 
activity of  tryptophan hydroxylase (TPH; Cervo et al., 2005), the enzyme that 
catalyzes the synthesis of TRP into 5-HT. 
 A considerable reduction of the ratio TRP/ΣLNAA was found in the 
C57BL/6 mice following an increase of the dosing volume to 15 or 20 ml/kg 
(study 3). However, doubling the amount of TRP added to the control mixture 
(from 0.28% to 0.56% of total protein amount) did not completely prevent a 
slight decrease of the ratio after TRP+ treatment. Yet, by increasing the interval 
between administrations (from 30 to 60 min) a minor recovery of the ratio was 
observed after 2 h. This indicates that a single administration of 15 or 20 ml/kg 
results in a maximum depletion of 70 and 73% compared to baseline, 
respectively. However, by administrating twice over a certain period of time, 
the duration of the depletion will be prolonged, which has also been reported in 
rat studies of similar experimental design (Jans et al., 2008b). A similar pattern 
was also observed in the Swiss mice (study 1) where the maximum depletion 
(-77%) was measured after a double administration of 20 ml/kg. 
 Despite the considerable reduction of the ratio TRP/ΣLNAA in plasma, no 
changes in central TRP levels or 5-HT concentrations were observed 2 h after 
the first administration with either dosing volume (study 3). The conversion of 
TRP to 5-hydroxytrpytophan by isoforms of the TPH enzyme is the first and 
rate-limiting step in the biosynthesis of 5-HT. In the brain, this enzyme is only 
50% saturated, thus, the rate at which 5-HT is synthesised is limited only by 
substrate, i.e., TRP, availability (Boadle-Biber, 1993). Although most rat studies 
have reported ATD-induced decreases in central TRP and/or 5-HT (Jans et al., 
2008a; Jans et al., 2007a; Lieben et al., 2004a; Olivier et al., 2008), the extent of 
reduction seems controversial between studies and generally do not parallel the 
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acute changes in peripheral TRP levels. Yet, 5-HT seems to be synthesized 
from TRP by a different isoform of TPH in the periphery (TPH1) compared to 
the brain (TPH2; Walther and Bader, 2003). This suggests that peripheral 5-HT 
is not coupled to central 5-HT function and that ATD-induced changes in 
peripheral TRP and 5-HT might simply not predict central TRP and 5-HT 
alterations. The results of a study upon the relationship between serotonergic 
measures in periphery and brain of 7 week-old mice corroborates this concept, 
as no significant associations were found between blood and brain 5-HT levels 
or blood TRP levels and brain 5-HT concentration, whereas TRP and 5-HT in 
the brain were strongly correlated (Pietraszek et al., 1992). However, at this age, 
the rodent brain is still in development and may therefore regulate amino acid 
transportation into the brain in a different way (Seta et al., 1972). In addition, 
cerebral uptake of amino acids is assumed to take longer time in adult mice 
(Battistin et al., 1971) compared to adult rats (Oldendorf, 1971). Yet, in the 
present study, no changes in central TRP and 5-HT parameters were found at 
any of the earlier or later time-points explored, whereas a moderate, though 
significant, ATD-induced reduction of the ratio TRP/ΣLNAA in plasma could 
already be observed after 20 min (study 4). 
 Previous studies have revealed that stress might be a critical factor in 
mediating alterations in the ratio TRP/ΣLNAA in plasma and subsequent 
changes in behavioural performance (Markus et al., 2000a; Markus, 2007; 
Markus et al., 2000b). Together with other monoamine systems, brain 5-HT is 
critically involved in the mediation of the central response to stressors and 
subsequent behavioural adaptation (de Kloet et al., 2005). Acute stressors 
stimulate the hypothalamic-pituitary-adrenal (HPA) activity, thereby increasing 
central 5-HT necessary for stress coping (van Praag, 2004). In rats, both acute 
and repeated exposure to stressful stimuli have been shown to increase 
glucocorticoid levels and alter 5-HT turnover and release in both the 
hippocampus and frontal cortex (Chaouloff, 1993). Activation of the 
sympathetic nervous system increases TRP availability, most probably due to an 
acute increase in TPH levels as demonstrated after a single exposure of 
immobilization stress in male Sprague Dawley rats (Chamas et al., 2004). 
Overnight food deprivation, oral gavage administrations, blood sampling and 
the immobilization necessary for applying the former can all be considered 
highly stressful, yet are experimental procedures inevitably implicated in the 
application of the ATD method. As such, they may interfere with normal brain 
TRP metabolism and subsequent 5-HT synthesis, thereby acting as 
confounding factors for the pharmacokinetic and behavioural effects of ATD. 
While in the present study no isolated effects of the aforementioned 
experimental stressors were observed, multiple stressors together significantly 
altered the ratio TRP/ΣLNAA in plasma within 20 min (study 5). Whereas a 
significant decrease was found after food deprivation together with blood 
sampling, oral treatment by gavage after blood sampling and food deprivation 
increased the ratio TRP/ΣLNAA 20 min after treatment. The latter 
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combination represents the standard experimental situation and this suggests 
that a profound depletion of peripheral TRP is more difficult to establish 
because of an initial increase in the ratio due to the acute stress of the 
experimental procedures. Similarly, at a central level the combination of 
immobilization stress and food deprivation has been reported to increase brain 
TRP levels in rats considerably more than either of the stressors alone (Curzon 
et al., 1972). As more 5-HT is needed to be able to cope with the acute stressful 
situation, brain TRP levels rise to maintain adequate 5-HT concentration. 
 Although the reduction in hippocampal 5-HIAA levels 2 h after 2x20 ml/kg 
TRP- treatment did not reach statistical significance, the ratio 5-HIAA/5-HT in 
this brain area was significantly reduced (study 3). Similar patterns of reduced 
5-HT turnover in the hippocampus without affecting an analogous effect in 
prefrontal cortex have also been observed after ATD in rats (Jans et al., 2008a). 
Changes in central 5-HIAA concentration and the ratio of 5-HIAA to 5-HT 
have been reported as valid indices of altered 5-HT metabolism (Shannon et al., 
1986) and are generally used in animal studies to estimate the rate of 5-HT 
turnover, which is though to reflect neuronal release. When dietary precursor 
manipulation is applied, a reduction in 5-HT metabolism is generally attributed 
to a decrease in precursor availability. The present results, however, do not 
support this, as no reduction in central TRP or 5-HT levels was observed, at 
least not in comparison with TRP+ or saline treatment. As in the present study, 
brain measurements are generally taken at one specific time point which 
impedes a comparison of the central parameters to baseline values. Therefore, 
any statement upon ATD-induced absolute changes in central 5-HT or 
5-HIAA concentrations and potential underlying mechanisms remain merely 
speculative.  
 The ATD-induced decrease in the ratio 5-HIAA/5-HT in the hippocampus 
can also not explain the reduction in total distance moved in this group as 
measured during the 6 min exploration in the EZM (study 3). Total distance 
quantifies overall locomotion (Crawley and Paylor, 1997) and could be used as 
preliminary indicator of anxiety.  A significant decrease in overall locomotion 
was observed in the mice treated with the TRP-free mixture in the highest 
volume (20 ml/kg) compared to both saline and the TRP- treated mice in the 
lower volume (15 ml/kg). However, no difference was observed between the 
TRP+ and TRP- treated animals and no higher anxiety pattern could be 
revealed from the differences between the groups on the total time spent in the 
closed parts of the maze. It may therefore be speculated that the reduction in 
total distance moved is the result of the high administration volume interfering 
with behavioural performance in which the saline administration would appear 
to be less invasive than the high caloric mixture of proteins and carbohydrates. 
As 20 ml/kg is the maximum volume that may be orally administered to mice 
(Hull, 1995), twice this volume, albeit with a certain interval, is most likely to 
compromise their performance on behavioural tasks. 
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Although the lack of affective behavioural changes in the present study may 
reflect the unaltered 5-HT concentrations in the hippocampus and prefrontal 
cortex, ATD-induced increased anxiety and depressive-like behaviour have not 
been straightforwardly reported in rats after significant central 5-HT reduction 
(Brown et al., 1998; Jans et al., 2008a; Lieben et al., 2004b). Only one study 
reported an increase in mean immobility time in rats after a moderate reduction 
(-34%) of peripheral TRP levels which correlated with a significant decrease of 
TRP in both the frontal cortex (-31%) and the hippocampus (39%) (Blokland 
et al., 2002). Yet, these reductions in TRP levels were induced by a pure TRP-
free amino acid mixture and FST assessment took place 5 h after ingestion of 
the mixture with mean immobility times calculated from assessments over 3 
consecutive days. Methodological differences of this kind impede outcome 
comparisons between studies of the same species and rule out further 
extrapolation to other species. An important observation is that mood-lowering 
effects after ATD are only reported by healthy subjects with pre-existing 
abnormal functioning of the 5-HT system (Booij et al., 2002; Booij et al., 2005; 
Moreno et al., 2000; Van der Does, 2001). ATD-induced anxiety and 
depressive-like behaviour may therefore only become apparent if the challenge 
is applied in an already vulnerable system rather than in “healthy” mice or rats.   
 In conclusion, ATD appears to be a useful tool to lower peripheral TRP 
concentrations in mice in a manner comparable to that seen in rats. However, 
to translate the method from one species to the other, fundamental changes are 
required which appear to go beyond simply reducing administration volumes. 
In mice, oral administration by gavage with the TRP-free protein-carbohydrate 
mixture succeeded in reducing peripheral TRP levels significantly to levels 
comparable to those normally observed in rats after ATD with the same 
nutritional mixture. Yet, the extent of TRP depletion seems to depend greatly 
upon the specificity of the dosing volumes and the time frame of the repeated 
administrations. Moreover, extreme differences were found in the acute 
pharmacokinetic effects of the nutritional mixture between the Swiss and 
C57BL/6 mouse strain, due to an apparently slower metabolism in general and 
higher baseline peripheral TRP levels in particular in the latter. Surprisingly, in 
contrast to the central ATD effects in rats, the significant reduction of 
peripheral TRP in the C57BL/6 mouse did not parallel changes in brain TRP 
concentrations and did not seem to affect 5-HT synthesis or metabolism. This 
might explain the lack of ATD-induced anxiety and depression-like behaviour, 
although both 5-HT synthesis reduction and affective behavioural changes have 
also been reported controversially after ATD in rats. The present results 
suggest that the various experimental procedures related to ATD application 
possibly interfere as confounding stressors with the expected decrease in 
central TRP and 5-HT metabolism after ATD under normal physiological 
conditions in the mouse. The results of the present studies have important 
implications for the use of the ATD method in general and in particular for its 
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application in mice. More research is needed in this respect, using mice with 
pre-existing 5-HT dysfunction, as they might be more vulnerable to ATD. 
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Abstract  
Acute tryptophan depletion (ATD) decreases the serotonin 
(5-hydroxytryptophan; 5-HT) precursor tryptophan (TRP) in blood 
and is used both clinically and pre-clinically to investigate the 
involvement of 5-HT in the development of depressive 
symptomatology. Depression is associated with both central 5-HT 
dysfunction and abnormalities in the normal relationship between 
regional cerebral blood flow (CBF) and glucose metabolism 
(CMRG). In this study, ATD was applied in Wistar rats to investigate 
the cerebrovascular effects of acute changes in peripheral TRP. CBF 
or CMRG were measured 4 h after ATD initiation by quantitative 
autoradiographic imaging in 43 brain regions of interest (ROI). In 
plasma, ATD resulted in a 40% reduction in the ratio of TRP to the 
sum of all other large neutral amino acids, but had no measurable 
effect upon TRP or 5-HT levels in hippocampus or prefrontal 
cortex. Nevertheless, ATD significantly reduced local CBF in 11 of 
the 43 brain ROIs, while local CMRG remained unchanged. Global 
analysis of all 43 ROIs revealed a close correlation between CBF and 
CMRG within both treatment groups. However, the overall ratio 
(=slope) after ATD (m=1.07) was significantly decreased compared 
to the control group (m=1.27), indicating a state of relative cerebral 
oligaemia. Since ATD induced a significant lowering of peripheral 
TRP, without affecting central TRP or 5-HT concentrations, the 
decrease in CBF and global change in flow-metabolism coupling 
cannot be directly attributed to decreases in brain TRP availability. 
Nevertheless, these data suggest that cerebrovascular disturbances 
should be considered as a potential contributory factor in studies of 
serotonergic dysfunction, including depression, with important 
implications for imaging studies that use CBF alone as a measure of 
neuronal function. 
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Introduction 
Many physiological and functional processes are regulated by the serotonergic 
system, including mood and cognition, and these are most prominently 
impaired in clinical depression (Leonard, 1997; Maes and Meltzer, 1995). Acute 
tryptophan depletion (ATD) is a non-toxic challenge that can be used for 
repeated manipulation of the central serotonergic system in vivo and is currently 
used, in both preclinical and clinical research, to investigate the involvement of 
the serotonergic system in the pathogenesis and pathophysiology of mood 
disorders (Bell et al., 2005; for review see: Fadda et al., 2000b; Hood et al., 
2005; Neumeister, 2003). To date, however, the exact mechanism by which 
ATD exerts its neurophysiological effects, and to what extent changes in 5-HT 
neuronal activity contribute to the ATD-induced functional and behavioural 
alterations, is not fully understood.   
 The procedure generally consists of reducing the concentration of the 
monoamine serotonin (5-hydroxytryptamine; 5-HT) by temporarily lowering 
the levels of its dietary precursor tryptophan (TRP) in plasma (Biggio et al., 
1974; Gessa et al., 1975). A large body of preclinical literature provides 
evidence that ATD significantly decreases the levels of TRP in plasma, resulting 
in substantial reductions of TRP and 5-HT metabolites in the brain  (e.g. Biggio 
et al., 1974; e.g. Blokland et al., 2002; Cahir et al., 2007; Gessa et al., 1974; Jans 
et al., 2007a; Lieben et al., 2004a; Olivier et al., 2008). However, actual 
decreases in extracellular 5-HT have only been reported after ATD in 
combination with blockade of 5-HT reuptake (Bel and Artigas, 1996; Fadda et 
al., 2000a; Stancampiano et al., 1997). Nevertheless, ATD clearly induces 
cognitive deficits in rats (Jans et al., 2007a; Lieben et al., 2004b; Rutten et al., 
2007; van Donkelaar et al., 2008), whereas, alterations in affective behavioural 
parameters are somewhat controversial (Blokland et al., 2002; Brown et al., 
1998; Lieben et al., 2004b).  
 For clinical research, ATD challenge has been proposed as a potential tool 
for predicting subjects at risk of a future depressive episode (Booij et al., 2002; 
Booij et al., 2005b; Jans et al., 2007b; Moreno et al., 2000a), since mood-
lowering effects have only been reported in healthy subjects predisposed to 
serotonergic vulnerability (e.g. Booij et al., 2002; Booij et al., 2003; Klaassen et 
al., 1999; Neumeister et al., 2002; Neumeister et al., 2006; Smith et al., 1997). 
Nevertheless, 5-HT metabolism seems substantially lowered after ATD 
(Carpenter et al., 1998; Moreno et al., 2000b; Williams et al., 1999) and in all 
sub-populations evenly. This might explain why ATD-induced cognitive 
deficits have been observed in both healthy and vulnerable subjects (Booij et 
al., 2005a; Evers et al., 2005; Klaassen et al., 2002; Riedel et al., 1999; Riedel, 
2004; Sambeth et al., 2007; Sambeth et al., 2009). Taken together, the 
implications of preclinical and clinical ATD-induced behavioural effects for 
depression research do not appear to be straightforward. 
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In line with the serotonergic hypothesis of depression (Maes and Meltzer, 
1995), ATD-induced behavioural changes are thought to reflect decreased 
5-HT neuronal activity in brain regions responsible for the specific behavioural 
output. Under normal physiological circumstances, neuronal activity is closely 
related to energy generation which is in turn closely coupled to cerebral blood 
flow (Kuschinsky, 1991; Sokoloff, 1981a). 5-HT has important vasoactive 
properties and may thus be involved in both the modulation of metabolic 
demand and the regulation of substrate delivery (Cohen et al., 1996; Kelly et al., 
1988; McBean et al., 1991; Nobler et al., 1999). Interestingly, reduced local 
cerebral blood flow (CBF) in the anterior cingulate and subgenual prefrontal 
cortex has been observed in healthy subjects after ATD (Talbot and Cooper, 
2006). 
 Neuroimaging studies of depressed subjects have revealed abnormal CBF 
and local glucose metabolism (CMRG) in those brain regions implicated in 
emotional processing and behaviour (Drevets, 2000, 2001; Soares and Mann, 
1997). Positron emission tomography (PET) studies of medicated remitted 
subjects found that ATD-induced cognitive impairment and depressive relapse 
were associated with decreased metabolism in the orbital frontal, cingulate and 
parietal cortices and caudate nucleus (Bremner et al., 1997; Smith et al., 1999). 
In contrast, in unmedicated remitted subjects, increased metabolism was found 
in similar regions (Neumeister et al., 2004). Additionally, there is some evidence 
that changes in the relationship between CMRG and CBF are found in 
depression (Drevets, 2000) and a close correlation has been suggested to exist 
between the degree of uncoupling and the severity of the depressive symptoms 
(Dunn et al., 2005). Whether this might also be induced by ATD, is not known 
 The purpose of the present study was, to measure CMRG and CBF in 
parallel groups of rats following ATD in order to examine both the neural 
response and cerebrovascular effects of the treatment. It was hypothesised that 
by lowering peripheral levels of the 5-HT precursor TRP, the flow-metabolism 
relationship might be affected by a reduction in serotonergic vasoconstrictor 
tone. Such an effect might call into question the validity of using CBF as an 
index of neuronal activity in human imaging studies of ATD effects in 
particular, but also perhaps clinical depression in general.  
Experimental procedures 
Animals 
A total of 23 male Wistar rats (Charles River, UK) was used in this study, with 
an average weight of 350 grams at the start of the experiments. Animals were 
group-housed under standard laboratory conditions in a temperature controlled 
colony room (21 ± 2ºC) and maintained on a 12:12-hr light-dark schedule 
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(lights on from 07:00 h - 19:00 h). Food and water were available ad libitum until 
the night before the experimental day.  
 All efforts were made to minimize the number of animals used and their 
suffering. Animal procedures were performed with local ethical approval from 
the University of Edinburgh Ethical Review Process, and in accordance with 
the United Kingdom Animals (Scientific Procedures) Act 1986 and associated 
national and international guidelines.  
ATD treatment 
Acute reduction of plasma tryptophan levels was achieved by oral application 
with a TRP-free protein-carbohydrate nutritional mixture. This gelatine-based 
protein nutritional mixture (Gelatine hydrolysate, Solugel®; PB Gelatins, 
Tessenderlo, Belgium) comprises the entire range of amino acids (see Table 1 
for amino acid composition) in the form of peptides, as found in normal food 
(Lieben et al., 2004a). The addition of carbohydrates (Glucodry 210; 
Amylumgroup, Koog aan de Zaan, The Netherlands) activates the insulin 
response, and the resulting increase in protein synthesis promotes an optimized 
reduction in plasma TRP levels (Fernstrom, 1986; Lieben et al., 2004a; Markus 
et al., 1998). Potassium chloride (KCl) and calcium chloride dihydrate 
(CaCl2.2H2O) were obtained from Merck (Darmstadt, Germany). For the 
control group, L-tryptophan (Sigma, Zwijndrecht, The Netherlands) was added 
in an amount equivalent to 0.28% of total protein content, as adapted from 
Lieben et al. (2004a). Mixtures were dissolved in distilled water and freshly 
prepared on the day of the experiment. The availability of TRP for synthesis 
into 5-HT in the brain is also heavily influenced by the intake of other large 
neutral amino acids (LNAA; leucine [LEU], isoleucine [ILE], tyrosine [TYR], 
valine [VAL] and phenylalaline [PHE]), since they all compete at the blood-
brain barrier for the same amino acid L-carrier transport system (Fernstrom 
and Wurtman, 1972; Fernstrom, 1983). Therefore, a decrease in the ratio of 
TRP to the sum of other LNAAs in plasma (TRP/ΣLNAA) is normally used as 
the best predictor of reduced central availability of TRP (Fernstrom, 1979, 
1983). 
 Surgical procedures were carried out as described elsewhere (Ferrington et 
al., 2006; Kelly et al., 1995; Quate et al., 2004). For the measurement of the 
effects of ATD upon local CBF and CMRG, animals were randomly assigned 
to one of the treatment groups. One hour following recovery from surgery, 
animals were orally dosed by gavage, twice with a 90 min interval (Lieben et al., 
2004a). Administration consisted of the nutritional mixture, with (TRP+ group) 
or without TRP (TRP- group), in a volume of 10 ml/kg. Each administration 
contained 4 g/kg bodyweight of Solugel® and 2 g/kg Glucodry. The availability 
of dietary TRP was reduced by removing food from the cages on the night 
before the experiments. Water was available at all times during the experiment.  
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Table 1 Composition of the protein-carbohydrate nutritional mixture and determination of the 
amino acid content (g/100 ml water) of the gelatine based protein (Solugel®) 
Substance Amount (g) 
100  Protein (Solugel®) in 100 ml water 
    Alanine 
    Arginine 
    Aspartic Acid 
    Cysteine 
    Glutamic Acid 
    Glycine 
    Histidine 
    Hydroxylysine 
    Hydroxyproline 
    Isoleucine 
    Leucine 
    Lysine 
    Methionine 
    Phenylalanine 
    Proline 
    Serine 
    Threonine 
    Tryptophan 
    Tyrosine 
    Valine 
 8.4 
7.7 
4.5 
0.0 
10.0 
23.3 
0.9 
1.5 
12.3 
1.2 
2.6 
3.3 
0.9 
1.6 
13.7 
3.4 
1.9 
0.0 
0.6 
2.2 
Carbohydrate (Glucodry 210) in 50 ml water 
KCL in 10 ml water 
CaCl2.2H2O in 10 ml water 
L-tryptophan (TRP+ group) 
L-tryptophan (TRP-  group) 
50 
  0.095 
  2.318 
  0.28 
  0 
 
 
The median point of integrated specific 2-deoxyglucose in the brain, from 
which CMRG is derived, is around 10-20 min after an intravenous bolus 
injection of the tracer (Sokoloff et al., 1977) and CBF studies were timed to 
coincide with this, as previously described (Ferrington et al., 2006; Kelly et al., 
1995; Quate et al., 2004). Other studies using the same nutritional mixture 
(Solugel®) and dosing regime (Cahir et al., 2008; Jans et al., 2007a; Jans et al., 
2008; Lieben et al., 2004a; van der Plasse et al., 2007) have reported significant 
decreases in both peripheral and central TRP concentrations in male Wistar 
rats, approximately 4 h after the first oral administration of the TRP-free 
nutritional mixture. Therefore, CMRG and CBF measurements were initiated at 
220 and 240 min after the first oral administration by gavage, respectively (see 
also Fig. 1 for an overview of the different phases of the experiment). Mean 
arterial blood pressure and rectal temperature were monitored throughout the 
entire experiment.  
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Figure 1 Schematic diagram of the different stages of the experiment. ATD: acute tryptophan 
depletion; p.o.: per os, oral administration by gavage; BS0: baseline blood sampling, BS1: blood 
sampling at the end of the experiment (t1), i.e. at either 240 (cerebral blood flow; CBF) or 265 
min (cerebral metabolic rate of glucose; CMRG) after p.o.1. 
Measurement of local CMRG 
A total of 12 animals (TRP+ n=6; TRP- n=6) was used for the measurement of 
CMRG, using the fully quantitative [14C]-2-deoxyglucose autoradiographic 
imaging technique described previously (Sokoloff, 1981b). At 220 min after the 
first oral administration of the nutritional mixture, an intravenous injection of 
[14C]-2-deoxyglucose (1.3 MBq per rat in 0.75 ml saline; Sigma-Aldrich, UK) 
was administered at a constant rate over the first 30 s of the experiment. Over 
the subsequent 45 min, a total of 14 timed arterial blood samples was collected 
at pre-determined intervals and centrifuged in order to separate the plasma. 
Aliquots (20 μl) of each plasma sample were taken for the determination of 
[14C] and glucose by liquid scintillation analysis (Packard, Tricarb 2900TL) and 
semiautomated glucose oxidase enzyme assay (Beckman). At 45 min, the 
animals were killed by rapid intravenous injection of sodium pentobarbitone 
and the brains were immediately dissected out and cut in two. One hemisphere 
(at random) was rapidly frozen in pre-cooled 2-methylbutane (-45ºC) and 
mounted onto specimen holders with embedding medium (Shanon M-1; 
Thermo Electron Corp., Pittsburgh, PA, USA) and stored at -80ºC until 
sectioned. The other hemisphere was processed for subsequent amino acid and 
5-HT determination. 
Measurement of local CBF 
Local cerebral blood flow was measured in a parallel group of a total of 11 rats 
(TRP+ n=4; TRP- n=7), using the quantitative [14C]-iodoantipyrine 
autoradiographic imaging technique described previously (Sakurada et al., 
1978). The [14C]-iodoantipyrine (1.5 MBq per rat in 0.6 ml saline; ARC (UK) 
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Ltd, Cardiff, UK) was infused intravenously at a constantly increasing rate over 
45 s, at the end of which the animals were killed by decapitation and the brains 
dissected out and prepared as for the CMRG experiments. During the 
measurement, a maximum of 18 timed arterial blood samples was collected 
onto pre-weighted filter paper discs from the free flowing femoral arterial 
cannula. Prior to preparation for liquid scintillation analyses, the discs were re-
weighed, and assuming a specific gravity of 1.01, the volume of each sample 
was calculated. 
Preparation and analysis of autoradiograms 
Semi-serial sections (20 μm) of the frozen cerebral hemispheres were cut in the 
coronal plane in a cryostat (-22ºC). A series of three sections were retained 
from every 200 μm, thaw mounted onto a glass coverslip and rapidly dried on a 
hot plate maintained at 75ºC. Autoradiograms were prepared by applying these 
sections to X-ray film (Kodak, SB-5), together with a series of eight pre-
calibrated standards of known [14C] concentration (40-1069 nCi/g tissue 
equivalents: Amersham International, U.K.). Films were stored in a light-tight 
cassette at 4ºC for 7 days after which they were developed according to the 
manufacturers instructions.  
 Analysis of the autoradiograms was performed using a computer-based 
image analysis system (MCID/M5+, Imaging Research Inc., St. Catherine’s, 
Ontario, Canada). The optical densities of autoradiographic images from the 
regions of interest were sampled using a measuring frame of set dimensions 
that were kept constant between animals. Local tissue isotope concentrations 
were derived from the optical density of autoradiographic brain images, relative 
to the [14C] standards, and CMRG and CBF were calculated from tissue [14C] 
concentrations and arterial tracer profiles using the appropriate operational 
equations (Sakurada et al., 1978; Sokoloff, 1981b). Measurements were made in 
a total of 43 anatomically distinct and functionally diverse brain regions 
identified with reference to a rat stereotaxic atlas (Paxinos and Watson, 1998) 
and an in-house manual (gift from professor James McCulloch) in which 
photographs of autoradiographic images generated from serial sections of rat 
brain are juxtaposed against plates from the atlas, and the exact positioning of 
the measurement frame for regions of interest is delineated.  
Blood collection and preparation for amino acid analysis 
Prior to the first gavage, a blood sample (BS) was taken for determination of 
baseline amino acid levels in plasma (BS0; t0) and a second blood sample (BS1; 
t1) was taken at the end of the experiment, immediately prior to sacrifice, i.e. at 
240 and 265 min after the first oral administration by gavage for the CBF and 
CMRG measurements, respectively. For each blood sample, approximately 300 
μl of venous blood was taken via the femoral cannulae and collected in sodium 
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heparin coated tubes (Microvette ® CB 300, Sarstedt, Germany). The sample 
tubes were kept on ice until centrifuged for 10 min (14,000 x g) in order to 
separate the plasma. Aliquots of plasma were removed and stored at -80 ºC for 
subsequent amino acid determination.  
 Immediately prior to analysis, plasma samples were thawed to 4 ºC and 
deproteinized in cups containing (17 μl of 5 mg/10 ml) dry 5-sulfosalicylic acid 
(SSA; Merck, Darmstadt, Germany). Samples were vigorously vortex-mixed and 
then centrifuged for 10 min (50,000 x g). From the clear supernatant a 20 μl 
aliquot was mixed with 1960 μl distilled water to which 20 μl norvaline had 
been added, and stored in a temperature-maintained (7 ºC) sample 
compartment until high-performance liquid chromatography (HPLC) analysis. 
Brain tissue collection and preparation for amino acid and 5-HT analysis 
From the brain hemispheres collected at the end of the CBF and CMRG 
measurements, prefrontal cortex and hippocampus were dissected out onto dry 
ice and immediately stored at -80ºC.  For central amino acid determination, the 
frozen brain structures were transferred into pre-weighed 2 ml screw-lid cups 
and exact tissue weight was determined with an analytic balance. Approximately 
0.3 g of glass beads (1 mm diameter) were added to the cup together with ice-
cold 150 mΜ H3PO4 and 500 μΜ diethylene triamine pentaacetic acid. 
Samples were aerated with Argon and homogenized in a mini-bead beater set at 
high speed for 30 s. After a subsequent 3 min spin (4000 x g at 4ºC), the 
homogenate was transferred back into an eppendorf vial and centrifuged for a 
further 20 min (35,000 x g at 4ºC). The resulting supernatant was filtered 
through Millipore Ultrafree-MC filter cups for 1-2 hr (9000 x g at 4ºC). Finally, 
15 μl of 2 mM ascorbic acid was added to further protect against oxidative 
degradation processes, after which the samples were stored at -80ºC until 
HPLC analyses. 
 Plasma and brain amino acid concentrations were quantified using a fully 
automated HPLC system after precolumn derivatization with 
o-phthaldialdehyde (Domek-Lopacinska and Strosznajder; van Eijk et al., 1993). 
Fluorescence detection was used to quantify OPA-AA derivates of the amino 
acids. Central concentrations of 5-HT and the 5-HT metabolite 
(5-hydroxyindoleacetic acid; 5-HIAA) in hippocampus and prefrontal cortex 
were quantified at a later stage in the remaining supernatant by automated 
HPLC with dual electrochemical detection. The concentrations of total plasma 
and central amino acid concentrations were expressed as μmol/l, brain 
concentrations as ng/mg. 
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Statistical analysis 
All data are represented as mean ± standard error of the mean (S.E.M.) and 
unless otherwise stated, data sets were evaluated statistically using unpaired 
Student’s t-test. In all cases, acceptable levels of significance were set at P<0.05. 
 Differences between TRP+ and TRP- treatment groups and time effects (t0 
versus t1, of which the latter is the mean of 240 and 265 min measurements) 
within treatment groups were statistically evaluated for all absolute plasma 
LNAA concentrations as well as arginine (ARG) and citrulline (CIT). The 
plasma ratio TRP/ΣLNAA was calculated and expressed as percentage change 
from its corresponding baseline value. Central amino acid concentrations, 5-HT 
and 5-HIAA levels including 5-HT turnover rate were analyzed for 
hippocampus and prefrontal cortex separately. Extreme values in the plasma 
and brain biochemical data were calculated by means of Dixon’s Extremity test 
(Dixon, 1959) and excluded from statistical analysis. Analyses were performed 
using the Statistical Package for Social Science (SPSS) for Windows 
(Rel.12.0.1.2003, Chicago: SPSS Inc.). 
 Statistical analyses of local CBF and CMRG data were performed by 
Student’s t-test with acceptable levels of significance set at P<0.05. To provide 
an initial assessment of differences between treatment groups in the 
relationship of local CBF to local CMRG in each of 43 regions of interest 
(ROI) included in this study, the ratios of mean local CBF to mean local 
CMRG derived from each structure were analysed by Mann-Whitney U test 
using the curve fitting program GraphPad Prism, version 4.02 for Windows 
(GraphPad Software, San Diego California USA). More rigorous statistical 
analysis of the relationship was performed by repeated measures analysis of 
variance on the log transform of the data sets (McCulloch et al., 1982) using the 
BMDP/PC90 computerized statistical package (program 2V) (Jennrich et al., 
1990). In this analysis, “type of variable” was designated the grouping factor, 
and “brain region” was designated the repeated measures trial factor. While the 
experimental design was insufficient to allow a full multivariate profile analysis, 
inter-regional differences in the magnitude of the ratio of local CBF to local 
CMRG could be examined using an Univariate approach (Ford et al., 1991; 
Geiser and Greenhouse, 1958). 
Results 
Physiological parameters 
There were no significant differences in physiological parameters, either 
between treatment groups, within treatment groups (before and after 
treatment), or between animals with similar treatments used for either CBF or 
CMRG experiments. In particular, there were no significant differences in 
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plasma glucose levels between the groups of rats before treatment (8.7 ± 0.7 
mmol.L-1 and 8.6 ± 0.8 mmol.L-1 in TRP- and TRP+ groups, respectively) or at 
the time of the final experiment (8.9 ± 1.4 mmol.L-1 and 8.9 ± 1.8 mmol.L-1 in 
TRP- and TRP+ groups, respectively), and these remained steady throughout 
the measurement periods. 
Plasma amino acid concentrations 
Plasma levels of the LNAAs, as well as ARG and CIT were measured both 
prior to the first oral administration (baseline; t0) and at the end of the 
experiment (t1). Since no difference was found between either the plasma or 
brain biochemical results at t1 = 240 min (CBF) and at t1 = 265 min (CMRG) 
after the first oral administration, data were pooled to increase statistical power.  
 At baseline, no differences were observed in the LNAA concentrations 
between the subsequent treatment groups (Table 2). At the end of the 
experimental period (t1), the concentration of TRP was found to be 
significantly reduced (-33%) from baseline levels in the TRP- group [t(23) = 
3.723; P<0.01] and was also significantly lower (-38%) compared to the TRP+ 
group [t(21) = 5.317; P<0.01].  
Table 2 Absolute plasma amino acid (AA) concentrations in the two treatment groups (mean ± 
S.E.M. in μmol/l) at baseline (t0) and at the end of the experiments (t1) (pooled for CBF and 
CMRG experiments; TRP+; n=10, TRP-; n=9). 
Amino acid Baseline (t0) End of experiment (t1) 
 TRP+ TRP- TRP+ TRP- 
TRP   57 ± 3   54 ± 4   58 ± 3    36 ± 2*, a  
TYR   74 ± 5   71 ± 5   74 ± 6    69 ± 3 
PHE   65 ± 2   64 ± 2   92 ± 2a       89 ± 2a      
VAL 186 ± 9 187 ± 6 229 ± 10a  237 ± 8a      
ILE 100 ± 5 104 ± 4   88 ± 2a       88 ± 3a      
LEU 133 ± 6 140 ± 6 154 ± 4a     156 ± 6  
ARG 157 ± 10 177 ± 8 163 ± 10 155 ± 6 
CIT   70 ± 2   68 ± 2   84 ± 3a       79 ± 6a      
(*) indicates significant difference in AA concentration between the TRP+ and TRP- group. (a) 
indicates significant change over time (*, a) P<0.05. TRP: tryptophan, TYR: tyrosine, PHE: 
phenylalanine, VAL: valine, ILE: isoleucine, LEU: leucine, ARG: arginine, CIT: citrulline.  
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Some of the other AAs included in the analyses (PHE, VAL and CIT) were 
found to be significantly increased at t1 when compared to t0 in both treatment 
groups, while a significant increase in LEU was found only in the TRP+ 
treatment group. Significant decreases in ILE between t0 and t1 were found in 
both TRP+ and TRP- treatment groups (Table 2), but the reductions (-12% 
and -15%, respectively) were less marked than the treatment effects on TRP 
levels.  
 
Analysis of data in the form of ratios between TRP in plasma to the sum of all 
LNAAs with which TRP competes for transport across the blood-brain barrier 
(TRP/ΣLNAA) revealed a significant decrease (-40%; Fig. 2) from baseline in 
the TRP- group [t(20) = 4.534; P<0.01]. A decrease in the ratio TRP/ΣLNAA 
from baseline levels was also found following TRP+ treatment, but this was 
considerably smaller in magnitude (-8%) and was not significant [t(22) = 2.033; 
n.s.].  
 
 
Figure 2 Percentage change of the ratio TRP/ΣLNAA in plasma compared to baseline levels 
(mean + S.E.M.), 240-265 min after the first oral administration with the protein-carbohydrate 
nutritional mixture with (TRP+; n=10) or without TRP (TRP-; n=9). (*) significantly different 
from TRP+ group, (a) significantly different over time (**, aa) P<0.01 
Brain amino acids, 5-HT and 5-HIAA concentrations  
Despite there being significant reductions in plasma TRP following ATD, no 
significant differences in TRP levels were found in either hippocampus [t(8) = 
0.156; n.s.] or prefrontal cortex [t(11) = 0.935; n.s.] in the TRP- treatment 
group when compared to TRP+ controls (Table 3). In general, none of the 
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AAs appeared to be centrally affected by ATD, except for CIT where in the 
TRP- group, a significant decrease (-17%) was found in hippocampal CIT levels 
when compared to the TRP+ group [t(11) = 2.198; P=0.05].  In line with the 
unaltered brain TRP levels, no differences were found in 5-HT concentrations 
in hippocampus [t(9) = 0.505 ; n.s.] or prefrontal cortex [t(8) = 0.245; n.s.] after 
ATD compared to the TRP+ control group and also no ATD-induced changes 
were detected in 5-HIAA levels in hippocampus [t(11) = 0.354; n.s.] or 
prefrontal cortex [t(11) = 0.377; n.s.] (Table 3).  
Table 3 Absolute central amino acid (AA) concentrations and central 5-HT, 5-HIAA and 5-HT 
turnover (mean ± S.E.M. in ng/mg) 240-265 min (t1; pooled for CBF and CMRG experiments) 
after the first oral administration with the protein-carbohydrate nutritional mixture with (TRP+; 
n=10) or without TRP (TRP-; n=9) in rat hippocampus and prefrontal cortex. 
 Hippocampus Prefrontal cortex 
 TRP+ TRP- TRP+ TRP- 
TRP    22 ± 0.5    22 ± 0.7    22 ± 1.1    20 ± 1.4 
TYR    13 ± 0.6    13 ± 1.1    13 ± 1    13 ± 0.8 
PHE    19 ± 0.6    19 ± 0.4    20 ± 0.9    19 ± 0.7 
VAL    17 ± 0.6    15 ± 1.2    17 ± 1.8    16 ± 0.6 
ILE    11 ± 0.8    11 ± 0.5    11 ± 0.7    11 ± 0.7 
LEU    14 ± 0.8    12 ± 0.2    15 ± 0.7    14 ± 0.7 
ARG    35 ± 3.7    29 ± 3.4    21 ± 2    28 ± 4.8 
CIT    12 ± 0.8    10 ± 0.4*      9 ± 0.6      7 ± 1.3 
5-HT 0.30 ± 0.04 0.28 ± 0.01 0.23 ± 0.03 0.22 ± 0.02 
5-HIAA 0.27 ± 0.04 0.24 ± 0.05 0.26 ± 0.03 0.24 ± 0.05 
5-HT turnover 0.95 ± 0.09 0.90 ± 0.23 1.27 ± 0.09 1.04 ± 0.16 
(*) indicates significant difference in AA concentration between the TRP+ and TRP- group 
(P<0.05). TRP: tryptophan, TYR: tyrosine, PHE: phenylalanine, VAL: valine, ILE: isoleucine, 
LEU: leucine, ARG: arginine, CIT: citrulline, 5-HT: 5-hydroxytryptamine, 5-HIAA: 5-
hydroxyindoleacetic acid and 5-HT turnover: 5-HIAA/5-HT 
Local cerebral metabolic rate of glucose 
Although ATD produced a tendency towards decreased CMRG in the majority 
of the 43 brain ROIs analysed, none of them were statistically significant (Table 
4).  
Local cerebral blood flow 
ATD induced generalised decrease in CBF when compared to the TRP+ 
treatment group, and in 11 of the 43 brain areas analysed these decreases were 
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statistically significant (Table 4). Decreases in CBF were found throughout the 
hippocampal formation (molecular layer, -26%; dentate PO, -22%; dorsal CA1, 
-25%; CA2, -26%; CA3, -26%), but elsewhere in the brain CBF was also 
decreased in the globus pallidus, (-27%), lateral amygdala (-17%), ventrolateral 
thalamic nucleus (-22%), ventral tegmental area (-26%), and entorhinal cortex 
(-21%). The most profound decrease in CBF was measured in temperoparietal 
cortex (-40%) (Table 4). 
Table 4 Local cerebral metabolic rate of glucose (CMRG, μmol/100g/min) and local cerebral 
blood flow (CBF, ml/100g/min) 265 and 240 min, respectively, after the first oral administration 
with the protein-carbohydrate nutritional mixture with (TRP+; n=6 and n=4 for CMRG and 
CBF, respectively) or without TRP (TRP-; n=6 and n=7 for CMRG and CBF, respectively). Data 
are presented as mean ± S.E.M. The flow-metabolism coupling ratio (CBF/CMRG) was 
calculated from mean values for each brain area. 
Brain regions CMRG  CBF  Ratio 
CBF/CRMG 
 TRP+ 
(n=6) 
TRP- 
(n=6) 
TRP+ 
(n=4) 
TRP- 
(n=7) 
TRP+ 
 
TRP- 
 
Frontal cortex 106 ± 12   98 ± 5 109 ± 16   89 ± 8 1.03 0.91 
Orbital frontal cortex 142 ± 16 134 ± 8 168 ± 18 143 ± 13 1.18 1.06 
Dorsal medial prefrontal cortex   75 ± 8   76 ± 3   95 ± 10   78 ± 7 1.26 1.03 
Ventral medial prefrontal cortex 109 ± 12 109 ± 7 125 ± 16   99 ± 14 1.15 0.91 
Nucleus accumbens   88 ± 9   84 ± 3 121 ± 14 104 ± 9 1.38 1.24 
Corpus callosum   22 ± 3   19 ± 7   33 ± 5   28 ± 1 1.52 1.47 
Somatosensory cortex 119 ± 10 113 ± 6 151 ± 29 114 ± 7 1.27 1.01 
Anterior cingulate cortex   99 ± 10   98 ± 5 117 ± 17   95 ± 7 1.18 0.97 
Septal nucleus   61 ± 7   55 ± 4   74 ± 11   66 ± 4 1.21 1.20 
Medial striatum   94 ± 9   92 ± 6   99 ± 13   87 ± 4 1.06 0.95 
Lateral striatum 106 ± 11 106 ± 5 111 ± 14   95 ± 5 1.05 0.90 
Bed nucleus of striae terminalis   46 ± 5   45 ± 4   56 ± 5   48 ± 3 1.22 1.06 
Globus pallidus   54 ± 7   50 ± 3   65 ± 7   47 ± 3*↓ 1.21 0.95 
Antero ventral thalamic nucleus 105 ± 11   97 ± 12 133 ± 9 109 ± 8 1.27 1.12 
Antero hypothalamic nucleus   53 ± 7   58 ± 9   74 ± 9   62 ± 5 1.38 1.08 
Tempero parietal cortex 114 ± 11 109 ± 5 202 ± 32 121 ± 8*↓ 1.77 1.11 
Ventral lateral hypothalamic nucleus   62 ± 7   52 ± 3   82 ± 5   70 ± 5 1.34 1.35 
Medial thalamic nucleus 100 ± 8   95 ± 3 127 ± 15 109 ± 8 1.27 1.14 
Ventral lateral thalamic nucleus   88 ± 9   83 ± 4 128 ± 11 100 ± 6*↓ 1.45 1.20 
Medial amygdala   84 ± 10   79 ± 5 101 ± 7   80 ± 6 1.20 1.01 
Lateral amygdala   52 ± 5   49 ± 2   79 ± 4   66 ± 3*↓ 1.52 1.35 
Posterior cingulate cortex 105 ± 10   94 ± 5 126 ± 15 100 ± 8 1.20 1.07 
Lateral habenula 116 ± 15 108 ± 6 155 ± 21 121 ± 10 1.33 1.12 
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Brain regions CMRG  CBF  Ratio 
CBF/CRMG 
 TRP+ 
(n=6) 
TRP- 
(n=6) 
TRP+ 
(n=4) 
TRP- 
(n=7) 
TRP+ 
 
TRP- 
 
Subthalamic nucleus   84 ± 7   87 ± 3 149 ± 19 117 ± 7 1.78 1.35 
Mamillary body 110 ± 12   96 ± 9 141 ± 17 129 ± 19 1.29 1.34 
Piriform cortex   67 ± 8   60 ± 3   89 ± 8   73 ± 5 1.33 1.22 
Entorhinal cortex   69 ± 9   62 ± 2   81 ± 7   64 ± 4*↓ 1.17 1.02 
Molecular layer   90 ± 12   84 ± 5 114 ± 9   84 ± 6*↓ 1.27 1.01 
Dorsal subiculum   87 ± 9   86 ± 5   95 ± 7   82 ± 6 1.10 0.95 
Dentate PO   56 ± 7   55 ± 4   81 ± 7   63 ± 3*↓ 1.44 1.15 
Dorsal CA1   67 ± 9   61 ± 5   83 ± 8   62 ± 4*↓ 1.24 1.02 
CA2   65 ± 10   66 ± 5 105 ± 8   77 ± 6*↓ 1.60 1.17 
Ventral CA1   75 ± 10   64 ± 4 112 ± 4   93 ± 9 1.50 1.47 
Ventral subiculum   69 ± 7   64 ± 3 106 ± 11   92 ± 7 1.53 1.43 
CA3   71 ± 9   70 ± 3 103 ± 7   76 ± 3*↓ 1.44 1.09 
Ventral tegmental area   63 ± 9   61 ± 6   78 ± 7   58 ± 3*↓ 1.24 0.95 
Substantia nigra reticulata   59 ± 6   54 ± 3   80 ± 6   70 ± 4 1.35 1.29 
Substantia nigra compacta   76 ± 10   72 ± 4   93 ± 4   80 ± 4 1.22 1.11 
Dorsal raphe   74 ± 9   80 ± 6 106 ± 15   95 ± 12 1.44 1.19 
Median raphe   83 ± 8   75 ± 9 119 ± 28 109 ± 11 1.44 1.45 
Paramedian raphe   71 ± 11   64 ± 7   96 ± 23 106 ± 11 1.36 1.65 
Inferior colliculus 203 ± 26 178 ± 5 282 ± 62 229 ± 12 1.39 1.28 
Locus coeruleus   77 ± 9   64 ± 4 112 ± 29   83 ± 4 1.44 1.30 
Mean ratio     1.33 1.15* 
(*) indicates significant decreases in CBF after ATD compared to TRP+ control treatment * 
P<0.05. A significant decrease in the overall ratio was found after ATD compared to the TRP+ 
control group. 
Relationship between CBF and CMRG 
Decreases in CBF in response to ATD in the absence of any changes of similar 
magnitude in CMRG (Table 4), had marked effects upon the flow-metabolism 
coupling relationship normally found in the brain. In TRP+ control rats, there 
was clearly an association between CBF and mean CMRG in the brain as a 
whole (r = 0.93) and the overall ratio between blood flow and glucose use, as 
illustrated by the slope of the best-fitting straight line, was 1.27 (Fig. 3). In 
those animals treated with ATD, the relationship between CBF and CMRG 
remained largely intact (r = 0.91) (Fig. 3), although the slope of the line defining 
the overall relationship (m=1.07) was lower than in the control group (Fig. 3) 
and indicated a degree of tissue oligaemia. Examining the brain areas 
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individually, the flow-metabolism ratio was found to decrease in all but 4 of the 
43 brain areas in ATD-treated rats (Table 4), and over the brain as a whole 
analyses of the ratios (Mann-Whitney U-test) indicated a significant decrease in 
the ATD group (mean ratio = 1.15) when compared to controls (mean ratio = 
1.33). 
 
 
Figure 3 The relationship between local cerebral blood flow (CBF) and local cerebral metabolic 
rate of glucose (CMRG) using data generated from all 43 brain regions of interest after ATD and 
TRP+ treatment. Data points represent mean CBF and CMRG for each region together with the 
best fitting straight line defined by y = mx + c, where x and y are the variables (CMRG and CBF, 
respectively), m = the slope of the line and c = the intercept. 
Discussion 
The conversion of the essential amino acid TRP to 5-hydroxytrpytophan by 
isoforms of the enzyme tryptophan hydroxylase is the first step in the 
biosynthesis of 5-HT. In the brain, this enzyme is only 50% saturated, and 
therefore the rate at which 5-HT is synthesised is limited only by substrate 
(TRP) availability. The ATD challenge method is thus a relatively easy 
procedure with which to rapidly and reversibly decrease circulating TRP 
concentrations, and thereby decrease substrate availability for synthesis into 
5-HT both peripherally and in the brain. Previous rat studies of similar 
experimental design to that used here, including the same nutritional mixture 
(Cahir et al., 2008; Jans et al., 2007a; Lieben et al., 2004a), found profound 
decreases in the ratio TRP/ΣLNAA in plasma following ATD in Wistar rats 4 
h after the first administration, ranging from -60% to -78%. However, less 
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robust central effects were reported ranging from -17% (non-significant) to 
-66% in hippocampus and -20% (non-significant) to -70% in frontal cortex. 
Moreover, even where significant effects were found in brain tissue, the 
response was often variable, with coefficients of variation in some instances 
approaching 50%. 
 In the present study, we induced an acute depletion of plasma TRP levels in 
exactly the same way as reported previously, by administering 10 ml/kg, twice 
with a 90 min interval, of a TRP-free protein-carbohydrate nutritional mixture. 
Around 4 h after the first oral administration, this treatment resulted in a 
significant 40% decrease in the plasma TRP/ΣLNAA ratio from baseline levels, 
which compares favourably to the 8% decrease in the TRP+ treated control 
group. It remains unclear why only a moderate reduction in peripheral TRP was 
found in the present study. Most of the significant peripheral changes of other 
amino acids over time in both treatment groups, as well as the slight reduction 
in the TRP/ΣLNAA ratio after TRP+ treatment, are likely to be attributed to 
the boost of specific amino acids following administration of the nutritional 
mixture. However, in the present study the ATD treatment did not have any 
significant effect upon TRP and 5-HT levels in either hippocampal or 
prefrontal cortical tissue. Also the 5-HIAA concentrations remained unaffected 
after ATD. This is perhaps not surprising given that more pronounced 
decreases in plasma TRP/ΣLNAA ratios reported previously failed to induce 
consistent inter-study effects in these two brain areas. Further analysis of brain 
tissue revealed that ATD had no significant effect upon other central amino 
acid concentration, with the exception of CIT where a decrease in hippocampal 
CIT concentration was found only in the TRP- group. A similar decrease in the 
central concentrations of CIT following ATD have also been observed 
previously by others Lieben et al. (2004a), and given that ARG is catalysed into 
CIT and nitric oxide (NO) (Dawson and Dawson, 1996), it has been proposed 
that decreases in CIT might parallel decreases in NO synthesis (NOS) and that 
such a mechanism might underlie the effects that ATD has upon memory 
processing (Prast and Philippu, 2001), and could also influence cerebral blood 
vessels (Kelly et al., 1994).   
 Under normal physiological conditions, the rate of glucose metabolism in 
the brain provides an index of changes in regional neuronal activity and 
changes in glucose metabolism are found to be closely coupled to changes in 
CBF (Kuschinsky, 1991; Sokoloff, 1981a). On this basis, abnormalities in either 
of these closely linked neurophysiological parameters in depressive subjects are 
thought to reflect changes in 5-HT neurotransmission in brain areas that can be 
functionally linked to the complexity of depressive symptomatology displayed 
(Drevets et al., 1998a, 1998b; Drevets et al., 1999; Drevets, 2000). Certainly in 
animal studies, acute pharmacological manipulations of central 5-HT systems 
have previously been found to induce alterations in glucose utilization (Grasby 
et al., 1992; Kelly et al., 1988), but changes in CBF are not always found to be 
directly related, either quantitatively or qualitatively, to changes in underlying 
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metabolic demand (Quate et al., 2004). This uncoupling has been attributed to 
the fact that 5-HT possesses potent vasoactive properties (Edvinsson and 
MacKenzie, 1976) and 5-HT fibers have been identified innervating cerebral 
arteries, arterioles and veins (Steinbusch, 1981). Thus, there is the potential for 
5-HT to play an important role in the regulation and modulation of 
haemodynamic processes, independent of underlying metabolism, through 
vasoconstriction of cerebral blood vessels and consequent decreases in blood 
flow (Bonvento et al., 1991; Cohen et al., 1996; Kelly et al., 1988; McBean et al., 
1991). 
 Although it was anticipated that depletion of 5-HT by ATD might alter 
neuronal function and metabolic activity in the brain, the absence of any 
changes in CMRG in the TRP- group is certainly in keeping with the lack of 
treatment-induced change in central 5-HT in this study. In contrast, the ATD 
treatment produced significant effects upon CBF, notably in hippocampus and 
cortex which were the areas used for TRP analysis. In these areas, significant 
decreases in CBF were measured, indicating either an increase in constrictor 
tone or loss of dilator tone, rather than the loss of serotonergic constrictor that 
might have been expected following ATD. Interestingly, decreases in CBF after 
ATD have also been found in the dorsal anterior cingulate cortex of healthy 
human subjects, which has been attributed to differential effects of reduced 
5-HT upon ventral and dorsal neural systems (Talbot and Cooper, 2006). A 
similar mechanism could be responsible for the effects on CBF found in this 
study, and if ATD was more effective at reducing the availability of 5-HT at 
serotonergic synapses in the raphe than at projection terminals, the resultant 
disinhibition of raphe neurons would increase cerebrovascular constrictor tone 
and produce the reductions in CBF that were in fact measured. Given the small 
mass of raphe tissue, it would be difficult to verify if such mechanisms were in 
action, although perhaps electrophysiological analysis of raphe function 
following ATD might provide some further insides. Alternatively, the decreases 
in CBF could be explained by a loss of dilator tone, as found for example when 
either endothelial or neuronal NOS is inhibited (Kelly et al., 1994; Kelly et al., 
1995). The involvement of NO might be suggested by the changes in brain 
levels of CIT as described earlier, but whatever the underlying mechanism, the 
decreases in CBF in this study following ATD treatment in the absence of a 
qualitatively similar change in CMRG, represents a state of cerebral oligaemia 
with significant downwards resetting of mean flow-metabolism ratios (from 
1.33 to 1.15).  
 While considerable evidence exists for ATD-induced decreased central 
5-HT availability in both human subjects (e.g. Carpenter et al., 1998; Williams et 
al., 1999) and animals (e.g. Biggio et al., 1974; Lieben et al., 2004a; Moja et al., 
1989), the extent to which a decrease in 5-HT synthesis results in disturbed 
5-HT neuronal activity remains unclear. An actual reduction of extracellular 
5-HT after ATD has only been reported in combination with 5-HT reuptake 
inhibitors (Bel and Artigas, 1996; Fadda et al., 2000b; Stancampiano et al., 
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1997). It is suggested that the use of 5-HT reuptake blockade is necessary to 
raise 5-HT to optimal levels for detection. It might also suggest, however, that 
in the absence of de novo synthesis, 5-HT function can be largely maintained 
from transmitter being recycled into the presynaptic cell from the synapse. 
Furthermore, it appears that basal 5-HT release in the prefrontal cortex of rats 
is not affected by ATD (van der Plasse et al., 2007). In line with this, the results 
of the present study indicate that the underlying mechanism of the ATD 
method possibly goes beyond a straightforward alteration in 5-HT activity.  
 In the present study, the acute decrease of peripheral TRP levels resulted in 
a downwards resetting of the flow-metabolism coupling relationship in the 
brain, as indicated by the decrease in the mean ratio of metabolism to blood 
flow over all brain areas. This parallels preliminary findings of an uncoupling of 
flow from metabolism in unipolar depressed patients compared to bipolar 
patients and healthy controls (Dunn et al., 2005). However, controversy exists 
about the exact location and direction of the neurophysiological abnormalities 
in depressive subjects (Drevets, 2000; Soares and Mann, 1997), although 
depressive illness is generally characterized by decreases in cerebral blood flow 
and glucose metabolism in limbic and prefrontal cortex structures. As outlined 
previously though, it seems unlikely that a decrease in 5-HT alone accounts for 
the specific decreases in haemodynamic regulation, which also supports the 
notion that depression in general cannot be simplistically described as a plain 
serotonergic dysfunctional disorder.   
 In summary, despite the extensive use of the ATD method in depression 
research, the exact mechanism through which ATD exerts its 
neurophysiological effect is still poorly understood. Consequently, to what 
extent the ATD induced functional and behavioural alterations can be directly 
attributed to changes in 5-HT neuronal activity remains uncertain. In the 
present study, the ATD-induced decrease in peripheral TRP levels resulted in a 
resetting of the normal relationship between local CBF and CMRG, indicating a 
state of relative cerebral oligaemia, without affecting central TRP levels.  
Therefore, a more additive role for a dysfunctional 5-HT system as an 
underlying mechanism of the ATD method might be implied. Additionally, 
cerebrovascular dysfunction might be a potential contributory factor underlying 
the onset of depressive symptomatology, including cognitive deficiencies. More 
generally, whereas the precise direction of flow- metabolism coupling 
alterations in depression remains uncertain, the results of the present study 
have important implications for imaging studies that use CBF alone as a 
measure of neuronal function. 
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Abstract 
Although 3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’) 
is known to cause significant serotonergic terminal depletion, reports 
of depressive symptomatology after repeated recreational use of the 
drug are controversially. Both depression and MDMA abuse are 
associated with disturbed serotonin (5-hydroxytryptamine; 5-HT) 
metabolism and cerebrovascular abnormalities. In the present study, 
the effects of repeated MDMA pretreatment were measured upon 
local cerebral blood flow (CBF) and cerebral metabolic rate of 
glucose (CMRG) in male Wistar rats after an acute tryptophan 
depletion (ATD) challenge. Three weeks prior to oral administration 
of a nutritional mixture without tryptophan (TRP), animals were 
repeatedly treated with MDMA. Subsequently, the effects of ATD 
upon CBF and CMRG were measured in 43 brain areas using [14C]-
iodoantipyrine and [14C]-2-deoxyglucose quantitative autoradiog-
raphy, respectively. MDMA induced significant 5-HT neurotoxicity 
and ATD resulted in a mean 40% reduction of the ratio TRP/sum 
large neutral amino acids in plasma. Global analysis of all brain 
regions revealed a close CBF:CMRG correlation in all groups and a 
downwards resetting of the relationship of CBF to CMRG was only 
observed after ATD treatment in the drug-naïve control animals. 
This actually indicates that ATD induced a significant upwards 
resetting of this relationship after MDMA pretreatment compared to 
controls. These results suggest that ATD produces a degree of 
cerebrovascular hyperperfusion in animals pretreated with MDMA 
which could indicate a predisposition to cerebrovascular accidents, in 
particular haemorrhagic stroke. Moreover, it is tempting to speculate 
that changes in CBF might contribute to the behavioural dysfunction 
of depression, which remains to be further elucidated. 
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Introduction 
3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) is a semisynthetic 
entactogen of the phenethylamine family (Nichols and Oberlender, 1990). 
Acute administration of the psychoactive amphetamine analogue induces a 
rapid and excessive release of the monoamines norepinephrine (NE), serotonin 
(5-hydroxytryptamine; 5-HT) and dopamine (DA), of which the latter two are 
thought to be responsible for its simultaneous hallucinogen-like (serotonergic) 
and stimulant-like (dopaminergic) effects in humans. The increase in 
extracellular levels of the monoamines is subsequently maintained and even 
prolonged due to the inhibition by MDMA of monoaminergic reuptake 
mechanisms and the monoamine oxidase (MAO) enzyme. In rats and non-
human primates, repeated administration or high-dose MDMA deactivates the 
enzyme tryptophan hydroxylase (TPH), thereby inhibiting 5-HT synthesis 
(Stone et al., 1987). The resulting long-lasting depletion of brain 5-HT causes 
serious neurotoxicity in the axon terminals of 5-HT neurons (Baumann et al., 
2007; Green et al., 2003; Ricaurte et al., 2000), eventually causing a selective loss 
of 5-HT nerve terminals (Commins et al., 1987; O'Hearn et al., 1988). This 
5-HT axon terminal degeneration is reflected in a considerable and persistent 
decrease in 5-HT transporter (SERT) binding sites (Battaglia et al., 1987; 
Schmidt, 1987). 
  Despite the persistent MDMA-induced neurotoxicity, functional 
impairments in laboratory animals do not parallel the supposed irreversible 
consequences of the principle alterations in the 5-HT system. This is, however, 
in keeping with the observation that neurotoxic MDMA exposure rarely causes 
persistent changes in baseline measures of neural function (Baumann et al., 
2007), which in turn might explain why long-term effects reported upon brain 
functioning in human subjects remain controversial (Guillot, 2007). Any 
functional deficit might, therefore, remain at a sub-clinical level and only 
become apparent as a result of challenges to the 5-HT system. Thus, systemic 
pharmacological challenges of the 5-HT system have been shown to effectively 
unmask consequences of MDMA-induced toxicity and additionally provide 
more insight into its underlying mechanisms (Taffe et al., 2002).  
 Acute tryptophan depletion (ATD) is a non-pharmacological tool that 
indirectly challenges the 5-HT system by lowering the plasma levels of its 
dietary precursor TRP (Bell et al., 2005; for review see: Fadda, 2000; Hood et 
al., 2005; Neumeister, 2003). Currently, the method represents the most well 
established human challenge test to investigate the involvement of the 5-HT 
system in the pathogenesis and pathophysiology of depression. Moreover, ATD 
has been proposed as a potential tool for predicting subjects at risk of a future 
depressive episode, as mood-lowering effects have only been reported in 
healthy subjects with pre-existing abnormal 5-HT functioning (Booij et al., 
2002; Booij et al., 2005; Moreno et al., 2000; Van der Does, 2001). The method 
is non-toxic and thus reversible, thereby allowing the manipulation of the 
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central 5-HT system in vivo repeatedly and the assessment of the functional 
effects of an acute change in 5-HT metabolism in the brain (Fadda et al., 
2000b). In human subjects with a history of MDMA abuse, ATD-induced 
altered TRP metabolism has been associated with persistent memory 
impairments (Curran and Verheyden, 2003) and altered sensitivity to ATD was 
found in rhesus monkeys exposed to neurotoxic doses of MDMA (Taffe et al., 
2003).  
 The present study was conducted to investigate possible persistent effects of 
repeated MDMA administration upon both neuronal and cerebrovascular 
function in adult brain that might be manifested in altered sensitivity to an 
acute challenge of the 5-HT system. Therefore, the effects of repeated MDMA 
pretreatment upon local CBF and CMRG were measured in parallel groups of 
male Wistar rats under an ATD challenged condition, thereby investigating the 
relationship between cerebrovascular function and 5-HT changes in general and 
MDMA-induced serotonergic dysfunction as a vulnerability factor for 
depression and cognitive dysfunction in particular.   
Experimental procedures 
Animals 
The principles of laboratory animal care were followed throughout all 
experiments with particular attention paid to minimizing the number of animals 
used. All animal procedures were performed with local ethical approval and in 
accordance with the United Kingdom Animals (Scientific Procedures) Act, 
1986 and associated guidelines. A total of 44 male Wistar rats weighing between 
150 and 200g at the outset were used in this study. Animals were group-housed 
under a 12-hour light/dark cycle (lights on from 07:00 h - 19:00 h) with access 
to food and water ad libitum until the night before the experiment. Room 
temperature in the animal house was maintained at 21 ± 2ºC. 
MDMA pretreatment 
Three weeks prior to the experimental procedures, 21 animals were taken at 
random from the colony and pretreated with 20 mg.kg-1 of MDMA ((±)-3,4-
methylenedioxymethamphetamine hydrochloride (Ultrafine Ltd., Manchester, 
U.K.), twice daily (9:00 AM and 5:00 PM), for 4 consecutive days (2 x 4 x 20 
mg.kg-1 i.p.). The remaining group of animals (n=23) served as control group. 
MDMA was dissolved in saline and animals injected with a dose equivalent to 
15 mg.kg-1 free base in a volume of 1 ml.kg-1. This specific dosing regime has 
previously been shown to result in significant decreases of 5-HT, 5-HIAA and 
5-HT uptake sites, reflecting a neurotoxicity that is specific to serotonergic 
systems, which are still in evidence after 6 months (Battaglia et al., 1988).  
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Acute tryptophan depletion 
As in previous studies by our group, acute reduction of plasma tryptophan 
levels was achieved by means of oral administration by gavage of a TRP-free 
protein-carbohydrate nutritional mixture. (Gelatine hydrolysate, Solugel®; PB 
Gelatins, Tessenderlo, Belgium; for amino acid composition see: van Donkelaar 
et al., 2008). Carbohydrates (Glucodry 210; Amylumgroup, Koog aan de Zaan, 
The Netherlands) were added to the nutritional mixture to activate the insulin 
response. A sudden rise in insulin increases protein synthesis, thereby 
promoting an optimized reduction in plasma TRP levels (Fernstrom, 1986; 
Lieben et al., 2004a; Markus et al., 1998). Since TRP competes at the blood-
brain barrier with the other large neutral amino acids (LNAAs; leucine [LEU], 
isoleucine [ILE], phenylalaline [PHE], tyrosine [TYR], valine [VAL]) for the 
same amino acid L-carrier transport system (Fernstrom and Wurtman, 1972; 
Fernstrom, 1983), a decrease of the ratio of TRP to the sum of the other 
LNAAs in plasma (TRP/ΣLNAA) is normally used as the best predictor of 
reduced central availability of TRP (Fernstrom, 1979, 1983).  
 Potassium chloride (KCl) and calcium chloride dihydrate (CaCl2.2H2O) 
were obtained from Merck (Darmstadt, Germany). For the control group, 
L-tryptophan (Sigma, Zwijndrecht, The Netherlands) was added in an amount 
equivalent to 0.28% of total protein content, as adapted from Lieben et al. 
(2004a). Mixtures were dissolved in distilled water and freshly prepared on the 
day of the experiment.  
 For the measurement of the effects of MDMA pretreatment and ATD 
upon local CBF and CMRG, animals were randomly assigned to the TRP- or 
TRP+ treatment groups. Surgical procedures to allow the fully quantitative 
measurement of CBF and CMRG were carried out as described elsewhere 
(Ferrington et al., 2006; Kelly et al., 1995; Quate et al., 2004). One hour 
following recovery from surgery, animals were orally dosed by gavage, and 
again after a 90 min interval (Lieben et al., 2004a). The oral dosing consisted of 
the nutritional mixture, either with (TRP+ group) or without TRP (TRP- 
group), in a volume of 10 ml/kg. Each administration contained 4 g/kg 
bodyweight of Solugel® and 2 g/kg Glucodry. The availability of dietary TRP 
was reduced by removing food from the cages on the night before the 
experiments. Water was available at all times during the experiments.  
 Previous studies using the same nutritional mixture (Solugel®) and dosing 
regime (Cahir et al., 2007; Jans et al., 2007; Jans et al., 2008b; Lieben et al., 
2004a; van der Plasse et al., 2007) have reported significant decreases in both 
peripheral and central TRP concentrations in male Wistar rats, approximately 4 
h after the first oral administration of the TRP-free nutritional mixture. The 
measurements of CMRG and CBF were initiated at 220 and 240 min 
respectively after the first oral administration by gavage. The median point of 
integrated specific 2-deoxyglucose in the brain, from which CMRG is derived, 
is around 10-20 min after an intravenous bolus injection of the tracer (Sokoloff 
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et al., 1977) and CBF studies were timed to coincide with this, as previously 
described (Ferrington et al., 2006; Kelly et al., 1995; Quate et al., 2004).. Mean 
arterial blood pressure and rectal temperature were monitored throughout the 
entire experiment.   
Measurement of local CMRG 
A total of 10 MDMA pretreated animals (TRP+ n=4; TRP- n=6) and 12 
control animals (TRP+ n=6; TRP- n=6) were used for the measurement of 
CMRG, using the fully quantitative [14C]-2-deoxyglucose autoradiographic 
imaging technique described previously (Sokoloff, 1981). At 220 min after the 
first oral administration of the nutritional mixture, an intravenous injection of 
[14C]-2-deoxyglucose (1.3 MBq per rat in 0.75 ml saline; Sigma-Aldrich, UK) 
was administered at a constant rate over the first 30 s of the experiment. Over 
the subsequent 45 min, a total of 14 timed arterial blood samples were collected 
at pre-determined intervals and centrifuged in order to separate the plasma. 
Aliquots (20 μl) of each plasma sample were taken for the determination of 
[14C] and glucose by liquid scintillation analysis (Packard, Tricarb 2900TL) and 
semiautomated glucose oxidase enzyme assay (Beckman), respectively. At 45 
min, the animals were killed by rapid intravenous injection of sodium 
pentobarbitone and the brains were immediately dissected out and cut in two. 
One hemisphere (at random) was rapidly frozen in pre-cooled 2-methylbutane 
(-45ºC), mounted onto specimen holders with embedding medium (Shanon 
M-1; Thermo Electron Corp., Pittsburgh, PA, USA) and stored at -80ºC until 
sectioned. The other hemisphere was processed for subsequent amino acid and 
5-HT determination. 
Measurement of local CBF 
Local cerebral blood flow was measured in a parallel group of animals. A total 
of 11 (TRP+ n=5; TRP- n=6) MDMA pretreated and 11 control rats (TRP+ 
n=4; TRP- n=7) were used, using the quantitative [14C]-iodoantipyrine 
autoradiographic imaging technique described previously (Sakurada et al., 
1978). The [14C]-iodoantipyrine (1.5 MBq per rat in 0.6 ml saline; ARC (UK) 
Ltd, Cardiff, UK) was infused intravenously at a constantly increasing rate over 
45 s, at the end of which the animals were killed by decapitation and the brains 
dissected out and prepared as for the CMRG experiments. During the 
measurement, a maximum of 18 timed arterial blood samples were collected 
onto pre-weighed filter paper discs from the freely flowing femoral arterial 
cannula. Prior to preparation for liquid scintillation analysis, the discs were re-
weighed, and assuming a specific gravity of 1.05, the volume of each sample 
was calculated. 
Thesis_Donkelaar_v8.pdf   111 30-7-2009   15:08:00
Chapter 4 
 112 
Preparation and analysis of autoradiograms 
Semi-serial sections (20 μm) of the frozen cerebral hemispheres were cut in the 
coronal plane in a cryostat (-22ºC). A series of three sections were retained 
from every 200 μm, thaw mounted onto a glass coverslip and rapidly dried on a 
hot plate maintained at 75ºC. Autoradiograms were prepared by applying these 
sections to X-ray film (Kodak, SB-5), together with a series of eight pre-
calibrated standards of known [14C] concentration (40-1069 nCi/g tissue 
equivalents: Amersham International, U.K.). Films were stored in a light-tight 
cassette at 4ºC for 7 days after which they were developed according to the 
manufacturers instructions.  
Analysis of the autoradiograms was performed using a computer-based 
image analysis system (MCID/M5+). Local tissue isotope concentrations were 
derived from the optical density of autoradiographic brain images relative to the 
[14C] standards, and CMRG and CBF were calculated from tissue [14C] 
concentrations and arterial tracer profiles using the appropriate operational 
equations. Measurements were made in a total of 43 anatomically distinct and 
functionally diverse brain regions identified with reference to a rat stereotaxic 
atlas (Paxinos and Watson, 1998). 
Determination of serotonergic lesion 
Three weeks after the repeated MDMA dosing regime, 5-HT terminal depletion 
was determined by radioligand binding autoradiography of [3H]-paroxetine 
binding to 5-HT transporter sites as described by De Souza and Kuyatt (1987a). 
These transporter sites are localized to 5-HT terminals and MDMA-induced 
long-term reductions in radioligand binding have been shown to correlate with 
anatomical evidence of terminal depletion (Battaglia et al., 1987). Sections at 5 
different levels throughout the brain of MDMA-pretreated and control animals 
were thaw-mounted onto gelatin covered glass slides and stored at -80oC for 
subsequent [3H]-paroxetine autoradiographic binding analysis of 5-HT uptake 
sites. Procedures were carried out according to the protocol described by De 
Souza and Kuyatt (1987a), with the addition of two 5 minute prewashes in 
buffer (50mM TRIS-HCl, 120mM NaCl, 5mM KCl, pH = 7.7 at 23oC) to 
remove [14C]-tracers from the tissue (De Souza and Kuyatt, 1987b; Sharkey et 
al., 1991b). Sections were then incubated in the same buffer containing a 
saturating concentration (250pM) of [3H]-paroxetine (specific activity 23.1 
Ci/mmol; New England Nuclear). Non-specific binding was defined in 
adjacent sections by [3H]-paroxetine binding in the presence of 4µM citalopram 
(Tocris Bioscience, Bristol, UK). Following incubation, the sections were 
washed in buffer, dipped in deionised water and rapidly dried under a stream of 
cold air. The slides, together with a set of [3H]-containing standards (Amersham 
Microscales) were apposed to x-ray film (Amersham Hyperfilm) in a light-tight 
cassette and stored at -80oC for 4-6 weeks. Films were further processed 
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according to the manufacture's instructions and analysis of the autoradiographic 
images was performed as described above. In this case, local tissue isotope 
concentrations were derived from the optical density of the images relative to 
appropriate [3H]- containing standards. Radioligand binding was subsequently 
calculated from the tissue concentrations and the specific activity of the 
[3H]-paroxetine.  
Blood collection and preparation for amino acid analysis 
Prior to the first gavage, a blood sample (BS) was taken for determination of 
baseline amino acid levels in plasma (BS0; t0) and a second blood sample (BS1; 
t1) was taken at the end of the experiment, immediately prior to sacrifice, i.e. at 
240 and 265 min after the first oral administration by gavage for the CBF and 
CMRG measurements, respectively. For each blood sample, approximately 300 
μl of venous blood was withdrawn via the femoral cannula and collected in 
sodium heparin coated tubes (Microvette ® CB 300, Sarstedt, Germany). The 
sample tubes were kept on ice until centrifuged for 10 min (14,000 x g) in order 
to separate the plasma. Aliquots of plasma were removed and stored at -80 ºC 
for subsequent amino acid determination.  
 Immediately prior to analysis, plasma samples were thawed to 4 ºC and 
deproteinized in cups containing (17 μl of 0.5 mg.ml-1) dry 5-sulfosalicylic acid 
(SSA; Merck, Darmstadt, Germany). Samples were vigorously vortex-mixed and 
then centrifuged for 10 min (50,000 x g). From the clear supernatant a 20 μl 
aliquot was mixed with 1960 μl distilled water to which 20 μl norvaline had 
been added, and stored in a temperature-maintained (7 ºC) sample 
compartment until high-performance liquid chromatography (HPLC) analysis. 
Brain tissue collection and preparation for amino acid and 5-HT analysis 
From the brain hemispheres collected at the end of the CBF and CMRG 
measurements, prefrontal cortex and hippocampus were dissected out onto dry 
ice before storage at -80ºC.  For central amino acid determination, the frozen 
brain tissue samples were transferred into pre-weighed 2 ml screw-lid cups and 
exact tissue weight was determined with an analytical balance. Approximately 
0.3 g of glass beads (1 mm diameter) were added to the cup together with ice-
cold 150 mΜ H3PO4 and 500 μΜ diethylene triamine pentaacetic acid. Samples 
were aerated with Argon and homogenized in a mini-bead beater set at high 
speed (3 x 30 s with cooling in between runs). After a subsequent 3 min spin 
(4000 x g at 4ºC), the homogenate was transferred back into an Eppendorf vial 
and centrifuged for a further 20 min (35,000 x g at 4ºC). The resulting 
supernatant was filtered through Millipore Ultrafree-MC filter cups for 1-2 hr 
(9000 x g at 4ºC). Finally, 15 μl of 2 mM ascorbic acid was added to further 
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protect against oxidative degradation processes, after which the samples were 
stored at -80ºC until HPLC analyses. 
 Plasma and brain amino acid concentrations were quantified using a fully 
automated HPLC system after pre-column derivatization with 
o-phthaldialdehyde (Domek-Lopacinska and Strosznajder; van Eijk et al., 1993). 
Fluorescence detection was used to quantify OPA-AA derivates of the amino 
acids. Central concentrations of 5-HT and the 5-HT metabolite 
(5-hydroxyindoleacetic acid; 5-HIAA) in hippocampus and prefrontal cortex 
were quantified in the remaining supernatant at a later stage by automated 
HPLC with dual electrochemical detection. The concentrations of total plasma 
and central amino acid concentrations were expressed as μmol.L-1, and brain 
concentrations as ng.mg-1. 
Statistical analysis 
The mean concentrations of all absolute plasma LNAAs, were determined 
separately for each experimental condition and each time-point and 
TRP/ΣLNAA ratios were calculated accordingly. Plasma amino acid 
concentrations were measured both prior to the first oral administration 
(baseline; t0) and at the end of the experiments (t1). Since no differences were 
found in both the MDMA pretreatment group and the control group between 
either plasma or brain biochemical results at t1 = 240 min (CBF) and at t1 = 
265 min (CMRG) after the first oral administration, data in each group were 
pooled to increase statistical power.  
 Changes in the ratio TRP/ΣLNAA over time were analyzed by means of 
repeated measures analysis of variance (ANOVA) with Pretreatment and ATD 
Treatment as between-subject factors and Time as within-subject variable. To 
further analyze pretreatment and ATD treatment effects, two-way ANOVAs 
were performed for each time-point separately. Central TRP, 5-HT, 5-HIAA 
concentrations and the 5-HT turnover (5-HIAA/5-HT), were analyzed for 
hippocampus and prefrontal cortex separately by means of two-way ANOVA 
with Pretreatment and ATD Treatment as between subject factors. Post hoc 
testing with Bonferroni correction was used wherever appropriate. Extreme 
values in the plasma and brain biochemical data were calculated using Dixon’s 
Extremity test (Dixon, 1959) and excluded from statistical analysis. Analyses 
were performed using the Statistical Package for Social Science (SPSS) for 
Windows (Rel.12.0.1.2003, Chicago: SPSS Inc.). 
 Local CBF and CMRG data were analyzed by two-way ANOVA with 
Pretreatment and ATD treatment as between subject factors. To provide an 
initial assessment of differences between treatment groups in the relationship of 
local CBF to local CMRG in each of 43 regions of interest (ROI) included in 
this study, the ratios of mean local CBF to mean local CMRG derived from 
each structure were analyzed by Mann-Whitney U test using the curve fitting 
program GraphPad Prism, version 4.02 for Windows (GraphPad Software, San 
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Diego California USA). More rigorous statistical analysis of the relationship was 
performed by repeated measures ANOVA on the log transform of the data sets 
(McCulloch et al., 1982) with Measurement (CBF or CMRG) as the between-
subject factor, and “brain region” as within-subject variable. This analysis was 
performed using the BMDP/PC90 computerized statistical package (program 
2V) (Jennrich et al., 1990). While the experimental design was insufficient to 
allow a full multivariate profile analysis, inter-regional differences in the 
magnitude of the ratio of local CBF to local CMRG could be examined using 
an Univariate approach (Ford et al., 1991; Geiser and Greenhouse, 1958). 
 Data from radioligand binding were analyzed using unpaired Student’s t-test 
for grouped data. All data are represented as mean ± standard error of the 
mean (S.E.M.) and acceptable levels of significance were set at P<0.05.  
Results 
Physiological parameters 
There were no significant differences in physiological parameters, either 
between pretreatment and ATD treatment groups, within ATD treatment 
groups (before and after treatment), or between animals with similar treatments 
used for either CBF or CMRG experiments. In particular, there were no 
significant differences in plasma glucose levels between the MDMA 
pretreatment group and control animals (1.45 ± 0.16 mg.ml-1 and 1.48 ± 0.12 
mg.ml-1) or within the groups before ATD treatment (1.49 ± 0.16 mg.ml-1 and 
1.52 ± 0.13 mg.ml-1 in TRP- and TRP+ groups, respectively) or at the end of 
the experiment (1.51 ± 0.21 mg.ml-1 and 1.49 ± 0.17 mg.ml-1 in TRP- and 
TRP+ groups, respectively). Thus, plasma glucose levels remained steady 
throughout the measurement periods. 
Plasma amino acid concentrations  
The TRP/ΣLNAA ratio in plasma (Fig. 1) significantly decreased over time 
[F(1, 37) = 58.82, P<0.001] depending upon TRP- or TRP+ treatment 
condition [F(1, 37) = 28.27, P<0.001]. A significant ATD treatment effect 
indicated that the TRP/ΣLNAA ratio was lower after TRP- compared to 
TRP+ control treatment [ATD treatment: F(1, 37) = 13.40, P<0.01]. In 
general, higher TRP/ΣLNAA levels were found in the MDMA pretreated 
group [Pretreatment: F(1, 37) = 7.58, P<0.01] after both TRP- and TRP+ 
treatment [F(1, 37) = 0.66, n.s.]. Separate analysis per time-point revealed no 
group differences at baseline (t0) [F(1, 44) = 1.25, n.s.]. At t1, the ratio 
TRP/ΣLNAA was significantly lower after ATD compared to TRP+ control 
treatment [F(1, 40) = 44.27, P<0.01] and post hoc analyses revealed that this 
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decrease was found in both pretreatment conditions (MDMA pretreatment 
-37%, controls: -40%). At this time-point, the levels of the ratio TRP/ΣLNAA 
were significantly higher after MDMA pretreatment compared to the control 
pretreatment condition [F(1, 40) = 44.27, P<0.01], however, post hoc analyses 
revealed that this was only the case in the TRP+ group. Thus, MDMA pre-
treatment does not alter the effect of ATD upon the ratio TRP/ΣLNAA in 
plasma. 
 
 
Figure 1 The effect of ATD (TRP-) upon the ratio TRP/ΣLNAA in plasma (mean + S.E.M.) at 
baseline (t0) and 240-265 min after the first oral administration (t1), 3 weeks after repeated 
MDMA pretreatment compared to control animals. (*) significantly different from TRP+ control 
treatment; (#) significantly different from control pretreatment condition; (a) significantly 
different over time (*, #, a) P<0.05. 
Brain TRP 
ATD did not affect the TRP levels (Fig. 2A) in the hippocampus [F(1, 18) = 
0.04, n.s.], yet  TRP concentrations appeared to be generally higher in the 
MDMA pretreatment group [F(1, 18) = 178.41, P<0.001]. This main effect of 
Pretreatment would appear to be independent of ATD treatment condition, as 
no Pretreatment x ATD Treatment interaction was found [F(1, 18) = 0.070, 
n.s.]. As in the hippocampus, ATD did not alter the TRP levels in the 
prefrontal cortex [F(1, 33) = 1.48, n.s.]. However, in contrast to the 
pretreatment effect in the hippocampus, lower TRP levels in the prefrontal 
cortex were found in the MDMA pretreatment group [F(1, 33) = 52.67, 
P<0.001], independent of ATD treatment [F(1, 33) = 0.54, n.s.]. 
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Brain 5-HT 
ATD did not affect 5-HT concentrations (Fig. 2B) in the hippocampus [F(1, 
17) = 1.45, n.s.]. However, the concentrations were significantly lower in 
MDMA pretreated animals [F(1, 17) = 186.93, P<0.001] after both TRP- and 
TRP+ treatment [F(1, 17) = 0.334, n.s.]. In the prefrontal cortex, 5-HT levels 
appeared higher after ATD compared to TRP+ treatment, although no main 
effect of ATD Treatment was found [F(1, 26) = 0.62, n.s.]. As in the 
hippocampus, lower 5-HT concentrations were found in the MDMA pretreated 
animals [F(1, 26) = 40.51, P<0.001], again independent of ATD treatment 
condition [F(1, 26) = 1.20, n.s.].  
Brain 5-HIAA 
No main effect of ATD Treatment upon 5-HIAA levels (Fig. 2C) was found in 
the hippocampus [F(1, 20) = 0.31, n.s.]. In the MDMA pretreated animals, the 
concentration of 5-HIAA was higher compared to the control animals [F(1, 20) 
= 14.79, P<0.01]. This Pretreatment effect may be supposed to be independent 
of ATD treatment as no Pretreatment x ATD treatment interaction was found 
[F(1, 20) = 0.34, n.s.]. However, post hoc analyses revealed that higher 
hippocampal 5-HIAA concentrations in MDMA pretreated animals were only 
found after TRP- treatment, not after TRP+ control treatment. In the 
prefrontal cortex, ATD did not alter the 5-HIAA concentrations [F(1, 33) = 
0.01, n.s.]. Moreover, the concentrations appeared to be similar in both 
pretreatment conditions [F(1, 33) = 0.16, n.s.], independent of ATD treatment 
[F(1, 33) = 0.48, n.s.]. 
5-HT turnover 
ATD did not affect the 5-HIAA/5-HT ratio (Fig. 2D) in hippocampus [F(1, 
17) = 0.05, n.s.], however, 5-HT turnover appeared to be much higher in 
MDMA pretreated animals compared to controls [F(1, 17) = 13.17, P<0.01], 
independent of ATD treatment [F(1, 17) = 0.05, n.s.]. A similar pattern was 
found in the prefrontal cortex, with no main effect of ATD Treatment [F(1, 20 
= 0.06, n.s.], a significantly higher ratio in the MDMA pretreated group [F(1, 
20) = 8.38, P<0.01], and no Pretreatment x ATD Treatment interaction [F(1, 
20) = 0.05, n.s.].  
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Figure 2 The effect of ATD upon central concentrations of, (A) TRP, (B) 5-HT and (C) 5-HIAA 
and (D) 5-HT turnover in hippocampus and prefrontal cortex (mean + S.E.M.), 240-265 min 
after the first oral administration (t1), 3 weeks after repeated MDMA pretreatment compared to 
control animals. (#) significantly different from control pretreatment condition. (#) P<0.05.  
Radioligand binding 
Three weeks after the repeated MDMA administration regime [3H]-Paroxetine 
binding to 5-HT transporter sites in frontal cortex was significantly reduced 
(-45%) compared to control animals [t(6) = 3.39; P<0.05]. A 57% reduction 
was found in the dorsal medial prefrontal cortex [t(6) = 2.53; P<0.05] while the 
greatest reductions (-96%) were found in the anterior cingulate cortex [t(9) = 
4.26; P<0.05]. Hippocampal subfields were also significantly affected, with an 
86% decrease in binding found in CA1 [t(9) = 4.86; P<0.05], a 92% decrease in 
CA2 [t(9) = 5.89; P<0.05] and a 79% decrease in CA3 regions [t(9) = 5.17; 
P<0.05]. No significant changes in binding were found in the entorhinal cortex 
or dentate gyrus, and the dorsal, median and paramedian raphe also remained 
unaffected by the repeated MDMA administration regime (Fig. 3). 
Local cerebral metabolic rate of glucose 
A significant main effect of MDMA Pretreatment upon local CMRG was 
observed in 12 out of the 43 ROIs analyzed (Table 1). In three areas, the dorsal 
medial prefrontal cortex, bed nucleus of the striae terminals and the lateral 
amygdala this was due to increased CMRG in MDMA pretreated animals 
compared to controls. In the other nine brain areas, however, the main effect 
of Pretreatment was the result of decreases in CMRG. In both cases (increases 
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or decreases) the MDMA Pretreatment effects were not altered by subsequent 
ATD treatment and in general, no significant main effect of ATD Treatment 
upon CMRG was found.   
 
 
Figure 3 [3H]-Paroxetine binding (mean + S.E.M.), 3 weeks after repeated MDMA pretreatment 
(n=5) compared to saline control rats (n=6). Data represent the [3H]-paroxetine specific binding 
Bmax (fmol/mg tissue) measured in each of the different brain areas. (*) P<0.05; significant 
decrease from control animals.  
Table 1 Local cerebral metabolic rate of glucose (CMRG, μmol/100g/min) at t1 after TRP+ 
treatment or ATD (TRP-) in MDMA pretreated and control rats. Data are represented as mean ± 
S.E.M.  
Brain regions CMRG    Two-way ANOVA 
 control  MDMA  P values 
 TRP+ TRP- TRP+ TRP- Pretreat ATD Interaction 
Frontal cortex 106 ± 12   98 ± 5   93 ± 3   91 ± 7    
Orbital frontal cortex 142 ± 16 134 ± 8 123 ± 2 113 ± 4    
Dorsal medial prefrontal cortex   75 ± 8   76 ± 3 103 ± 3   96 ± 10 0.01   
Ventral medial prefrontal cortex 109 ± 12 109 ± 7   77 ± 3   73 ± 6 0.00   
Nucleus accumbens   88 ± 9   84 ± 3   86 ± 3   92 ± 6    
Corpus callosum   22 ± 3   19 ± 7   24 ± 1   24 ± 3    
Somatosensory cortex 119 ± 10 113 ± 6   90 ± 2   99 ± 7 0.02   
Anterior cingulate cortex   99 ± 10   98 ± 5   91 ± 3   89 ± 7    
Septal nucleus   61 ± 7   55 ± 4   59 ± 6   59 ± 4    
Medial striatum   94 ± 9   92 ± 6   80 ± 2   83 ± 6    
Lateral striatum 106 ± 11 106 ± 5   88 ± 1   89 ± 8 0.04   
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Brain regions CMRG    Two-way ANOVA 
 control  MDMA  P values 
 TRP+ TRP- TRP+ TRP- Pretreat ATD Interaction 
Bed nucleus of striae terminalis   46 ± 5   45 ± 4   61 ± 2   68 ± 4 0.00   
Globus pallidus   54 ± 7   50 ± 3   45 ± 1   48 ± 3    
Antero ventral thalamic nucleus 105 ± 11   97 ± 12   84 ± 1   92 ± 7    
Antero hypothalamic nucleus   53 ± 7   58 ± 9   51 ± 2   56 ± 5    
Tempero parietal cortex 114 ± 11 109 ± 5   85 ± 5   79 ± 2 0.00   
Ventral lateral hypothalamic nucleus   62 ± 7   52 ± 3   55 ± 3   51 ± 3    
Medial thalamic nucleus 100 ± 8   95 ± 3   85 ± 4   79 ± 5 0.02   
Ventral lateral thalamic nucleus   88 ± 9   83 ± 4   79 ± 6   75 ± 6    
Medial amygdala   84 ± 10   79 ± 5   48 ± 1   52 ± 6 0.00   
Lateral amygdala   52 ± 5   49 ± 2   74 ± 1   66 ± 6 0.00   
Posterior cingulate cortex 105 ± 10   94 ± 5   89 ± 3   88 ± 7    
Lateral habenula 116 ± 15 108 ± 6   94 ± 3   85 ± 3 0.03   
Subthalamic nucleus   84 ± 7   87 ± 3   79 ± 3   78 ± 4    
Mamillary body 110 ± 12   96 ± 9 102 ± 0   94 ± 6    
Piriform cortex   67 ± 8   60 ± 3   63 ± 5   54 ± 2    
Entorhinal cortex   69 ± 9   62 ± 2   72 ± 3   68 ± 2    
Molecular layer   90 ± 12   84 ± 5   79 ± 3   75 ± 4    
Dorsal subiculum   87 ± 9   86 ± 5   70 ± 3   67 ± 5 0.01   
Dentate PO   56 ± 7   55 ± 4   58 ± 2   57 ± 4    
Dorsal CA1   67 ± 9   61 ± 5   59 ± 1   60 ± 3    
CA2   65 ± 10   66 ± 5   60 ± 4   56 ± 4    
Ventral CA1   75 ± 10   64 ± 4   68 ± 6   62 ± 3    
Ventral subiculum   69 ± 7   64 ± 3   64 ± 5   56 ± 4    
CA3   71 ± 9   70 ± 3   66 ± 2   65 ± 4    
Ventral tegmental area   63 ± 9   61 ± 6   53 ± 2   46 ± 3    
Substantia nigra reticulata   59 ± 6   54 ± 3   51 ± 3   46 ± 2    
Substantia nigra compacta   76 ± 10   72 ± 4   69 ± 2   63 ± 5    
Dorsal raphe   74 ± 9   80 ± 6   72 ± 11   71 ± 4    
Median raphe   83 ± 8   75 ± 9   73 ± 9   71 ± 4    
Paramedian raphe   71 ± 11   64 ± 7   66 ± 9   61 ± 4    
Inferior colliculus 203 ± 26 178 ± 5 167 ± 3 148 ± 10 0.03   
Locus coeruleus   77 ± 9   64 ± 4   70 ± 11   78 ± 4    
Where effects are significant (P<0.05), levels of significance generated by ANOVA are provided 
in columns designated Pretreat (main effect of MDMA Pretreatment); ATD (main effect of ATD 
Treatment); Interaction (Pretreatment x ATD effect).  
Local cerebral blood flow 
A significant main effect of MDMA pretreatment was also found in the effects 
upon CBF (Table 2). Evidence for increased CBF in MDMA pretreated animals 
was found not only in those areas where CMRG was increased (dorsal medial 
prefrontal cortex, bed nucleus of the striae terminals and lateral amygdalae) but 
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also in other brain regions, such as septal nucleus, substantia nigra compacta 
and locus coeruleus. While a significant main effect of ATD treatment was only 
found in the entorhinal cortex and molecular layer, there was evidence of a 
significant interaction between MDMA pretreatment and acute ATD (see Table 
2, Interaction). 
Relationship between CBF and CMRG 
Global analysis of all ROIs revealed a close correlation between CBF and 
CMRG after TRP+ and TRP- treatment in both the MDMA pretreated (r= 
0.88 and 0.87, respectively) and control animals (r= 0.93 and 0.91, respectively). 
A significant increase in the global ratio between blood flow and glucose use 
was found after ATD in the MDMA pretreated animals when compared to 
controls as illustrated by a shift in the slope of the best-fitting straight line from 
1.07 in controls to 1.48 in MDMA pretreated animals (P<0.01;  Fig. 4). In 
contrast, there was no such difference following TRP+ administration in 
MDMA pretreated animals compared to controls (P = 0.36). Examining the 
brain areas individually, the flow-metabolism ratio was found to decrease in all 
but 4 of the 43 brain areas in ATD-treated rats (data not shown) and over the 
brain as a whole analyses of the ratios (Mann-Whitney U-test) indicated a 
significant decrease in the ATD group (mean ratio = 1.15) when compared to 
controls (mean ratio = 1.33). These data suggest that ATD produces a degree 
of cerebrovascular hyperperfusion in animals pretreated with MDMA. 
Table 2 Local cerebral blood flow (CBF, ml/100g/min) at t1 after TRP+ treatment or ATD 
(TRP-) in MDMA pretreated and control rats. Data are represented as mean ± S.E.M. 
Brain regions CBF    Two-way ANOVA 
 control  MDMA  P values 
 TRP+ TRP- TRP+ TRP- Pretreat ATD Interaction 
Frontal cortex 109 ± 16 89 ± 8 120 ± 9 114 ± 4    
Orbital frontal cortex 168 ± 18 143 ± 13 149 ± 14 156 ± 17    
Dorsal medial prefrontal cortex 95 ± 10 78 ± 7 116 ± 9 116 ± 6 0.00   
Ventral medial prefrontal cortex 125 ± 16 99 ± 14 90 ± 8 91 ± 3    
Nucleus accumbens 121 ± 14 104 ± 9 133 ± 12 122 ± 7    
Corpus callosum 33 ± 5 28 ± 1 27 ± 2 32 ± 4    
Somatosensory cortex 151 ± 29 114 ± 7 143 ± 17 146 ± 8    
Anterior cingulate cortex 117 ± 17 95 ± 7 126 ± 19 123 ± 6    
Septal nucleus 74 ± 11 66 ± 4 83 ± 10 88 ± 5 0.03   
Medial striatum 99 ± 13 87 ± 4 91 ± 7 100 ± 9    
Lateral striatum 111 ± 14 95 ± 5 115 ± 8 118 ± 9    
Bed nucleus of striae terminalis 56 ± 5 48 ± 3 76 ± 9 88 ± 6 0.00   
Globus pallidus 65 ± 7 47 ± 3 56 ± 8 65 ± 2   0.01 
Antero ventral thalamic nucleus 133 ± 9 109 ± 8 120 ± 9 121 ± 11    
Antero hypothalamic nucleus 74 ± 9 62 ± 5 73 ± 4 75 ± 8    
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Brain regions CBF    Two-way ANOVA 
 control  MDMA  P values 
 TRP+ TRP- TRP+ TRP- Pretreat ATD Interaction 
Tempero parietal cortex 202 ± 32 121 ± 8 102 ± 13 123 ± 14 0.01  0.01 
Ventral lateral hypothalamic nucleus 82 ± 5 70 ± 5 72 ± 5 76 ± 5    
Medial thalamic nucleus 127 ± 15 109 ± 8 97 ± 4 108 ± 12    
Ventral lateral thalamic nucleus 128 ± 11 100 ± 6 123 ± 11 133 ± 11    
Medial amygdala 101 ± 7 80 ± 6 79 ± 6 88 ± 6   0.04 
Lateral amygdala 79 ± 4 66 ± 3 89 ± 6 96 ± 6 0.01   
Posterior cingulate cortex 126 ± 15 100 ± 8 123 ± 14 124 ± 11    
Lateral habenula 155 ± 21 121 ± 10 147 ± 14 150 ± 13    
Subthalamic nucleus 149 ± 19 117 ± 7 150 ± 11 143 ± 14    
Mamillary body 141 ± 17 129 ± 19 162 ± 26 153 ± 36    
Piriform cortex 89 ± 8 73 ± 5 99 ± 12 93 ± 13    
Entorhinal cortex 81 ± 7 64 ± 4 95 ± 5 88 ± 7 0.00 0.04  
Molecular layer 114 ± 9 84 ± 6 113 ± 9 104 ± 11  0.04  
Dorsal subiculum 95 ± 7 82 ± 6 92 ± 7 88 ± 5    
Dentate PO 81 ± 7 63 ± 3 78 ± 6 96 ± 8 0.02  0.01 
Dorsal CA1 83 ± 8 62 ± 4 81 ± 5 88 ± 7 0.06  0.03 
CA2 105 ± 8 77 ± 6 86 ± 6 92 ± 3 0.02   
Ventral CA1 112 ± 4 93 ± 9 128 ± 12 124 ± 20    
Ventral subiculum 106 ± 11 92 ± 7 108 ± 7 112 ± 19    
CA3 103 ± 7 76 ± 3 99 ± 4 108 ± 8# 0.02  0.01 
Ventral tegmental area 78 ± 7 58 ± 3 63 ± 7 72 ± 9   0.04 
Substantia nigra reticulata 80 ± 6 70 ± 4 83 ± 1 82 ± 10    
Substantia nigra compacta 93 ± 4 80 ± 4 98 ± 3 99 ± 11 0.05   
Dorsal raphe 106 ± 15 95 ± 12 124 ± 16 154 ± 55    
Median raphe 119 ± 28 109 ± 11 141 ± 16 110 ± 13    
Paramedian raphe 96 ± 23 106 ± 11 120 ± 14 103 ± 9    
Inferior colliculus 282 ± 62 229 ± 12 255 ± 17 268 ± 29    
Locus coeruleus 112 ± 29 83 ± 4 134 ± 9 127 ± 16 0.02   
Where effects are significant (P<0.05), levels of significance generated by ANOVA are provided 
in columns designated Pretreat (main effect of MDMA Pretreatment); ATD (main effect of ATD 
Treatment); Interaction (Pretreatment x ATD effect).  
 
Using a more rigorous statistical design developed specifically for data from 
these types of experiment (McCulloch et al., 1982), we confirmed that the ratio 
of blood flow to metabolism was reset to a significantly lower value in the 
TRP+ group (P<0.05) despite the more conservative nature of this approach. 
Repeated measures analysis of variance indicated that this occurred 
homogeneously in all neuroanatomical regions included in the study. Within 
each group, significant interregional differences in the ratio of blood flow to 
metabolism were detected using Greenhouse-Geiser (P = 0.03) and Huynh-
Feldt (P = 0.01) corrections, but there was no evidence that this heterogeneity 
differed between groups (Greenhouse-Geiser, P = 0.64; Huynh-Feldt, P = 0.71). 
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Figure 4 The relationship between local cerebral blood flow (CBF) and local cerebral metabolic 
rate of glucose (CMRG) in 43 brain regions of interest after ATD treatment in MDMA 
pretreated rats and controls. Data points represent mean CBF and CMRG for each region 
together with the best fitting straight line defined by y = mx + c, where x and y are the variables 
(CMRG and CBF, respectively), m=the slope of the line and c = the intercept. 
Discussion 
Although its exact underlying mechanism is not fully understood, MDMA-
induced changes in cerebrovascular function have been proposed as a potential 
contributing factor to the oxidative stress that eventually results in 5-HT 
neurotoxicity (Darvesh et al., 2002; Ferrington et al., 2006). Therefore, 
cerebrovascular insufficiency might contribute to an increased incidence of 
functional impairments, including the development of neuropsychiatric 
symptoms. As behavioural deficits might only become apparent when the 
already vulnerable system is additionally challenged, the present study 
investigated the potential persistent effects of repeated MDMA exposure upon 
neuronal and cerebrovascular function in rats subjected to an ATD challenge. 
 The MDMA dosing regime used in the present study is known for its 
persistent neurodegenerative effect in rats as quantified by measuring reduced 
densities of 5-HT transporter sites (Battaglia et al., 1987). The present results 
show a marked decrease in [3H]-paroxetine-labelled 5-HT reuptake sites 
throughout the brain 3 weeks after exposure to the drug, thereby confirming its 
neurotoxic effect. In agreement with other studies using the same dosing 
regime (Battaglia et al., 1991; Sharkey et al., 1991a), significant and regionally 
selective decreases in [3H]-paroxetine binding were observed in both frontal 
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cortex areas and subregions of the hippocampus, without affecting the dorsal 
and medial raphe nuclei. Similar persistent and selective depletions of 
serotonergic terminals have also been reported after a single exposure to 
MDMA (Ferrington et al., 2006; Kirilly et al., 2006). 
 The plasma ratio TRP/ΣLNAA was significantly lowered following ATD in 
both MDMA pretreated and drug-naïve rats to an equal extent (-37% and -40% 
compared to baseline levels, respectively). ATD was accomplished by 
administrating a TRP-free protein-carbohydrate mixture which has previously 
been reported to induce profound peripheral TRP decreases (Jans et al., 2008b; 
Lieben et al., 2004a; Lieben et al., 2004b). However, similar, less robust 
peripheral effects have also been reported by others and might be due to the 
strain of rat (Jans et al., 2008a) or sex differences (Jans et al., 2007), as well as 
pre-existing differences in stress vulnerability (Jans and Blokland, 2008; Olivier 
et al., 2008). In contrast to previous studies that measured ATD-induced 
biochemical alterations at the same 4 h time-point (Jans et al., 2007; Lieben et 
al., 2004a), no ATD effects were found upon central TRP levels, independent 
of MDMA pre-treatment. The moderate peripheral TRP depletion might, thus, 
not have been sufficient to result in a significant decrease of TRP availability to 
the brain. In addition, it has been suggested that ATD-induced changes in 
peripheral TRP might not predict central alterations, as distinct metabolic 
regulation and synthesis mechanisms might be implicated (Olivier et al., 2008; 
Walther and Bader, 2003). In line with this, no ATD effects upon 5-HT or its 
metabolite were found and pretreatment with MDMA did not differentially 
affect this outcome. Although other rat studies of similar experimental design 
reported decreased 5-HT levels after ATD, specifically in the hippocampus 
(Jans et al., 2008a; Lieben et al., 2004a; Olivier et al., 2008), it seems unlikely 
that ATD actually reduces extracellular 5-HT concentrations (Trulson, 1985; 
van der Plasse et al., 2007) without a prior systemic increase in 5-HT levels (Bel 
and Artigas, 1996; Fadda et al., 2000a; Stancampiano et al., 1997). Thus, in 
general, ATD-induced behavioural alterations are not easily ascribed directly to 
changes in 5-HT neuronal activity and while alternative underlying mechanisms 
have been suggested (Moore et al., 2000), these remain to be further elucidated. 
However, rationale for using this method as a challenge tool was that ATD-
induced impaired object recognition in rats has been reported consistently (Jans 
et al., 2008a; Jans et al., 2007; Jans and Blokland, 2008; Lieben et al., 2004b; 
Olivier et al., 2008), even after only moderate peripheral depletions of the 5-HT 
precursor (Rutten et al., 2007) and without affecting central 5-HT 
concentrations (van Donkelaar et al., 2008). Together, these results support the 
notion that while ATD-induced cognitive dysfunction and affective behavioural 
alterations in both animals and human subjects can be directly ascribed to a 
lowering of peripheral TRP concentrations, the underlying mechanism might 
go beyond a straightforward alteration in the 5-HT system itself. 
 MDMA is known to decrease the activity of the TPH enzyme (Stone et al., 
1987), which catalyzes the hydroxylation of TRP into the naturally occurring 
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amino acid 5-hydroxytryptophan (5-HTP). This initial conversion step within 
the 5-HT biosynthetic pathway is rate-limiting, as TPH is not fully saturated 
with the amount of TRP normally present in the brain. Therefore, the amount 
of TRP ultimately converted into 5-HT depends upon substrate availability 
(Boadle-Biber, 1993) and MDMA-induced decreased TPH activity eventually 
results in less TRP being converted into the direct 5-HT precursor 
5-hydroxytryptophan. The increased hippocampal TRP levels, as observed in 
the present study, seem to reflect MDMA-induced TPH deactivation and 
subsequent substrate accumulation. This might additionally provide an 
explanation for the higher plasma TRP/ΣLNAA ratio found in the TRP+ 
treatment condition of MDMA pretreated animals compared to drug-naïve rats. 
It is thus tempting to speculate that the accumulation of central TRP provides 
the necessary feedback for regulating, in this case diminishing, peripheral TRP 
uptake into the brain. On the other hand, but along similar lines, an 
autoregulating compensatory mechanism might increase peripheral TRP levels 
in the attempt to maintain adequate central metabolism. Thus, although ATD 
challenge decreases peripheral TRP levels in MDMA pretreated compared to 
control rats similarly, the increase in central TRP in the MDMA pretreated 
animals together with the higher peripheral levels might indicate that peripheral 
TRP metabolism and its uptake into the brain are affected by MDMA-induced 
5-HT neurotoxicity. 
 Furthermore, the significant depletion of 5-HT in both hippocampus and 
prefrontal cortex of MDMA treated animals is in line with the 5-HT synthesis 
inhibition due to MDMA-induced TPH deactivation. However, the observed 
increase in hippocampal 5-HIAA levels seems difficult to explain, as decreased 
5-HT synthesis normally parallels less catabolism resulting in less inactive 
5-HIAA end product formation. Yet, an increase in 5-HIAA concentration 
could be a consequence of increased 5-HT catabolism leading to the 
subsequent depletion of 5-HT concentration. However, decreased 5-HIAA 
concentration is one of the markers of MDMA-induced disrupted 5-HT 
metabolism that is normally reported after MDMA abuse (Callahan et al., 2001) 
and is usually explained by the MDMA-induced inhibition of the intracellular 
enzyme MAO-A (Leonardi and Azmitia, 1994).   
 The present study shows a persistent effect of repeated MDMA 
pretreatment upon CMRG with locally increased, but mainly decreased activity 
across the anatomically discrete ROIs at different levels of the brain. However, 
the distribution of MDMA-induced metabolic changes does not exactly mirror 
the distribution of MDMA-induced 5-HT terminal depletion. This reflects the 
measure of integrative function afforded by the 2-deoxyglucose technique and 
therefore, the observed changes in CMRG cannot be directly ascribed to 
decreased 5-HT functioning in the corresponding areas. These findings are in 
certainly in keeping with previous studies. A single acute administration of 
MDMA has been shown to increase metabolic activity in many brain areas 
(Ando et al., 2006; Balogh et al., 2004; Quate et al., 2004), whereas a persistent 
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hypometabolic response and an uncoupling from CBF has been found in the 
longer term (Ferrington et al., 2006). In contrast to the effects of MDMA 
pretreatment upon both CMRG and CBF, ATD did not affect local CMRG or 
CBF, although some brain regions appeared to be differentially affected by 
ATD in combination with MDMA pretreatment. Thus, the present results 
suggest that ATD in animals with serious 5-HT terminal depletion results in a 
significant upwards resetting of the relationship of CBF to CMRG as compared 
to the control group. 
 In the absence of any evidence in this study that an acute decrease in 
peripheral TRP by means of ATD has any effect upon central 5-HT systems, it 
is difficult to suggest with any certainty a mechanism by which ATD 
potentiates the MDMA pretreatment-induced hyperperfusion. As already 
briefly mentioned above, peripheral 5-HT function may be uncoupled from 
central 5-HT function as the neurotransmitter is synthesized from TRP by the 
TPH1 isoform in the periphery and the TPH2 isoform in the brain (Walther 
and Bader, 2003). In the periphery, one of the main functions of 5-HT is the 
regulation of vascular tone (Rapport et al., 1948). While it is possible that ATD 
induces changes in the bioavailability of 5-HT peripherally, and in the blood 
could remove 5-HT-dependent vasoconstrictor tone, it is unlikely that 
cerebrovascular function could be influenced in any way so long as the blood-
brain barrier remained intact. A more plausible explanation might be that while 
the effects of ATD upon central 5-HT systems were below the threshold of 
detection in brain tissues harvested in this study, they were of sufficient 
magnitude to reduce cerebrovascular constrictor tone under conditions in 
which the bioavailability of perivascular 5-HT was compromised by prior 
MDMA-induced depletion of 5-HT terminals. Moreover the evidence from this 
and previous studies of a persistent cerebrovascular effect of MDMA might 
suggest that the cerebrovasculature is more sensitive to the loss of endogenous 
5-HT than is the neuropil. 
  To summarize, the present results show that MDMA pretreatment and 
ATD interact to produce a small but significant potentiation of MDMA-
induced cerebrovascular dysfunction. The resulting decrease in cerebrovascular 
tone and consequent hyperperfusion could indicate a predisposition to 
cerebrovascular accident and haemorrhagic stroke in particular. More widely, it 
is of interest that the 5-HT dysfunction induced by MDMA is paralleled, albeit 
more subtly, by the decrease in transporter function found in some cases of 
depression, for which ATD is used as a clinical diagnostic probe. While it 
would stretch the available evidence to suggest that cerebrovascular dysfunction 
is the root cause of depressive illness, it is tempting to speculate that changes in 
CBF might contribute to the behavioural dysfunction of depression. 
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Abstract 
Acute tryptophan depletion (ATD) is extensively used to investigate 
the implication of serotonin (5-hydroxytryptamine; 5-HT) in the 
onset and treatment of depression and cognitive disorders. 
Brain-derived neurotrophic factor (BDNF) is strongly linked to the 
5-HT system and plays an essential role in mood and memory 
processes. The present study investigated the effects of ATD upon 
BDNF in serum, hippocampus and prefrontal cortex in the rat to 
further explore the underlying mechanism of ATD. ATD 
significantly decreased peripheral tryptophan (TRP) levels and 
moderately interrupted 5-HT metabolism 4 h after administration of 
the nutritional mixture. Although no direct effects of ATD upon 
serum or brain BDNF concentrations were found, a stress-mediated, 
decrease in BDNF was observed in the prefrontal cortex. Moreover, 
brain TRP levels correlated positively with BDNF in both the 
prefrontal cortex and hippocampus. Thus, BDNF-mediated 
mechanisms due to ATD and/or its application stress might underlie 
ATD-induced neurochemical and behavioural alterations. 
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Introduction 
The implication of the serotonin (5-hydroxytryptamine; 5-HT) system and 
serotonergic vulnerability factors in the onset and treatment of depressive 
symptomatology is being extensively investigated with so-called serotonergic 
challenge tools. Most widely used, both clinically and pre-clinically, is the acute 
tryptophan depletion (ATD) method, which manipulates the availability of the 
essential amino acid tryptophan (TRP), the dietary 5-HT  precursor (Bell et al., 
2005; Hood et al., 2005; Neumeister, 2003; Young, 1993). Through 
administration of a TRP-free nutritional mixture, plasma TRP levels are 
decreased and thus less of the precursor is available to be converted into 5-HT 
(Fadda et al., 2000b; Fernstrom, 1983). Since this method is relatively easy to 
apply and non-toxic, it can be safely and repeatedly used in both human 
subjects and rodents (Blokland et al., 2004; Fadda et al., 2000b).  
 ATD is known to substantially lower peripheral TRP levels and 
hippocampal 5-HT concentrations in rats (Lieben et al., 2004a) and profound 
disrupted 5-HT metabolism has been reported in human subjects (Carpenter et 
al., 1998; Williams et al., 1999). However, actual decreases in extracellular 5-HT 
have only been observed after ATD in combination with blockade of 5-HT 
reuptake (Bel and Artigas, 1996; Fadda et al., 2000a; Stancampiano et al., 1997). 
Nevertheless, ATD consistently induces object memory deficits in rats (Jans et 
al., 2007a; Lieben et al., 2004b; Lieben et al., 2005; Olivier et al., 2008; Rutten et 
al., 2007; van Donkelaar et al., 2008). In addition, impaired memory processes 
have been reported in both healthy human subjects and subjects with pre-
existing abnormal central 5-HT regulation, whereas mood-lowering effects are 
only observed in the latter (Booij et al., 2002; Booij et al., 2003; Klaassen et al., 
1999; Neumeister et al., 2002; Neumeister et al., 2006; e.g. Smith et al., 1997). It 
thus remains unclear to what extent ATD-induced cognitive dysfunction and 
other behavioural changes can be directly ascribed to alterations in 5-HT 
neuronal activity (Moore et al., 2000; van der Plasse et al., 2007).  
 Extensively studied is the link between 5-HT and brain-derived 
neurotrophic factor (BDNF), a member of the nerve growth factor gene family 
and the most abundant of the neurotrophins in the brain (Ernfors et al., 1990). 
BDNF plays an important role in differentiation, outgrowth and survival of 
peripheral and central neurons during brain development (Ghosh et al., 1994; 
McAllister et al., 1995) and in neuronal recovery after brain damage (Hicks et 
al., 1999). Moreover, the protein appears to have important neurotransmitter-
modulating effects throughout adult life upon monoamine (Mattson et al., 
2004; Siuciak et al., 1996) and neuropeptide function (Croll et al., 1994; Nawa et 
al., 1994). High levels of BDNF mRNA are found in the hippocampus and the 
cerebral cortex (Conner et al., 1997; Ernfors et al., 1990; Hofer et al., 1990), 
which explains the involvement of BDNF in mechanisms implicated in 
depression, including cognitive dysfunction.  
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5-HT stimulates the expression of BDNF through production of cyclic 
adenosine monophosphate (cAMP) and activation of cAMP-response element-
binding (CREB) protein (Duman et al., 1997; Duman, 1998; Mattson et al., 
2004). On the other hand, BDNF promotes the function, growth and sprouting 
of 5-HT neurons (Mamounas et al., 1995; Mamounas et al., 2000) and increases 
5-HT synthesis by enhancing tryptophan hydroxylase (TPH) mRNA levels 
(Siuciak et al., 1998). It has been shown that BDNF mediates the effects of 
antidepressants and has itself antidepressant properties (Altar et al., 2003; 
Nibuya et al., 1995; Nibuya et al., 1996). Furthermore, decreased levels of 
BDNF in serum have been reported in depressed patients, whereas 
antidepressant treatment is able to reverse the attenuated BDNF levels (Gonul 
et al., 2005; Karege et al., 2005; Shimizu et al., 2003). While a decrease in 
circulating BDNF was found in patients with remitted major depressive 
disorder after ATD, a suggested compensatory increase was found in healthy 
subjects (Neumeister et al., 2005). In rats, however, no ATD-induced changes 
were observed upon peripheral or central BDNF levels (Cahir et al., 2008). Of 
note, BDNF is extremely stress-responsive (Smith et al., 1995a), which is 
supported by studies showing that both acute and repeated immobilization 
stress considerably decreases BDNF mRNA expression in the rat 
hippocampus, even within 1 h (Smith et al., 1995b; Ueyama et al., 1997). Stress-
induced changes in BDNF are not only glucocorticoid-mediated (Prickaerts et 
al., 2006), but might be regulated additionally by alterations in the activity of 
specific 5-HT receptors (Vaidya et al., 1997; Vollmayr et al., 2000). 
Experimental stressors related to ATD application procedures might, thus, also 
influence central BDNF levels. 
 Neurotrophins in general play an important role in neuronal plasticity, 
including long-term potentiation (LTP). BDNF has been shown to directly 
modulate hippocampal LTP (Figurov et al., 1996) and mice lacking BDNF 
show impaired LTP regulation (Korte et al., 1995). As LTP is assumed to be 
the underlying substrate of learning and memory processes (Bliss and 
Collingridge, 1993), BDNF is thought to be a potential mediator of memory 
formation in general and is known to be required specifically for memory 
consolidation (Lee et al., 2004). ATD in human subjects selectively impairs 
memory consolidation (Riedel et al., 1999), which has been attributed to 
lowered 5-HT in hippocampal areas (Riedel, 2004), however, a direct link to 
changes in BDNF remains to be elucidated. It is nevertheless tempting to 
speculate that the consistently reported ATD-induced cognitive dysfunctions, 
as observed in both healthy and vulnerably subjects, but also in rats, might be 
attributed, directly or indirectly, to BDNF-mediated alterations in learning and 
memory processing. 
 The aim of the present study was to further explore the underlying 
mechanism of ATD in rats by determining its effects upon BDNF levels in 
serum, hippocampus and prefrontal cortex while controlling for possible 
confounding stress effects of the specific experimental procedures. In the first 
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place, it was hypothesized that reduced 5-HT metabolism, due to depletion of 
its precursor, would result in alterations of peripheral and central BDNF levels. 
In addition, we speculated upon the potential of experimental stressors to 
decrease basal BDNF levels. Possible stress-induced decreased central BDNF 
concentrations might alter TRP metabolism and synthesis into 5-HT, thereby 
interfering with pure ATD effects. These observations could contribute to a 
better understanding of ATD-induced cognitive dysfunction and affective 
behavioural changes. 
Experimental procedures 
Animals 
Forty six-month-old male Wistar rats (Charles River, The Netherlands) were 
used, weighing between 450-500 g at the start of the experiments. On arrival, 
animals were housed individually in standard Makrolon cages on sawdust 
bedding and maintained on a reversed 12:12-h light-dark schedule (lights on 
from 18:00 h - 06:00 h) in a temperature-controlled (21 ± 2ºC) and air-
conditioned colony room. Background noise was provided by a radio playing 
softly at all times. Handling and treatment of the animals was not started until 
two weeks after arrival and food and tap water were freely available throughout 
this period.  
 All efforts were made to minimize the number of animals used and their 
suffering. Experimental procedures were approved by the local ethical 
Committee on Animal Experimentation of the Maastricht University and were 
in accordance with governmental guidelines. 
Nutritional mixture 
Acute reduction of plasma TRP levels was accomplished by administering a 
TRP-free protein-carbohydrate nutritional mixture (Gelatine hydrolysate, 
Solugel®; PB Gelatins, Tessenderlo, Belgium). Compared to pure amino acid 
mixtures, the gelatin-based mixture comprises the entire range of amino acids 
in the form of peptides, as found in normal food and naturally lacks the 
essential amino acid TRP (for amino acid content and composition of the 
mixture see: van Donkelaar et al., 2008). The addition of carbohydrates 
(Glucodry 210; Amylumgroup, Koog aan de Zaan, The Netherlands) activates 
the insulin response and the resulting increase in protein synthesis promotes an 
optimized reduction in plasma TRP levels (Fernstrom, 1986; Lieben et al., 
2004a; Markus et al., 1998). 
 To the control mixture, L-tryptophan (Sigma, Zwijndrecht, The 
Netherlands) was added in an amount equivalent to 0.28% of total protein 
content, as adapted from Lieben et al. (2004a). Potassium chloride (KCl) and 
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calcium chloride dihydrate (CaCl2.2H2O) were obtained from Merck 
(Darmstadt, Germany). Nutritional mixtures were dissolved in distilled water 
and freshly prepared in the afternoon the day before the actual experiment and 
stored at 4 ºC until the day of the experiment. 
ATD treatment 
After adaptation to the new environment and the reversed light-dark cycle, 
animals were handled and habituated to the oral administrations by gavage, two 
weeks before the start of the experiments. Rats were deprived of food 
overnight (±15 h) prior to the experimental day to avoid TRP uptake from the 
standard animal chow. Water remained freely available at all times.   
 Experimental procedures took place in the dark phase of the animals’ light-
dark cycle, between 9:00 and 14:00 h. Animals were randomly assigned to one 
of three treatment conditions (n=10 per group), receiving either saline or the 
nutritional mixture with (TRP+ group) or without TRP (TRP- group). Each 
experimental dose contained 4 g of Solugel® and 2 g of Glucodry 210 per kg 
bodyweight and was administered twice in a volume of 10 ml/kg with a 90 min 
interval, 240 min prior to decapitation. 
 In addition, a fourth experimental group of animals (n=10) was included. 
These animals did not receive any oral treatments and were not deprived of 
food the night before the experimental day. This group served to measure 
baseline central BDNF levels and was used as a control group against the saline 
treated group to discard potential stress effects of the food deprivation in 
general and the oral applications by gavage in particular.  
Collection and preparation of blood samples 
For determination of plasma amino acid concentrations and BDNF in serum, 
baseline blood samples were taken by means of saphenous vein puncture (Hem 
et al., 1998), 30 min prior to the first treatment administration. Approximately 
100 μl (for ± 50 μl plasma) was captured into heparin coated tubes 
(Microvette® CB 300, Sarstedt, Germany) which were kept on ice until 
centrifuged. Another 50 μl (for ± 25 μl serum) was captured in standard cups 
and left at room temperature for approximately 1 h followed by 1 h at 4 ºC. A 
second blood sample was taken by collecting trunk blood at time of 
decapitation, i.e. 4 h after the first treatment administration. All samples were 
centrifuged at 4 ºC using a Hettish EBA 12 centrifuge with 10 min at 14,000 x g 
for separating the plasma and 15 min at 2000 x g for separating serum. Both 
plasma and serum were transferred into cups which were immediately frozen in 
liquid nitrogen and stored at -80 ºC until further analysis.  
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Collection and preparation of tissue samples 
At time of decapitation, prefrontal cortex and hippocampus were dissected out 
bilaterally. Right hemisphere tissue was homogenized for determination of 
central amino acid and 5-HT, the 5-HT metabolite (5-hydroxyindoleacetic acid; 
5-HIAA) and dopamine (DA) concentrations, whereas left hemisphere tissue 
was used for central BDNF analysis. After dissection, tissue was weighted on a 
microbalance in pre-weighed 2.0 μl screw-lid cups and immediately frozen in 
liquid nitrogen prior to storage at -80ºC. All tissue dissections were performed 
by the same investigator (E. L. van Donkelaar) to preserve consistency. At a 
later stage, 250 μl of a 5-sulfosalicylic acid solution, including 15 μl (of 2 mM 
per 85 μl supernatant) of ascorbic acid to protect against monoamine 
degradation processes by oxidation, was added to the tissue. Further, the cups 
were filled with approximately 0.3 g of glass beads (1.0 mm diameter) and brain 
tissue was homogenized in a mini-bead beater set at high speed (3 x 30 s with 
cooling in between runs). Subsequently, samples were stored at -80 ºC until 
further analyses.  
Biochemical analysis 
Plasma and brain amino acid concentrations were quantified using fully 
automated high-performance liquid chromatography (HPLC) with fluorescence 
detection (van Eijk et al., 1993). The concentrations of free plasma and central 
amino acids were expressed as μmol/l, brain concentrations as ng/mg. Since 
TRP competes at the blood-brain barrier with the other large neutral amino 
acids (LNAAs; leucine [LEU], isoleucine [ILE], phenylalaline [PHE], tyrosine 
[TYR], valine [VAL]) for the same amino acid L-carrier transport system 
(Fernstrom and Wurtman, 1972; Fernstrom, 1983), a decrease of the ratio of 
TRP to the sum of the other LNAAs in plasma (TRP/ΣLNAA) is normally 
used as the best predictor of reduced central availability of TRP (Fernstrom, 
1979, 1983). Central concentrations of 5-HT, 5-HIAA and DA in the 
hippocampus and prefrontal cortex were quantified by automated HPLC with 
dual electrochemical detection. 
 BDNF in serum and brain homogenates was measured as previously 
described  (Scheepens et al., 2003; Van den Hove et al., 2006) and according to 
manufacturer’s instructions using the BDNF Emax® ImmunoAssay system from 
Promega (Madison, MI, USA) and high affinity EIA/RIA 96-well plates 
(Corning, NY, USA). The resultant absorbency was read using a microplate 
reader at 405 nm (Biorad, CA, USA). Serum and tissue homogenate samples 
were diluted within the range of the standard curve and expressed as pg/l and 
ng/g. All samples were measured in duplicate.  
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Statistical analyses 
Unless otherwise stated, all data were evaluated statistically using independent 
Student’s t-tests. To reveal procedural stress effects, the group that received no 
treatment at all was compared with the saline condition. Saline and TRP+ 
treatment were compared to establish differences between the two control 
groups, while ATD effects were revealed by comparing the TRP- group with 
the TRP+ control group. Because multiple (three) comparisons were made, the 
level of significance was adjusted (post hoc correction) to P<0.05/3 = P<0.017.    
 Mean concentrations of plasma amino acids were determined for each 
treatment condition and time-point separately and TRP/ΣLNAA ratios were 
calculated accordingly. Changes in the ratio TRP/ΣLNAA and serum BDNF 
over time were analyzed by means of two-way analysis of variance (ANOVA) 
with Treatment as between-subject factor and Time as within-subject variable. 
Subsequently, separate one-way ANOVAs were performed to analyze 
differences between treatment conditions per time-point. Post hoc multiple 
(three) comparisons were made, as mentioned above, to further characterize the 
treatment effects (significance set at P<0.017). Mean central amino acid 
concentrations, 5-HT, 5-HIAA, 5-HT turnover rate (5-HIAA/5-HT) and DA 
levels, as well as central BDNF levels were analyzed for hippocampus and 
prefrontal cortex separately. The relationship between the most prominent 
peripheral and central parameters was examined by calculating Pearson’s 
correlation coefficient (rp) with the levels of significance set at P<0.05. 
 Extreme values representing artefacts in the raw data arising from the 
HPLC analyses and BDNF ELISA were analyzed by means of Dixon’s 
Extremity test (Dixon, 1959) and only those values for a given animal were 
excluded from statistical analysis. Data are represented as mean ± standard 
error of the mean (S.E.M.).  
Results 
Plasma amino acids 
An overview of the concentration of the LNAAs in plasma can be found in 
Table 1. No treatment effects were found at baseline and only the TRP levels in 
plasma were selectively decreased 4 h after ATD compared to the TRP+ 
control treatment [t(17) = 5.964; P<0.017. Decreased levels of TYR [t(18) = 
6.317; P<0.017], ILE [t(18) = 7.156; P<0.017] and LEU [t(18) = 5.736; 
P<0.017] were found after TRP+ treatment compared to saline treatment 4 h 
after treatment initiation. 
 ATD decreased the ratio TRP/ΣLNAA in plasma (Fig. 1) over time [F(1, 
34) = 22.79; P<0.001], however, not in the same way for all treatment 
conditions [F(3, 34) = 3.66; P<0.05]. An overall treatment effect was found 
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[F(3, 34) = 3.94; P<0.05] and post-hoc analysis showed that the TRP+ 
treatment significantly differed from the TRP- group and from the group that 
did not receive any treatment. 
Table 1 Large neutral amino acid (LNAA) concentrations (mean ± S.E.M. in μmol/l) in rat 
plasma at baseline and 240 min after the first oral administration with either saline or the protein-
carbohydrate nutritional mixture with (TRP+) or without TRP (TRP-) or after no treatment at all.  
LNAA 
 
Treatment Time 
  Baseline t240 
TRP no treatment   80 ± 9   76 ± 11 
 saline 107 ± 12   77 ± 8 
 TRP+ 107 ± 9   97 ± 8 
 TRP- 104 ± 13   43 ± 4* 
TYR no treatment   76 ± 3   70 ± 3 
 saline   84 ± 7   66 ± 3  
 TRP+   92 ± 4   42 ± 3# 
 TRP-   90 ± 4   45 ± 2 
PHE no treatment   67 ± 1   90 ± 8 
 saline   77 ± 7   76 ± 4  
 TRP+   75 ± 4   90 ± 5 
 TRP-   73 ± 3   96 ± 5 
VAL no treatment 147 ± 6 177 ± 5 
 saline 166 ± 15 179 ± 6 
 TRP+ 165 ± 8 185 ± 5 
 TRP- 159 ± 1 205 ± 6 
ILE no treatment 124 ± 6 168 ± 14 
 saline 136 ± 14 168 ± 7 
 TRP+ 123 ± 5 104 ± 5# 
 TRP- 127 ± 2 118 ± 8 
LEU no treatment 162 ± 7 196 ± 10 
 saline 186 ± 17 208 ± 6 
 TRP+ 170 ± 7 164 ± 4# 
 TRP- 175 ± 2 179 ± 6 
(#) TRP+ group significantly different from saline; (*) TRP- group significantly different from 
TRP+ group. (#,*) P<0.017. TRP: tryptophan, TYR: tyrosine, PHE: phenylalanine, VAL: 
valine, ILE: isoleucine, LEU: leucine 
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No differences were found between the TRP+ and the saline group. Separate 
one-way ANOVAs to reveal treatment effects per time-point showed no 
differences at base-line [F(3, 39) = 0.998; n.s.]. However, a significant treatment 
effect was found 4 h after the first treatment administration [F(3, 37) = 7.92; 
P<0.001]. Post hoc multiple comparisons revealed that the ratio TRP/ΣLNAA 
in plasma was significantly lower after TRP- [t(16) = 5.525; P<0.017] and saline 
treatment [t(18) = -2.912; P<0.017] compared to TRP+ treatment. No 
differences were found between the saline group and the group that received 
no treatment at all [t(18) = -0.082; n.s.]. 
 
 
Figure 1 The ratio TRP/ΣLNAA in plasma (mean + S.E.M.) at baseline and 240 min after the 
first oral administration with either saline or the protein-carbohydrate nutritional mixture with 
(TRP+) or without TRP (TRP-) or after no treatment at all. The group that received no 
treatment at all did not differ from the saline group. Significant decreases were found 4 h after 
treatment with TRP- (*) and saline (#) compared to TRP+ treatment. */# P<0.017. Percentage 
indicates mean change from corresponding baseline levels after ATD treatment.   
Brain amino acids, 5-HT, 5-HIAA and DA 
Table 2 shows the concentrations of central amino acids and the monoamines 
5-HT and DA, 5-HIAA and 5-HT turnover rate (5-HIAA/5-HT).  
 
Whereas ATD significantly decreased the TRP levels in plasma, no ATD 
effects were found upon central TRP concentrations in the hippocampus [t(16) 
= 1.213; n.s.] or prefrontal cortex [t(15) = 0.744; n.s.]. In the hippocampus, a 
significant decrease of both 5-HIAA concentrations (-33%) [t(16) = 3.384; 
P<0.017]  and the 5-HT turnover (-28%) [t(14) = 3.034; P<0.017] were 
observed 4 h after ATD compared to the TRP+ control group. Other 
treatment effects were only found between the TRP+ and saline control 
groups. TRP+ treatment decreased the TYR levels in the hippocampus [t(18) = 
4.627; P< P<0.017] and prefrontal cortex [t(18) = 3.468; P<0.017]. This was 
also the case for the concentration of ILE with decreased levels in both the 
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hippocampus [t(18) = 5.184; P<0.017]  and the prefrontal cortex [t(17) = 3.725; 
P<0.017]. Further, TRP+ treatment increased the concentration of VAL in the 
hippocampus [t(16) = -2.690; P<0.017]. No differences were found upon any 
of the parameters measured between the group that did not receive any 
treatment and the saline control group. 
Table 2 Absolute LNAAs, 5-HT, 5-HIAA, 5-HT turnover and DA concentrations (mean ± 
S.E.M. in ng/mg) in rat hippocampus and prefrontal cortex, 240 min after the first oral 
administration with either saline or the protein-carbohydrate nutritional mixture with (TRP+) or 
without TRP (TRP-) or after no treatment at all. 
 Treatment Brain tissue 
 
 Hippocampus 
 
Prefrontal cortex 
 
TRP no treatment   9.30 ± 0.28 13.60 ± 0.60 
 saline   8.73 ± 0.52 13.40 ± 0.85 
 TRP+   8.37 ± 0.57 12.62 ± 1.18 
 TRP-   7.51 ± 0.33 11.66 ± 0.34 
TYR no treatment 10.83 ± 0.38 11.98 ± 1.19 
 saline   9.79 ± 0.49 10.99 ± 0.49 
 TRP+   7.14 ± 0.30 #   8.39 ± 0.57 # 
 TRP-   7.85 ± 0.38   8.41 ± 0.24 
PHE no treatment   9.81 ± 0.37 11.95 ± 0.38 
 saline   9.10 ± 0.42 11.99 ± 0.50 
 TRP+ 10.98 ± 0.60 13.41 ± 0.89 
 TRP- 11.74 ± 0.53 14.18 ± 0.32 
VAL no treatment 13.97 ± 0.48 14.59 ± 0.55 
 saline 13.29 ± 0.30 14.53 ± 0.56 
 TRP+ 15.47 ± 0.68 # 16.65 ± 0.91 
 TRP- 17.69 ± 0.70 18.06 ± 0.64 
ILE no treatment   7.36 ± 0.22   9.21 ± 0.42 
 saline   7.00 ± 0.23   8.79 ± 0.33 
 TRP+   5.34 ± 0.22 #   6.63 ± 0.49 # 
 TRP-   5.95 ± 0.24   7.40 ± 0.16 
LEU no treatment 11.63 ± 0.37 12.52 ± 0.41 
 saline 11.58 ± 0.25 12.41 ± 0.33 
 TRP+ 10.70 ± 0.31 11.71 ± 0.39 
 TRP- 11.71 ± 0.41 12.81 ± 0.44 
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 Treatment Brain tissue 
 
 Hippocampus 
 
Prefrontal cortex 
 
5-HT no treatment   0.22 ± 0.01   0.43 ± 0.05 
 saline   0.23 ± 0.01   0.45 ± 0.06 
 TRP+   0.24 ± 0.02   0.38 ± 0.07 
 TRP-   0.20 ± 0.01   0.39 ± 0.04 
5-HIAA no treatment   0.17 ± 0.01   0.20 ± 0.01 
 saline   0.17 ± 0.01   0.22 ± 0.01 
 TRP+   0.15 ± 0.01   0.20 ± 0.02 
 TRP-   0.10 ± 0.01*   0.18 ± 0.02 
5-HT turnover no treatment   0.78 ± 0.05   0.49 ± 0.05 
 saline   0.75 ± 0.06   0.51 ± 0.06 
 TRP+   0.71 ± 0.05   0.68 ± 0.12 
 TRP-   0.51 ± 0.03*   0.53 ± 0.10 
DA no treatment   0.61 ± 0.04   0.23 ± 0.02 
 saline   0.67 ± 0.02   0.22 ± 0.02 
 TRP+   0.71 ± 0.12   0.22 ± 0.02 
 TRP-   0.80 ± 0.07   0.21 ± 0.02 
(#) TRP+ group significantly different from saline; (*) TRP- group significantly different from 
TRP+ group. (#,*) P<0.017. LNAAs: large neutral amino acids, TRP: tryptophan, TYR: tyrosine, 
PHE: phenylalanine, VAL: valine, ILE: isoleucine, LEU: leucine, 5-HT: serotonin, 5-HIAA: 5-
hydroxyindolacetic acid, 5-HT turnover: 5-HIAA/5-HT, DA: dopamine. 
Serum and central BDNF 
Serum BDNF levels (Fig. 2) did not change over time [F(1, 32) = 3.84; n.s.] and 
no overall treatment effect was found [F(3, 32) = 0.51; n.s.]. Separate one-way 
ANOVAs to reveal treatment effects per time-point showed that no differences 
in serum BDNF levels between the treatment conditions could be observed at 
baseline [F(3, 39) = 0.50; n.s.] or 4 h after the first oral administration [F(3, 35) 
= 1.08; n.s.].  
 
ATD did not affect BDNF levels in the hippocampus [t(15) = 0.140; n.s.] or 
the prefrontal cortex [t(15) = 0.672; n.s.] compared to the TRP+ group (Fig. 3). 
No differences in BDNF levels were found between the TRP+ and saline 
control groups in hippocampus [t(18) = 0.608; n.s.] or prefrontal cortex [t(14) = 
-0.320; n.s.]. Saline treatment compared to the group that did not receive any 
treatment at all significantly decreased the BDNF levels in the prefrontal cortex 
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[t(13) = 4.210; P<0.017] without affecting hippocampal BDNF levels [t(16) = 
-0.031; n.s.]. 
 
 
Figure 2 Serum BDNF levels (mean + S.E.M. in pg/ml) at baseline and 240 min after the first 
oral administration with either saline or the protein-carbohydrate nutritional mixture with 
(TRP+) or without TRP (TRP) or after no treatment at all. ATD did not affect serum BDNF 
levels.  
Correlations 
Correlation analysis was performed to reveal significant associations between 
peripheral and central parameters as depicted in Table 3. Absolute plasma TRP 
levels and the ratio TRP/ΣLNAA were highly correlated (rp = 0.94, P<0.05). 
Positive associations were also found between peripheral TRP levels and 5-HT-
related parameters in the hippocampus, not, however, in the prefrontal cortex. 
Only in the brain, TRP concentrations correlated with 5-HT itself in both the 
hippocampus (rp = 0.31, P<0.05) and prefrontal cortex (rp = 0.46, P<0.05). A 
highly mutual pattern of positive correlations was also observed between the 
5-HT related parameters within the hippocampus.   
 Serum BDNF did not significantly correlate with hippocampal BDNF levels 
(rp = 0.01, P=0.97) or BDNF levels in the prefrontal cortex (rp = 0.25, P=0.19). 
Although ATD did not significantly affect the central BDNF levels, a positive 
correlation was found between both TRP and BDNF in the hippocampus (rp = 
0.37, P<0.05) and TRP and BDNF in the prefrontal cortex (rp = 0.42, P<0.05).  
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Figure 3 Central BDNF concentrations in hippocampus and prefrontal cortex (mean + S.E.M. in 
ng/g), 240 min after the first oral administration with either saline or the protein-carbohydrate 
nutritional mixture with (TRP+) or without TRP (TRP-) or after no treatment at all. * P<0.017; 
BDNF levels were significantly decreased in the prefrontal cortex after saline treatment 
compared to the group that received no treatment at all. No ATD effects (TRP+ compared to 
TRP-) were found upon BDNF concentration and no differences were found between the TRP+ 
and saline treatment groups. 
Discussion 
In the present study, ATD was applied to further explore the underlying 
mechanism of the serotonergic challenge tool by investigating the relationship 
between the 5-HT system and BDNF protein levels. Furthermore, effects of 
experimental stress upon BDNF concentrations were measured as a potential 
confounding factor for ATD-induced functional and behavioural alterations in 
the rat. ATD was accomplished by administering a TRP-free protein-
carbohydrate nutritional mixture to measure the effects of an acute change in 
peripheral TRP, the dietary 5-HT precursor, upon BDNF protein levels in 
serum and rat hippocampus and prefrontal cortex. Whereas 4 h after ATD 
treatment initiation, the ratio TRP/ΣLNAA in plasma was decreased with 56%, 
no direct ATD effects were observed upon absolute TRP or 5-HT levels in the 
brain at this specific time-point. However, both the concentration of the 5-HT 
metabolite, 5-HIAA, and the 5-HT turnover rate were significantly decreased in 
the hippocampus, indicative of an ATD-induced diminished 5-HT metabolism 
in this brain region. Although ATD did not directly alter peripheral or central 
BDNF levels 4 h after treatment initiation, a positive correlation was found 
between TRP concentrations and BDNF levels at this time-point in both the 
hippocampus and the prefrontal cortex. Moreover, a decrease in BDNF levels 
was observed in the prefrontal cortex after oral application by gavage, thereby 
hippocampus prefrontal cortex
0
50
100
150
200
250
no treatment
saline
TRP+
TRP-
*
Brain tissue
B
D
N
F 
(n
g/
g)
Thesis_Donkelaar_v8.pdf   146 30-7-2009   15:08:02
Acute tryptophan depletion and brain-derived neurotrophic factor  
 147 
confirming our hypothesis that experimental stressors decrease basal BDNF 
levels and possibly interfere with ATD neurochemical effects. 
 The ATD challenge method is extensively applied in both clinical and 
preclinical research to explore the implication of the 5-HT system in a variety 
of cognitive and affective disorders. However, the exact underlying mechanism 
through which it exerts its neurophysiological effect is still poorly understood. 
Additionally, it remains unclear to what extend ATD-induced cognitive 
dysfunctions and affective behavioural alterations are due to actual changes in 
5-HT neuronal activity. In the present study, ATD substantially decreased 
peripheral TRP levels and the ratio TRP/ΣLNAA 4 h after treatment initiation 
in line with other studies of similar experimental design (Jans et al., 2007a; Jans 
and Blokland, 2008; Lieben et al., 2004a; Olivier et al., 2008). The lower 
TRP/ΣLNAA ratio in plasma after both saline and no treatment compared to 
TRP+ treatment can be ascribed to the lack of nutrients to maintain an optimal 
level of blood amino acid concentrations.  Additionally, these results provide 
evidence that the boost of large neutral amino acids in the absence of TRP is 
the key factor for depleting TRP in plasma, as the TRP- treatment group was 
the only group that decreased the ratio significantly from baseline levels.  
Nevertheless, no direct ATD effects upon central TRP or 5-HT levels were 
found at this time-point. However, the reduction of hippocampal 5-HIAA 
suggests that less 5-HT is broken down into its inactive metabolite, presumably 
caused by a reduced availability of the precursor itself (Fernstrom and Hirsch, 
1977). This is also reflected in the significant decrease of the 5-HT turnover 
rate, i.e. the ratio 5-HIAA/5-HT. Both decreased concentrations of 5-HIAA 
and a decrease in the ratio of the concentrations of 5-HIAA to 5-HT are valid 
indices of reduced 5-HT metabolism (Shannon et al., 1986). Since dietary 
precursor manipulation was applied, this reduced 5-HT metabolism could be 
fully ascribed to a reduction in precursor availability or even to a reduction in 
the monoamine oxidase enzyme (MAO), thereby reducing the catabolic rate 
(Fernstrom and Hirsch, 1977). The latter would provide an explanation for the 
fact that 5-HT turnover reduces whereas 5-HT levels remain unchanged, as 
found in the present study.  
 A strong negative association was observed between 5-HT and 5-HT 
turnover in the prefrontal cortex, without any correlations between 5-HT 
turnover and 5-HIAA concentrations. It, thus, seems that ATD-induced 
biochemical alterations are limited to the hippocampus, which would 
corroborate the notion that the method is reliable and relatively stable for its 
cognitive dysfunctional effects in both human subjects and rats. Impaired 
memory consolidation processes after ATD in healthy subjects (Riedel et al., 
1999) have been generally attributed to decreased 5-HT in hippocampal areas 
(Riedel, 2004). Studies of similar ATD experimental design, using the same 
nutritional mixture and dosing regime, consistently report profound object 
memory impairments in rats 4 h after the first oral administration, as measured 
by the object recognition task (Jans et al., 2007a; Jans and Blokland, 2008; 
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Lieben et al., 2004b; Olivier et al., 2008). Further, even a moderate depletion of 
TRP in plasma (Rutten et al., 2007) and single dosing within a relatively short 
period of time (van Donkelaar et al., 2008) considerably interfered with optimal 
object recognition performance and thus the ATD method can be considered a 
reliable memory deficit model. Since BDNF is required for specific memory 
processes (Lee et al., 2004), the positive associations found between central 
TRP and BDNF in the present study are in favour of the suggestion that ATD-
induced cognitive dysfunctional behaviour is BDNF-mediated.  
 In addition, higher concentrations of TRP, 5-HT and 5-HIAA can be 
observed in the prefrontal cortex compared to the hippocampus. This could 
provide an explanation for the fact that, under normal physiological conditions, 
a considerable manipulation of the dietary precursor does not affect the TRP 
concentration sufficiently to alter 5-HT synthesis and metabolism in this brain 
area. In other words, enough TRP will remain available to maintain the rate-
limiting enzyme TPH saturated and the rate of 5-HT synthesis unmodified 
(Boadle-Biber, 1993), which is in line with the fact that ATD only has a mood-
lowering effect in so-called serotonergic vulnerable subjects due to pre-existing 
5-HT dysfunction (Booij et al., 2002; Jans et al., 2007b). 
 Given that disrupted 5-HT metabolism does not unconditionally imply 
diminished 5-HT neuronal activity, the underlying mechanism of the ATD-
induced behavioural changes might go beyond alterations in the 5-HT system. 
The pivotal role of disrupted BDNF regulation in both depressive 
symptomatology and cognitive dysfunction, as well as the co-regulating 
mechanisms between BDNF and the 5-HT system in general, led us to explore 
the effects of ATD upon peripheral and central BDNF levels 4 h after 
treatment initiation. In line with a previous study, which measured ATD-
induced changes in BDNF plasma levels (Cahir et al., 2008), ATD in the 
present study did not affect BDNF levels in serum or central BDNF 
concentrations in the hippocampus or prefrontal cortex. We measured serum 
BDNF, since BDNF is released into the plasma through platelet activation or 
clotting processes (Fujimura et al., 2002). However, it has been suggested that 
changes in serum BNDF might only reflect an in-vitro-effect of alterations in 
platelet release (Cahir et al., 2008; Karege et al., 2005). Yet, since BDNF in 
whole blood is essentially stored in blood platelets, much higher concentrations 
of BNDF are found in serum than in plasma (Radka et al., 1996). Although it is 
generally accepted that neurotrophins, including BDNF, do not easily cross the 
blood-brain barrier in vivo (Pardridge, 2002), evidence exists that BDNF is 
transported into the brain by a saturable transport mechanism (Pan et al., 1998). 
It, therefore, has been suggested that peripheral changes might reflect central 
processes. However, this is not supported by the results of the present study as 
BDNF in serum did not correlate with BNDF levels in the hippocampus or 
prefrontal cortex. Yet, positive correlations have been found between plasma 
BDNF and BNDF concentrations in the dorsal raphe/periaqueductal grey 
region of the brain (Cahir et al., 2008).  
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Whereas no differences were observed in central BDNF protein levels between 
the experimental groups that received either saline or the nutritional mixture 
with (TRP+ group) or without TRP (TRP- group), a significant decrease in 
BDNF levels was found in the prefrontal cortex of the saline treated rats 
compared to the group that did not receive any treatment at all. Although 
blood sampling procedures were similar between all groups, the latter was not 
deprived of food overnight, retained free access to food throughout the entire 
experiment and did not receive any oral applications by gavage. Overnight food 
deprivation and oral gavage procedures can be seen as considerably stressful 
and might interfere with normal brain TRP metabolism (Curzon et al., 1972). 
Both acute and repeated exposures to stressful stimuli have been shown to 
increase glucocorticoid levels and alter 5-HT turnover and release in both the 
hippocampus and frontal cortex (Chaouloff, 1993). Acute and repeated stress 
decrease BDNF mRNA in the hippocampus within 1 h (Smith et al., 1995b), 
partly due to the negative feedback of increased corticosterone levels. Thus, a 
stress-related decrease in prefrontal BDNF might change 5-HT and its 
associated parameters in all groups similarly, thereby interfering with ATD-
induced alterations in 5-HT metabolism. Stress-induced changes in BDNF 
might have interfered with the ATD-induced alterations in 5-HT metabolism in 
general and in the prefrontal cortex in particular. Further studies are needed to 
elucidate the direct effect of an acute decrease in central BDNF levels upon 5-
HT metabolism in the brain.  
 In conclusion, although ATD did not directly affect serum or central 
BDNF levels, positive correlations were found between TRP and BDNF in 
both the hippocampus and prefrontal cortex. The ATD-induced changes in 
5-HT metabolism might not have been sufficient to cause significant alterations 
in peripheral and central BDNF protein levels. Moreover, other factors 
influencing BDNF, including experimental stressors, might have interfered with 
5-HT metabolism in general, thereby preventing or changing the expected 
ATD-induced neurochemical alterations. Nevertheless, the positive relationship 
between TRP and BDNF levels in the brain found in the present study suggests 
that central BDNF is linked to TRP. Although this supports the speculation 
that ATD-induced rat object memory impairment in particular and 
dysfunctional cognitive behaviour in general might be hippocampal BDNF-
mediated, ATD application-related stress affecting prefrontal BDNF seems 
involved in this respect as well. 
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Abstract 
The underlying mechanism of short-term memory improvement 
after inhibition of specific phosphodiesterases (PDEs) is still poorly 
understood. The present study aimed to reveal the ability of PDE5 
and PDE2 inhibitors, that increase cyclic guanosine monophosphate 
(cGMP) and both cyclic adenosine monophosphate (cAMP) and 
cGMP, respectively, to reverse an object recognition deficit induced 
by acute tryptophan depletion. Acute tryptophan depletion is a 
pharmacological challenge tool to lower central serotonin 
(5-hydroxytryptamine; 5-HT) levels by depleting the availability of its 
dietary precursor tryptophan. Short-term object memory was tested 
in male Wistar rats by exposing them to the object recognition task. 
First, the effects of acute tryptophan depletion upon object 
recognition 2 h after administration of the nutritional mixture were 
established. Subsequently, acute tryptophan depletion was combined 
with the PDE5 inhibitor vardenafil (1, 3 and 10 mg/kg) or with the 
PDE2 inhibitor BAY 60-7550 (0.3, 1 and 3 mg/kg), 30 min prior to 
testing. Acute tryptophan depletion significantly lowered plasma 
tryptophan levels and impaired object recognition performance. 
Vardenafil (3 and 10 mg/kg) and BAY 60-7550 (3 mg/kg) were able 
to attenuate the acute tryptophan depletion induced object 
recognition impairment. Thus, both PDE5 and PDE2 inhibition 
improved short-term object recognition performance after an acute 
tryptophan depletion induced deficit. The underlying mechanisms, 
however, remain poorly understood and further studies are needed 
to determine whether the present findings can be explained by a 
direct effect of enhanced cAMP and cGMP levels upon 5-HT 
activity, or even other neurotransmitter systems, and possibly an 
interaction with synthesis of nitric oxide or effects upon cerebral 
blood flow function.  
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Introduction 
The second messenger molecules cyclic adenosine monophosphate (cAMP) 
and cyclic guanosine monophosphate (cGMP) play an important role in 
intracellular signalling and appear to be differentially involved in learning and 
memory processes (Bernabeu et al., 1996; Bernabeu et al., 1997; Prickaerts et 
al., 2002a; Rutten et al., 2007b). Both cAMP and cGMP are selectively 
hydrolyzed by phosphodiesterase (PDE) enzymes and inhibition of the PDEs 
appears to be a reliable method to improve memory processes by increasing the 
levels of either cAMP, cGMP or both (Blokland et al., 2006).  
 From the eleven subclasses of PDEs, enhanced memory performance has 
been demonstrated after inhibition of PDE2 (Boess et al., 2004; Rutten et al., 
2007b), PDE4 (Rutten et al., 2006; Zhang et al., 2005) and PDE5 (Devan et al., 
2006; Prickaerts et al., 2004). Only recently, pro-cognitive effects have also been 
observed after PDE9 inhibition (Van der Staay et al., in press) and inhibition of 
PDE10 is gaining increasing interest for the improvement of cognitive deficits, 
specifically those related to schizophrenia (Schmidt et al., 2008). The PDE 
inhibitors (PDE-Is) type 4 and 5 selectively increase central cAMP and cGMP, 
respectively. PDE2 breaks down both cAMP and cGMP, thus, inhibition leads 
to enhanced concentrations of both second messengers (Boess et al., 2004). 
Whereas several mechanisms may explain the cognitive enhancing properties of 
PDE inhibition for long-term memory, the underlying mechanism for short-
term memory improvement is still poorly understood (Boess et al., 2004; Devan 
et al., 2004; Rutten et al., 2007a). 
 Elevated levels of cAMP and cGMP enhance long term potentiation, which 
is assumed to be the underlying substrate of memory formation (Bliss and 
Collingridge, 1993), through activation of the cAMP/PKA/CREB (Impey et 
al., 1996) and cGMP/PKG/CREB pathway (Lu et al., 1999), respectively. This 
requires gene transcription or protein synthesis and provides an explanation for 
improvement of long-term memory processes after PDE inhibition (Blokland 
et al., 2006), not however for short-term memory enhancement. To date, short-
term memory improvement after PDE2 inhibition has only been demonstrated 
in mice exposed to a spontaneous alternation task, in which the PDE2-I 2-
(3,4-dimethoxybenzyl)-7-{(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl}-5-meth-
yl imidazo[5,1-f][1,2,4]triazin-4(3H)-one (BAY 60-7550) was able to fully 
reverse the working memory deficit induced by the N-methyl-D-aspartate 
(NMDA) receptor blocker MK-801 (Boess et al., 2004).  Improved object 
recognition performance was also found in rats after treatment with the less 
selective PDE5-I zaprinast, which reversed a memory deficit induced by the 
nitric oxide synthase (NOS) inhibitior 7-nitroindazole (Prickaerts et al., 1997). 
In a learning task for rats, NOS inhibition (NOS-I) with N(omega)-nitro-L-
arginine methyl ester (L-NAME) also induced impaired performance, which 
was attenuated after treatment with the highly selective PDE5-I sildenafil 
(Devan et al., 2006). Activation of presynaptic cGMP by elevated levels of nitric 
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oxide (NO), which is a retrograde messenger (Murad et al., 1978), is short-
lasting without the requirement of protein synthesis or gene transcription and 
might thus underlie short-term memory processes. 
 In general, a direct link has been proposed between the levels of cAMP and 
changes in neurotransmitter (acetylcholine, noradrenaline, serotonin and 
histamine) release and activity (Lourenco et al., 2006; Silvestre et al., 1999), 
which could underlie the improvement of short-term memory after inhibition 
of PDE4 (Rutten et al., 2006; Rutten et al., 2007a). Along similar lines, 
involvement of the serotonin (5-hydroxytryptophan; 5-HT) system was 
demonstrated in a recent study in which the highly selective PDE4-I rolipram 
was tested for object recognition performance in a serotonergic deficit model 
induced by acute tryptophan depletion (ATD; Rutten et al., 2007a). Rolipram 
reversed the ATD-induced short-term memory deficits, suggested to be due to 
an interaction with specific neurotransmitter systems.    
 An acute decrease of central 5-HT concentrations can be accomplished by 
applying the ATD method. ATD is a 5-HT challenge tool that manipulates the 
availability of the essential amino acid tryptophan (TRP), the dietary precursor 
of 5-HT (Bell et al., 2005; Neumeister et al., 2005; Young, 1993). By 
administering a TRP-free nutritional mixture, plasma TRP levels are depleted 
and less of the precursor is available for synthesis into 5-HT (Fadda et al., 2000; 
Fernstrom, 1983). The ATD method is widely used both clinically and pre-
clinically as a tool to investigate the implication of the 5-HT system in affective 
disorders (Booij et al., 2003).  
 ATD-induced memory deficits have been observed in both healthy and 
serotonergic vulnerable human subjects (Booij et al., 2005; Evers et al., 2005; 
Jans et al., 2007b; Klaassen et al., 1999; Riedel et al., 1999; Riedel, 2004; 
Sambeth et al., 2007). Moreover, as mentioned above, Rutten et al. (2007a) 
demonstrated that ATD significantly reduces object recognition performance in 
Wistar rats both 1 h and 3 h after administration of the nutritional mixture. 
Similar short-term memory deficits induced by ATD in the rat object 
recognition task have also been demonstrated by others (Jans et al., 2007a; 
Lieben et al., 2004b; Lieben et al., 2005). Thus, the ATD method appears to be 
a reliable deficit model in which memory enhancing compounds, including 
PDE-Is, can be tested (Rutten et al., 2007a).  
 The aim of the present study was to further explore the link between PDE2 
and PDE5 inhibition, the 5-HT system and changes in short-term memory 
performance. In addition to the short-term memory enhancing effects of the 
PDE4-I rolipram (Rutten et al., 2007a), we investigated the ability of the 
PDE5-I vardenafil and the PDE2-I BAY 60-7550 to reverse an ATD-induced 
impairment in object recognition performance. 
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Experimental procedures 
Animals 
A total of 23 six-month-old male Wistar rats (Charles River, The Netherlands) 
were used, weighing between 450 and 500 g at the start of the experiments. On 
arrival, animals were housed individually in standard Makrolon TM (Type III) 
cages on sawdust bedding and maintained on a 12:12-hr light-dark schedule 
(lights on from 18:00 h - 06:00 h) in a temperature controlled (21 ± 2ºC) and 
air-conditioned testing room. Animals were housed in the room where testing 
took place with background noise being provided by a radio playing softly at all 
times. Handling and treatment of the animals was not started until two weeks 
after arrival and food and tap water was freely available throughout this period.  
 All experimental procedures were approved by the local ethical Committee 
on Animal Experimentation of the Maastricht University and were in 
accordance with governmental guidelines. 
Drugs and chemicals 
The TRP-free gelatine hydrolysate (Solugel®) was obtained from PB Gelatins 
(Tessenderlo Belgium). Glucodry 210 was obtained from the Amylumgroup 
(Koog aan de Zaan, The Netherlands). Potassium chloride (KCl) and 
calciumchloride-dihydrate (CaCl2.2H2O) were purchased from Merck 
(Darmstadt, Germany). L-tryptophan was obtained from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Vardenafil and BAY 60-7550 were kindly 
donated by the Chemistry Department of Pharma Research, Bayer AG 
(Wuppertal, Germany). 
Treatments 
Acute tryptophan depletion 
After adaptation to the new environment and the reversed light/dark cycle, 
animals were handled and habituated to the oral administrations by gavage, two 
weeks before the start of the experiments. Rats were food deprived overnight 
prior to each experimental day to avoid any TRP uptake from the standard 
animal chow. For acute reduction of plasma TRP levels, rats were administered 
a TRP-free protein-carbohydrate nutritional mixture (TRP- group). The 
gelatine-based protein nutritional mixture (Solugel®) comprises the entire range 
of amino acids (see Table 1) in the form of peptides, as seen in normal food. 
The addition of carbohydrates activates the insulin response, thereby enhancing 
protein synthesis which results in an optimized reduction of plasma TRP levels 
(Lieben et al., 2004a; Markus et al., 1998). 
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Table 1 Composition of the protein-carbohydrate nutritional mixture and determination of the 
amino acid content (g/100 ml water) of the gelatine based protein (Solugel®) 
Substance Amount (g) 
100  Protein (Solugel®) in 100 ml water 
    Alanine 
    Arginine 
    Aspartic Acid 
    Cysteine 
    Glutamic Acid 
    Glycine 
    Histidine 
    Hydroxylysine 
    Hydroxyproline 
    Isoleucine 
    Leucine 
    Lysine 
    Methionine 
    Phenylalanine 
    Proline 
    Serine 
    Threonine 
    Tryptophan 
    Tyrosine 
    Valine 
 8.4 
7.7 
4.5 
0.0 
10.0 
23.3 
0.9 
1.5 
12.3 
1.2 
2.6 
3.3 
0.9 
1.6 
13.7 
3.4 
1.9 
0.0 
0.6 
2.2 
Carbohydrate (Glucodry 210) in 50 ml water 
KCL in 10 ml water 
CaCl2.2H2O in 10 ml water 
L-tryptophan (TRP+ group) 
L-tryptophan (TRP-  group) 
50 
  0.095 
  2.318 
  0.28 
  0 
 
 
 
 TRP availability for synthesis into 5-HT also depends on the intake of other 
large neutral amino acids (LNAAs; leucine, isoleucine, tyrosine, valine and 
phenylalaline), since they all compete for the same amino acid L-carrier 
transport system for crossing the blood brain barrier (Fernstrom and Wurtman, 
1972; Fernstrom, 1983). Therefore, a decrease of the ratio TRP/ΣLNAAs has 
been used in the present study as the best predictor of reduced availability of 
central TRP (Fernstrom, 1979, 1983).   
 To the control mixture, L-TRP was added in an amount of 0.28% of the 
total protein content (TRP+ group). In addition, a saline group was included to 
control for any effects of the nutritional compounds in general. Nutritional 
mixtures were dissolved in distilled water and freshly prepared in the afternoon 
the day before and stored at 4 ºC until the morning of the day of the 
experiment. Each experimental dose contained 4 g/kg bodyweight of Solugel® 
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and 2 g/kg Glucodry and was administered once in a volume of 10 ml/kg 
between 8:30 and 12:30 h, 120 min prior to behavioural testing.  
Phosphodiesterase inhibitors 
Compounds were freshly prepared on the day of the experimental test trials and 
administered orally by gavage 30 min prior to the start of the first trial (T1) of 
the object recognition task and always in combination with ATD. Vardenafil 
was dissolved in 1% tylose (methyl-cellulose) and tested in doses of 1, 3 and 10 
mg/kg. BAY 60-7550 was suspended in 5% Tween 80 and 1% tylose and tested 
in doses 0.3, 1 and 3 mg/kg. Both PDE-Is were administered in a volume of 2 
ml/kg. Only the 1% tylose was used for the vehicle condition. 
Object recognition task 
The object recognition task was performed as described elsewhere (Prickaerts 
et al., 1997). The apparatus consisted of a circular arena, 83 cm in diameter. 
Half of the 40-cm high wall was made of grey polyvinyl chloride, the other half 
of transparent polyvinyl chloride. During the test sessions only a light bulb was 
switched on with intensity (20 lux) equally spread over the different parts of the 
apparatus. Two objects were placed in symmetrical position, at about 10 cm 
away from the grey wall. Four different objects were used with each object 
being available in triplicate: (1) a cone consisting of a grey polyvinyl chloride 
base (18 cm in diameter) with a collar on top made of brass (total height 16 
cm), (2) a standard transparent (dark-brown) glass bottle (diameter 10 cm, 
height 22 cm), (3) a massive metal cube (10 x 5 x 7.5 cm) with two holes 
(diameter 1.9 cm) and (4) a massive aluminium cube with a tapering top (13 x 8 
x 8 cm). The objects could not be displaced by the rats.  
 Adaptation and training procedures were similar as described by Rutten et 
al. (2007a). In the first week, the animals were handled daily and trained for the 
testing procedures. Training took place on two days, with one day in between 
and consisted of a 3 min exploration of the apparatus without objects. One 
week after the initial training sessions, animals were further adapted by 
exposing them to a 1 h and 24 h interval test session with objects, however, 
without any treatment applications. Subsequently, they were adapted to oral 
administration by gavage, once with saline (10 ml/kg) and once with the 
control mixture (TRP+; 10 ml/kg). In the following weeks, the effect of ATD 
upon object recognition was tested and subsequently the drug compounds were 
tested in combination with ATD. 
 A test session included two trials of 3 min each with a 1 h interval. During 
T1 the apparatus contained two identical objects. A rat was always placed in the 
apparatus facing the wall in the centre of the transparent front segment. After 
the first exploration period, the rat was returned to its home cage. 
Subsequently, after a specific delay interval, the rat was put back into the 
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apparatus for the second trial (T2). In T2 the apparatus contains two different 
objects, a familiar one (from T1) and a new one. The time spent exploring each 
object during T1 and T2 were recorded manually with a personal computer. 
 Exploration was defined as follows: directing the nose to the object at a 
distance of no more than 2 cm or touching the object with the nose. Sitting on 
the object or gnawing an object was not considered exploratory behaviour. To 
avoid the presence of olfactory trails and prevent any use of odour cues, the 
objects were thoroughly cleaned with water and 70% alcohol in between 
sessions. Moreover, each object was available in triplicate, with two objects 
being used in T1 and the third one for the recognition trial. This way, it was 
avoided that any of the two objects of T1 had to be used as the familiar object 
in T2. The order of the objects used per animal and per session was determined 
randomly and all combinations and locations of objects were used in a balanced 
manner to reduce potential biases due to preferences of particular locations or 
objects. 
 In the first experiment, the effects of a single dose of 10 ml/kg of either 
saline, TRP+ or TRP-, in combination with vehicle treatment, 30 min prior to 
testing, upon object memory was measured. In subsequent experiments, the 
ability of both vardenafil and BAY 60-7550 to reverse the ATD-induced 
impairment in object memory was tested. The same animals were used for all 
three experiments and all animals were exposed to each treatment condition in 
a randomized order. Three testing sessions were conducted per week with 48 h 
washout periods in between testing days.  
Blood samples 
At the end of the experiment, the ATD procedure was repeated, including 5 
different treatment conditions, for blood sampling only. For determination of 
peripheral amino acid concentrations, a baseline blood sample was taken by 
means of saphenous vein puncture, 30 min prior to oral administration with 
either saline (n=4), TRP+ (n=4) or TRP- (n=15). Thirty min before the animals 
were decapitated, the saline and TRP+ treatment groups additionally received 
an oral administration with the vehicle solution. The TRP- group received 
either the vehicle solution (n=5) or were treated with 3 mg/kg vardenafil (n=5) 
or BAY 60-7550A (n=5). Dose was chosen based upon least effective dose in 
behavioural task and timing procedures for the specific treatments were in 
accordance with those applied for behavioural testing. A second blood sample 
was taken by collecting trunk blood at time of decapitation, i.e. 120 min after 
ATD and 30 min after treatment with the vehicle or the PDE-Is.  
 Blood was captured into heparin coated tubes (Microvette® CB 300, 
Sarstedt, Germany) which were kept on ice until centrifuged. After 
centrifugation for 10 min at 14,000 x g at 4 ºC (Hettish EBA 12 centrifuge), 
plasma was transferred into cups which were immediately frozen in liquid 
nitrogen and stored at -80 ºC until further analysis. Free plasma amino acid 
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concentrations were determined by means of fully automated high-performance 
liquid chromatography and expressed in μmol per liter. 
Statistical analyses 
Biochemistry 
The mean concentrations of plasma amino acids were determined for each 
treatment condition and time-point separately and TRP/ΣLNAA ratios were 
calculated accordingly. Unexpectedly, a priori differences in baseline plasma 
ratios were found. Exclusion from analyses of extreme values (see below) might 
have contributed to the observed differences. Therefore, mean ratios (+ 
S.E.M.) are represented as percentage change form baseline levels. 
Changes in the ratio TRP/ΣLNAA over time were analyzed by means of two-
way analysis of variance (ANOVA) with Treatment as between-subject factor 
and Time as within-subject variable. Subsequently, one-way ANOVA was 
performed to analyze differences between treatment conditions at the 120 min 
time-point. A post hoc Bonferroni test was used to further characterize the 
treatment effects.  
 Extreme values, as calculated with Dixon’s Extremity test (Dixon, 1959), 
were excluded from statistical analysis. This occurred at baseline in the saline 
group (n=1) and in the TRP-/vehicle group (n=1). At the 120 min time-point, 
extreme values were found in the TRP-/vehicle group (n=1) and the TRP-
/BAY 60-7550 (n=1) group.  
Behaviour 
Behavioural analyses were in line with previous similar studies (Rutten et al., 
2007a). Basic parameters involved are depicted in Table 2 as adapted from 
Prickaerts et al. (1997).  
Table 2 Basic parameters involved in the object recognition task 
Exploration  Discrimination 
e1 = a1 + a2 d2 = (b – a3)/e2 
e2 = a3 + b  
e1 is the time spent in exploring both identical objects (a1 + a2) during the first trial. e2 indicates 
the time spent exploring both the familiar (a3) and the new (b) object in the second trial. d2 
indicates the relative difference in time spent between exploring the familiar and the new object, 
used as discrimination index. 
 
Both e1 and e2 indicate the total exploration activity during T1 and T2, 
respectively, whereas d2 is the relative difference in time spent between 
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exploring the familiar and the new object corrected for total exploration activity 
(e2). All parameters were analysed with one-way ANOVA for each PDE-I 
treatment separately, complemented with a Dunnett post hoc test. Differences 
in exploration time between the doses of each PDE-I treatment were further 
characterized with a Bonferroni post hoc test. 
 All data are represented as mean + standard error of the mean (S.E.M.) and 
acceptable level of significance was generally set at P<0.05.  
Results 
Plasma 
The percentage change of the ratio TRP/ΣLNAA in plasma is shown in Fig.1. 
ATD decreased the ratio over time [F(1, 14) = 399.72; P<0.001] and this 
decrease over time appeared to be different for the treatment conditions [F(4, 
14) = 12.96; P<0.001]. An overall treatment effect was found [F(4, 14) = 8.026; 
P<0.01]. Post hoc analysis showed that TRP+ treatment significantly differed 
from all TRP- treatments. No difference was found between the TRP- group 
treated with 3 mg/kg of vardenafil and the one treated with 3 mg/kg of BAY 
60-7550. Two hours after ATD, decreased TRP/ΣLNAA concentrations were 
observed in all TRP- treatment groups compared to both the saline and TRP+ 
treatment condition (see Fig.1). No differences were found between saline and 
TRP+ treatment. Also, no differences were found between the 3 different 
TRP- treatment conditions.  
 
 
Figure 1 Percentage change of the ratio TRP/ΣLNAA compared to baseline levels (mean + 
S.E.M.) 120 min after treatment. Significant decreases were found after treatment with  TRP-
/vehicle (+), TRP-/vardenafil (3 mg/kg) (#) and TRP-/BAY 60-7550 (3 mg/kg) (a) compared to 
both TRP+/vehicle and saline/vehicle treatment. ++/##/aa P<0.01. TRP-: tryptophan-free 
experimental mixture; TRP+: control mixture with tryptophan 
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Behaviour 
Table 3 shows the exploration times derived from all three behavioural 
experiments. 
Table 3 Total exploration times (mean ± S.E.M. in s) during the first (e1) and second (e2) trial of 
the object recognition task after ATD alone (Exp.1) or ATD in combination with different doses 
of vardenafil (Exp.2) or BAY 60-7550 (Exp.3) 
Experiment Drug ATD Dose  e1 e2 
1 vehicle saline   199 (17) 323 (28) 
  TRP+   203 (16) 345 (29) 
  TRP -   223 (17) 303 (18) 
      
2 vardenafil TRP -    1 mg/kg  227 (17) 264 (20) 
  TRP -    3 mg/kg  178 (14) 295 (18) 
  TRP -  10 mg/kg  167 (16)a 270 (22) 
      
3 BAY 60-7550 TRP - 0.3 mg/kg  290 (29) 286 (19) 
  TRP -    1 mg/kg  142 (14)b 244 (15) 
    TRP -    3 mg/kg  208 (17)b 294 (27) 
(a) indicates significantly different from 1 mg/kg (Exp. 2, P<0.05) (b) indicates significantly 
different from 0.3 mg/kg (Exp. 3, P<0.05)   
Experiment 1 
ATD did not have an effect upon the total exploration times during T1 or T2. 
The effect of ATD upon performance in the object recognition task is depicted 
in Fig. 2. An overall effect of ATD upon object recognition was found [F(2, 65) 
= 5.47; P<0.01]. Post hoc analyses showed that after ATD, performance in de 
object recognition task significantly deteriorated compared to the animals that 
were treated with the TRP+ control mixture. No differences were found 
between the saline group and the TRP+ treatment condition.  
Experiment 2 
As is shown in Table 3, vardenafil treatment decreased the total exploration 
time in T1 [F(2, 68) = 4.10; P<0.05], however, not in T2 [F(2, 68) = 0.66; n.s.]. 
Post hoc analysis showed that the total exploration time in T1 was significantly 
lower after the highest dose (10 mg/kg) of vardenafil compared to the lowest 
dose (1 mg/kg) of vardenafil. Fig. 3 shows the effects of ATD in combination 
with different doses of the PDE5-I vardenafil upon object recognition 
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performance. A dose-dependent increase in object recognition performance 
was found after treatment with vardenafil [F(3, 91) = 8.06; P<0.001]. Post hoc 
analyses showed that both the 3 mg/kg dose and the 10 mg/kg dose of 
vardenafil reversed the effects of TRP- treatment. 
Experiment 3 
As is shown in Table 3, treatment with BAY 60-7550 decreased the total 
exploration time in T1 [F(2, 68) = 12.49; P<0.001], however, not in T2 [F(2, 
65) = 1.64; n.s.]. Post hoc analyses showed that total exploration time was 
significantly lower after treatment with both 1 mg/kg and the 3 mg/kg of BAY 
60-7550, compared to the lowest dose (0.3 mg/kg). Fig. 4 shows the effects of 
ATD in combination with different doses of the PDE2-I BAY 60-7550. A 
dose-dependent increase in object recognition performance was found after 
treatment with BAY 60-7550 [F(3, 88) = 4.64; P<0.01]. Dunnett post hoc 
analyses revealed that the 3 mg/kg dose reversed the effects of TRP- treatment.  
 
 
 
Figure 2 The effects (mean + S.E.M.) of a single dose of 10 ml/kg saline, TRP+ (control mixture 
with tryptophan) or TRP- (tryptophan-free experimental mixture) upon discrimination 
performance (d2) in the object recognition task, 2 h after administration and in combination with 
vehicle treatment 30 min prior to T1. ** P<0.01 indicates significantly different from TRP+ 
group.  
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Figure 3 The effects (mean + S.E.M.) of vardenafil treatment upon ATD-induced deficits in the 
object recognition task. (*) indicates significant difference compared to the TRP-/vehicle 
treatment group * P<0.05, ** P<0.01 
 
 
 
 
 
 
 
Figure 4 The effects (mean + S.E.M.) of BAY 60-7550 treatment upon ATD-induced deficits in 
the object recognition task. * P<0.05 indicates significant difference compared to the TRP-
/vehicle treatment group. TRP-: tryptophan-free experimental mixture 
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Discussion 
In the present study, ATD was applied to impair short-term object recognition 
in rats and to be able to investigate the ability of PDE2 and PDE5 inhibitors to 
restore short-term memory deficits. ATD was established by administering a 
single dose of 10 ml/kg of a TRP-free protein-carbohydrate mixture, which 
resulted in a substantial decrease of the ratio TRP/ΣLNAA in plasma after 2 h 
and significantly impaired object recognition performance. Both the PDE5-I 
vardenafil (3 and 10 mg/kg) and the PDE2-I BAY 60-7550 (3 mg/kg) were 
able to reverse the ATD-induced memory deficit when administered 30 min 
prior to testing, i.e. 90 min after ATD. ATD in combination with vardenafil 
and BAY 60-7550 treatment resulted in significant decreases of the ratio 
TRP/ΣLNAA in plasma, without affecting the ratio differently compared to 
ATD alone. Therefore, the improvement in object recognition, as found in the 
present study, cannot be attributed to PDE-I induced normalization of the 
plasma TRP/ΣLNAA ratio.  
 Similar ATD-induced deficits in object memory performance have been 
found by others between 2 and 4 h after a double dose administration of the 
same nutritional mixture with reductions in the ratio TRP/ΣLNAA up to 60% 
and higher (Jans et al., 2007a; Lieben et al., 2004a). Corroborating earlier 
findings (Rutten et al., 2007a), our data suggest that a single administration of 
the same dose is already sufficient to reach a considerable reduction of the 
TRP/ΣLNAA ratio and impair object memory within 2 h. Taken together, 
these data indicate that a mean ratio TRP/ΣLNAA depletion of 50% and 
higher at 2 h compared to baseline levels, interferes with optimal cognitive 
performance in rats in this task. 
 Whereas ATD did not affect the exploration times, decreased total 
exploration was found in T1 after treatment with the highest dose of vardenafil 
(10 mg/kg) and after treatment with both 1 and 3 mg/kg of BAY 60-7550. 
However, no differences were found in exploration times during T2. Moreover, 
effects upon exploration times appear to be independent of the effects on d2 
measurements (Sik et al., 2003). Of note, the effective doses of the PDE-Is in 
this study are relatively high as compared to PDE-I treatment alone. Most 
likely, side effects of PDE2 and PDE5 inhibition interfered with locomotor 
activity.  
 Treatment with vardenafil selectively inhibits enzymatic activity of PDE5, 
which leads to increased intracellular concentrations of the second messenger 
molecule cGMP as found in hippocampal slices (de Vente et al., 1996; 
Prickaerts et al., 2002b; van Staveren et al., 2001). BAY 60-7550 is a highly 
selective inhibitor of PDE2 and enhances the concentration of both cGMP and 
cAMP (Boess et al., 2004). The present study shows that both vardenafil and 
BAY 60-7550 are able to normalize an ATD-induced short-term memory 
deficit in the object recognition task. Attenuation of ATD-induced object 
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memory impairment has also been observed after inhibition with the highly 
selective PDE4-I rolipram (Rutten et al., 2007a), which leads to increased levels 
of cAMP alone. The second messenger nucleotide cAMP appears to have a 
facilitatory effect upon the release of  the neurotransmitters dopamine, 
norepinephrine and 5-HT (Schoffelmeer et al., 1985). Thus, inhibition of 
PDE4, which increases intracellular cAMP concentrations, might enhance 
5-HT release and compensate for ATD-induced decreases in central 5-HT 
levels, thereby reversing the produced cognitive deficits. In addition, Lorenco et 
al. (2006) revealed that an increase in central 5-HT concentrations by means of 
selective 5-HT reuptake inhibitors corresponded to enhanced cAMP levels as 
measured by rolipram binding. Subsequently, it might be suggested that ATD-
induced lowering of central 5-HT levels goes in line with decreased availability 
of cAMP, which might underlie the cognitive deficits found after ATD. Yet, 
the 5-HT enhancing properties of cAMP might only partly explain our results. 
The cognitive improving effects of rolipram might additionally be ascribed to 
its facility to enhance the cholinergic system, as it is known that rolipram also 
counteracts a cholinergic induced object memory impairment caused by 
scopolamine (Rutten et al., 2006). 
 Similar to our results, BAY 60-5770 was able to antagonize a short-term 
memory deficit induced by MK-801, which blocks NMDA receptor activity 
(Boess et al., 2004) and the PDE5-I zaprinast reversed an object memory deficit 
caused by NOS inhibition (Prickaerts et al., 1997). Likewise, the PDE5-I 
sildenafil was able to reverse an impairment induced by NOS inhibition in a rat 
learning task (Devan et al., 2006). However, the underlying mechanism of the 
enhancing effects of PDE-Is upon short-term memory processes remain rather 
unclear. 
 The cGMP/PKG pathway is implicated in the early phase of long-term 
potentiation (Arancio et al., 1995; Zhu et al., 2001), which might be linked to 
short-term memory (Izquierdo et al., 2002). The enhancing effects of PDE5 
and PDE2 inhibition upon early phase long term potentiation can, besides 
directly increasing presynaptic cGMP levels, be mediated by activation of NOS 
post-synaptically (Domek-Lopacinska and Strosznajder, 2008). Since NO can 
freely diffuse back into the pre-synapse, it can increase cGMP levels by 
stimulating the synthesis of soluble guanylyl cyclase (sGC) (Murad et al., 1978). 
As the pre-synaptic mechanisms are short-lived and do not require gene 
transcription or protein synthesis, they might underlie the improvement of 
short-term object memory after PDE5 and PDE2 inhibition, as was found in 
the present study.  
 ATD might affect memory processes by affecting brain citrulline (CIT) 
concentrations, thereby decreasing NO synthesis (Prast and Philippu, 2001). It 
is known that arginine is catalysed into CIT and NO (Dawson and Dawson, 
1996). Decreased concentrations of CIT after ATD have been observed by 
Lieben et al. (2004a). Recently, as was already referred to above, it was revealed 
that BAY 60-7550 and the PDE5-I zaprinast increased NOS activity in the rat 
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hippocampus and striatum and improved object recognition performance after 
a 2 h interval (Domek-Lopacinska and Strosznajder, 2008). This effect of PDE 
inhibition upon NOS activity could also explain the present results by a direct 
effect upon 5-HT activity. Slight increases in NO concentrations most likely 
enhance 5-HT release whereas moderate increases rather decrease 5-HT release 
(Kaehler et al., 1999). The modulation of 5-HT release by NO might, therefore, 
depend on pre-existing NO concentrations and the effects might be differently 
regulated in distinct brain areas (Smith and Whitton, 2000). It remains to be 
demonstrated to what extent PDE5 and PDE2 inhibition leads to increases in 
NO concentrations. 
 The 5-HT neurotransmitter is a powerful vasoconstrictor, thus, alterations 
in endogenous 5-HT function may alter global or regional neuronal activity 
(Kelly et al., 1988). Consequently, ATD could result in an increase in local 
cerebral blood flow (CBF) due to vasodilatation. Surprisingly, a decrease in 
local CBF after ATD has been reported in humans (Talbot and Cooper, 2006). 
Whether this is also the case for rats remains to be established, though, it could 
explain the ATD-induced object memory deficits. PDE-Is can increase central 
cAMP and cGMP concentrations, which are both known vasodilators 
(Dundore et al., 1993). Thus, PDE-Is could attenuate possible cerebrovascular 
effects of ATD. However, this needs to be elucidated in further studies. 
 In summary, both the PDE5 inhibitor vardenafil and the PDE2 inhibitor 
BAY 60-7550 are able to reverse an ATD-induced object memory deficit. The 
PDE2-I might have an effect via a direct modulation of 5-HT 
neurotransmission, although the exact underlying mechanism of action appears 
to be rather complex. Furthermore, inhibition of PDE5 and PDE2 might 
counteract the ATD-induced deficit possibly through increasing presynaptic 
cGMP levels by inhibiting its degradation. It remains to be investigated whether 
these PDE-Is can stimulate sGC directly through increased levels of NO, 
although the latter can also influence 5-HT levels itself. Further studies are 
needed to determine whether the present findings can be explained by a direct 
effect of enhanced cAMP and cGMP levels upon 5-HT activity or even other 
neurotransmitter systems, and possibly an interaction with synthesis of nitric 
oxide. 
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The implication of the serotonin (5-hydroxytryptamine; 5-HT) system and 
serotonergic vulnerability in the onset of depressive symptomatology is being 
extensively investigated with tools that challenge 5-HT neurotransmission. 
Most widely used, clinically and pre-clinically, is the method of acute 
tryptophan depletion (ATD), which manipulates the availability of the essential 
amino acid TRP, the dietary 5-HT precursor. By administering a TRP-free diet, 
plasma TRP levels are depleted, thereby decreasing the availability of TRP in 
the brain and its synthesis into 5-HT. ATD-induced behavioural changes are, 
therefore, generally attributed to the presumed decrease in 5-HT release and 
subsequent blunted neurotransmission. However, direct evidence that ATD 
decreases extracellular 5-HT concentrations is lacking and it remains unclear to 
what extent changes in 5-HT neuronal activity contribute to ATD-induced 
neurochemical and behavioural alterations. Moreover, in rats, degrees of 
peripheral and central TRP reduction, as well as brain 5-HT concentrations and 
behavioural effects have not been consistently reported. To improve the 
interpretation of clinical ATD-induced symptoms and provide new insights 
into the implication of the 5-HT system in depressive disorders, the present 
thesis covers studies exploring potential alternative mechanisms by which ATD 
exerts its neurophysiological and behavioural effects in rodents.  
 
ATD was induced by administering a gelatin-based (i.e., TRP-free) protein-
carbohydrate nutritional mixture (Solugel®) which is well established in rats 
(Lieben et al., 2004a) and most suitable for comparing the implication of 5-HT 
in neurophysiological functions across species (Blokland et al., 2004). In search 
of genetic 5-HT-related vulnerability factors implicated in the onset of 
depressive disorders, it was initially intended to establish the rat model of ATD 
in mice with the aim to further apply the 5-HT challenge tool in genetic mouse 
models of depression (chapter 2). Several explorative studies in Swiss and 
C57BL/6 mice revealed that in both strains the extent of peripheral TRP 
depletion highly depended upon the specificity of the dosing volume and the 
time-frame of the multiple oral administrations. Moreover, extreme differences 
in ATD effects were found between strains and none of the profound 
peripheral TRP depletions paralleled central TRP or 5-HT changes, nor 
induced any anxiety or depressive-like behaviour. Yet, interfering ATD 
application-related stress effects were found to confound the ATD-induced 
effects upon the ratio of TRP to the sum of other large neutral amino acids 
(TRP/ΣLNAA) in plasma. To gain more insight into the potential mechanisms 
underlying the ATD-induced neurochemical and behavioural effects in general, 
explorative experiments were continued in the established rat model. Whereas 
significant reductions of peripheral TRP levels and the ratio TRP/ΣLNAA 
were observed, no ATD-induced measurable effects upon TRP and 5-HT 
levels in the brain could be revealed (Table1). It might be argued that the extent 
of the peripheral depletion was not sufficient. However, despite the lack of a 
clear central effect, ATD significantly reduced local cerebral blood flow (CBF) 
Thesis_Donkelaar_v8.pdf   177 30-7-2009   15:08:05
Chapter 7 
 178 
in subregions of the hippocampus (chapter 3) and potentiated cerebrovascular 
dysfunction induced by repeated 3,4-methylenedioxymethamphetamine 
(MDMA; ‘ecstasy’) treatment (chapter 4). Moreover, moderate reduction of 
precursor availability in plasma significantly impaired object memory 
performance which was acutely reversed by phosphodiesterase (PDE) 
inhibitors that increase cyclic adenosine monophosphate (cAMP) and/or cyclic 
guanosine monophosphate (cAMP) (chapter 6). Furthermore, ATD did not 
directly affect peripheral or central brain-derived neurotrophic factor (BDNF) 
protein levels, but a positive correlation was found between TRP and BDNF in 
the brain (chapter 5). Interestingly, in line with the confounding ATD 
application-related stress effects in mice, BDNF was significantly lower in the 
prefrontal cortex of all animals that underwent ATD-related application 
procedures compared to a group that was not exposed to any experimental 
stress, such as food deprivation or oral administration by gavage. 
 Taken together, neurophysiological and behavioural changes were observed 
after significant ATD-induced reductions of precursor availability in plasma, yet 
in the absence of central 5-HT reductions. These results support the notion 
that while ATD-induced cognitive dysfunction and affective behavioural 
alterations in both animals and human subjects can be directly attributed to a 
lowering of peripheral TRP concentrations, the exact underlying mechanism 
might go beyond a straightforward alteration in the 5-HT system itself. 
Table 1 Peripheral and central effect of acute tryptophan depletion in adult male Wistar rats as 
described in the studies of this thesis 
   Plasma Brain 
   % change from 
baseline 
% difference from TRP+ group 
Chapter Study 
 
Time TRP/ΣLNAA TRP 5-HT 5-HIAA 5-HIAA/5-HT 
3 ATD/  
Cerebrovascular 
dynamics 
T4 -40% - - - - 
4 ATD / MDMA T4 -37% (MDMA) 
-40% (control) 
- 
 
- - - 
5 ATD / BDNF T4 -56% - - -33%  
(hippo) 
-28%  
(hippo) 
6 ATD / PDE-Is T2 -73% n.a. n.a. n.a. n.a. 
ATD: acute tryptophan depletion (TRP-treatment); BDNF: brain-derived neurotrophic factor; 
hippo: hippocampus; MDMA: 3,4-methylenedioxymethamphetamine (‘ecstasy’); PDE-Is: 
phosphodiesterase inhibitors; T: time in h after first administration; TRP: tryptophan; 
TRP/ΣLNAA: the ratio TRP to the sum of other large neutral amino acids; 5-HT: 
5-hydroxytryptamine, serotonin; 5-HIAA: 5-hydroxyindoleacetic acid; (-) no change 
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Methodological considerations 
Measuring central effects of acute tryptophan depletion  
The ratio TRP/ΣLNAA in plasma 
ATD-induced reductions in central 5-HT availability have been extensively 
reported in both human subjects and animals. Yet, as outlined in the 
introduction of this thesis, most parameters applied to indicate reduced 5-HT 
synthesis or release appear to merely estimate decreases in 5-HT metabolism 
and neuronal activity, respectively, thereby remaining rather speculative. In 
general, the ratio TRP/ΣLNAA in plasma is used to estimate the amount of 
TRP available in the brain for synthesis into 5-HT, whereas in practise it 
provides only a rough estimation of the amount of TRP in the blood that will 
eventually be available to cross the blood-brain barrier (BBB). In most cases, 
including the studies in the present thesis, total peripheral TRP levels (free plus 
albumin-bound) are used for calculating the ratio to the sum of the other 
LNAAs. Although only the relatively small fraction of free TRP eventually 
crosses the BBB, TRP can easily dissociate from albumin near the BBB, thereby 
increasing the TRP-free pool and subsequent uptake into the brain. However, 
the direct effect of physiological factors such as hormones, exercise or mild 
stressors upon the rate of dissociation of TRP from albumin can only be taken 
into account if both total and free TRP levels are actually measured (Badawy, 
2009), which is normally not done. Thus, based upon total peripheral TRP 
levels alone, the ratio TRP/ΣLNAA in plasma might result in a distorted 
estimation of the rate of influx of TRP into the brain.  
 Moreover, other large neutral amino acids such as methionine (MET) and 
threonine (THR) are generally not included in the ratio as active competitors of 
plasma TRP. However, evidence exists that, together with the branched-chain 
amino acids (valine, leucine, isoleucine) and the aromatic amino acids (TRP, 
tyrosine, phenylalaline), MET and THR share the same L-amino acid transport 
carrier at the BBB (Oldendorf and Szabo, 1976; Pardridge, 1998; Smith, 2000). 
Thus, calculating the ratio TRP/ΣLNAA without taking into account all 
competitive amino acids is most likely to result in an overestimation of brain 
TRP influx and subsequent dissociation from brain TRP levels.  
The ratio 5-HIAA/5-HT in the brain 
In contrast to human subjects, animal models provide the possibility to directly 
measure changes in TRP, 5-HT and 5-HIAA concentration in specific areas of 
the brain. Only a few rat studies of similar experimental design as that used in 
the studies of this thesis, including the same nutritional mixture, have reported 
ATD-induced decreases in central TRP and/or 5-HT (Jans et al., 2008; Jans et 
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al., 2007; Lieben et al., 2004a; Olivier et al., 2008), mainly in the hippocampus. 
However, besides the fact that these central changes generally fail to parallel the 
acute changes in peripheral TRP levels, the extent of depletion seems highly 
variable between studies. In the studies of the present thesis, no significant 
changes in central TRP levels or 5-HT concentrations were observed, despite 
the considerable decrease in the ratio TRP/ΣLNAA in plasma. Although this 
might provide evidence for the fact that ATD does not considerably interfere 
with 5-HT synthesis in the brain, the ratio 5-HIAA/5-HT has been reported to 
better reflect changes in 5-HT synthesis and metabolism in general (Shannon et 
al., 1986). Together with brain 5-HIAA concentrations, the ratio 
5-HIAA/5-HT is normally used to calculate the 5-HT turnover rate and 
estimate changes in 5-HT release, reflecting neuronal activity. However, this 
seems to apply only under normal physiological conditions when the rate of 
5-HT synthesis remains constant. An increase in 5-HIAA levels would then 
increase the ratio 5-HIAA/5-HT and allows proper estimation of an increase in 
5-HT neuronal activity, as more 5-HT has presumably been released. 
Conversely, a decrease in 5-HIAA levels under a constant rate of 5-HT 
synthesis would decrease the ratio 5-HIAA/5-HT. Yet, ATD is applied to 
induce a decrease in 5-HT synthesis. As a decrease in intracellular 5-HT 
availability most likely results in a reduction of the amount of 5-HT available 
for release, less extracellular 5-HT will then be available to be catabolyzed into 
5-HIAA. Thus, ATD is likely to decrease both 5-HT and 5-HIAA, thereby 
maintaining the ratio 5-HIAA/5-HT constant. In line with this, no changes in 
the ratio 5-HIAA/5-HT were found 3 hr after ATD, whereas both 5-HT 
(-23%) and 5-HIAA (-39%) levels appeared to be significantly decreased in rat 
hippocampus (Brown et al., 1998). A decrease in this ratio after ATD would 
only occur if significantly less 5-HIAA is produced compared to the already 
reduced amount of 5-HT synthesised.  
 The conversion of TRP into the 5-HTP intermediate by the TPH2 isoform 
is the first and rate-limiting step in the biosynthesis of 5-HT. In the brain, this 
enzyme is only 50% saturated and therefore, the rate at which 5-HT is 
synthesised is limited only by substrate (i.e., TRP) availability (Boadle-Biber, 
1993). However, it seems difficult to directly attribute an ATD-induced 
decrease in the ratio 5-HIAA/5-HT to a reduction in TRP availability. Brain 
measurements are generally taken at only one specific time point which 
impedes a comparison of the central parameters to baseline values. In one of 
the studies (chapter 5), a decrease in 5-HIAA levels and in the ratio 
5-HIAA/5-HT was observed in the hippocampus. Such changes are normally 
interpreted as evidence for an ATD-induced reduction in 5-HT metabolism. 
However, 5-HT levels were not changed compared to TRP+ treatment and 
information upon baseline 5-HT values is lacking. Similar reductions of the 
ratio 5-HIAA/5-HT have also been observed by others after ATD in rats, but 
between the studies concomitant changes in 5-HIAA or 5-HT in specific brain 
areas do not seem to be in accordance with each other (Ardis et al., 2009; Cahir 
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et al., 2008; Jans et al., 2008). In general, it appears that ATD-induced absolute 
changes in central 5-HT or 5-HIAA concentrations and potential underlying 
mechanisms require further examination.  
 A decrease in the ratio 5-HIAA/5-HT after ATD seems more likely to be 
caused by factors influencing the catabolism of 5-HT, such as fluctuations in 
the activity of the monoamine oxidase (MAO) enzyme (Fernstrom and Hirsch, 
1977). An acute decrease in MAO activity would reduce the absolute amount of 
5-HIAA produced, thereby producing a relative increase in 5-HT levels. This 
would eventually lower the ratio 5-HIAA/5-HT independent of a reduction in 
precursor availability per se or the subsequent decrease in 5-HT synthesis and 
as such does not reflect a decrease in 5-HT release. Although an acute change 
in MAO activity could imply a compensatory mechanism activated upon the 
acute decrease in peripheral TRP levels, such a mechanism has not been 
described previously and thus remains to be further elucidated.  
Other rat studies of similar experimental design have directly reported 
ATD-induced decreased 5-HT levels after administration of the same TRP-free 
nutritional mixture (Jans et al., 2008; Lieben et al., 2004a; Olivier et al., 2008). 
This is generally thought to reflect an ATD-induced decrease in 5-HT 
synthesis. However, as mentioned previously, the decrease in 5-HT after TRP- 
treatment at one specific time point is normally only compared to the control 
TRP+ treatment group and not to its own baseline concentrations. Thus, 
without these baseline values prior to treatment, the extent to which the 
significant difference in 5-HT levels between the experimental (TRP-) and 
control (TRP+) treatment group actually imply a reduction in 5-HT release 
after ATD remains unclear. In addition, actual reductions of basal 5-HT release 
after ATD have only been reported in combination with 5-HT reuptake 
inhibitors (Bel and Artigas, 1996; Fadda et al., 2000; Stancampiano et al., 1997) 
not, however, without an initial increase of extracellular 5-HT levels (Trulson, 
1985; van der Plasse et al., 2007). It might be suggested that in the absence of de 
novo synthesis, 5-HT function can largely be maintained from transmitter being 
recycled into the presynaptic cell from the synaptic cleft. A possible decrease in 
5-HT and 5-HIAA might then reflect a decrease in the storage pool of 5-HT 
without affecting 5-HT release (Trulson, 1985).  
 Taken together, not only may the parameters used to calculate reductions in 
brain TRP availability and 5-HT metabolism be somewhat inaccurate, no direct 
evidence exists that the ATD-induced reductions in central 5-HT levels 
correlate with parallel changes in 5-HT neuronal activity. In general, therefore, 
ATD-induced behavioural alterations cannot easily be directly attributed to 
changes in 5-HT neuronal activity. This leaves the contribution of alternative 
mechanisms open, which is supported by the findings described in the present 
thesis.  
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Potential alternative mechanisms 
Decreased nitric oxide synthase activity 
The enzyme nitric oxide synthase (NOS) catalyzes the conversion of the amino 
acid arginine (ARG) into citrulline (CIT) and nitric oxide (NO; Dawson and 
Dawson, 1996). Thus, NOS inhibition results in less conversion of ARG into 
CIT and NO, and the amount of NO synthesis might be directly related to the 
levels of ARG and CIT. Significant lower CIT levels were found in the 
hippocampus after TRP- treatment compared to TRP+ treatment (chapter 3), 
which had been previously reported by others (Lieben et al., 2004a). However, 
in both cases the decrease in CIT concentration appeared to be independent of 
changes in its precursor ARG. This suggests that a decrease in peripheral TRP 
might directly affect the activity of NOS, and that decreases in CIT most likely 
parallel decreases in NO. Endogenous NO can modulate neuronal function 
through interference with the release of several neurotransmitters (Prast and 
Philippu, 2001), yet its precise interaction with the 5-HT system seems rather 
complex. Whereas slight increases in NO concentrations most likely enhance 
5-HT release, moderate increases appear to decrease 5-HT release (Kaehler et 
al., 1999). The modulation of 5-HT release by NO might therefore depend on 
pre-existing NO concentrations and the effects might be differently regulated in 
distinct brain areas (Smith and Whitton, 2000).  
 A decrease in the activity of NOS and subsequent decreased synthesis of 
NO after ATD could underlie the ATD-induced object memory impairments 
(Blokland et al., 1998). Hippocampal inhibition of NOS is known to impair 
object recognition performance in rats (Blokland et al., 1998; Prickaerts et al., 
2002). Since the ATD-induced decrease in brain CIT levels is seemingly caused 
by an interruption in NOS activity, this same decrease in NOS activity 
presumably also decreases the synthesis of NO, which could explain the ATD-
induced object recognition impairments found in the present thesis (chapter 6).  
 The second messenger molecules cyclic adenosine monophosphate (cAMP) 
and cGMP play an important role in intracellular signalling and are highly 
involved in learning and memory processes (Bernabeu et al., 1996; Bernabeu et 
al., 1997; Prickaerts et al., 2002; Rutten et al., 2007b). Both cAMP and cGMP 
are selectively hydrolyzed by PDE enzymes, and inhibition of PDE appears to 
be a reliable method for improving memory processes by increasing the levels 
of either cAMP, cGMP or both (Blokland et al., 2006). Administration of the 
PDE2 inhibitor, BAY 60-7550, and the PDE5 inhibitor, zaprinast, have shown 
to increase NOS activity in rat hippocampus and striatum, and improve object 
recognition performance (Domek-Lopacinska and Strosznajder, 2008). Thus, 
besides directly increasing presynaptic cGMP levels, the enhancing effects of 
PDE5 and PDE2 inhibition upon memory performance might also be 
mediated by activation of NOS post-synaptically (Domek-Lopacinska and 
Strosznajder, 2008). Since NO can freely diffuse back into the pre-synapse, it 
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can increase cGMP levels by stimulating the synthesis of soluble guanylyl 
cyclase (sGC) (Murad et al., 1978). An increase in NOS activity most likely 
increases NO concentrations, which might underlie the improvement of the 
ATD-induced memory impairment by the PDE2 inhibitor BAY 60-7550 and 
the PDE5 inhibitor vardenafil as revealed in the present thesis (chapter 6).  
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Figure 1 Potential underlying mechanism of acute tryptophan depletion-induced rat object 
memory impairment and its attenuation through phosphodiesterase inhibition 
A decrease in the ratio of tryptophan (TRP) to the sum of other large neutral amino acids 
(ΣLNAA) induced by acute tryptophan depletion (ATD) potentially directly affects (-) the activity 
of nitric oxide synthase (NOS), thereby decreasing central citrulline (CIT) levels independent of 
changes in the concentration of its precursor arginine (ARG). A decrease in CIT most likely 
parallels a reduction in nitric oxide (NO) which subsequently affects local cerebral blood flow 
(CBF) in brain areas highly implicated in object memory processes. Indicated with (+) is the 
possible mechanisms behind the improvement of object memory deficits by inhibition of either 
the phosphodiesterase (PDE) enzyme type 2 (PDE2-I) or type 5 (PDE5-I), thereby directly 
increasing the levels of cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine 
monophosphate (cGMP), respectively. Both second messenger molecules are highly implicated in 
learning and memory processes. Inhibition of both types of PDE also directly activates NOS, 
thereby increasing NO levels that stimulate the synthesis of soluble guanylyl cyclase (sGC) and 
cGMP pre-synaptically. The vasodilating properties of the PDE5 and PDE2 inhibitors might 
additionally attenuate ATD-induced decreases in CBF. (-) inhibition or decrease; (+) stimulation 
or increase 
Cerebrovascular abnormalities 
Under normal physiological conditions, the cerebral metabolic rate of glucose 
(CMRG) provides an index of changes in regional neuronal activity, and 
changes in glucose metabolism are found to be closely coupled to changes in 
CBF (Kuschinsky, 1991; Sokoloff, 1981). On this basis, abnormalities in either 
of these closely linked neurophysiological parameters in depressive subjects are 
thought to reflect changes in serotonergic neurotransmission in brain areas that 
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can be functionally linked to the complexity of depressive symptomatology 
displayed (Drevets et al., 1998a, 1998b; Drevets et al., 1999; Drevets, 2000). 
However, the 5-HT neurotransmitter is a powerful vasoconstrictor (Edvinsson 
and MacKenzie, 1976) and serotonergic fibers innervating cerebral arteries, 
arterioles and veins have been identified (Steinbusch, 1981). Thus, if depression 
is represented by decreased central 5-HT neurotransmitter concentrations, an 
increase in CBF would seem more likely. Likewise, ATD presumably reduces 
5-HT synthesis and thus decreases vasoconstrictor tone, thereby most likely 
increasing CBF due to vasodilation. Surprisingly, a decrease in local CBF 
following ATD has been reported in human subjects (Talbot and Cooper, 
2006) and was also observed in rats (chapter 3), where the acute decrease of 
peripheral TRP levels resulted in a downwards resetting of the cerebral flow-
metabolism coupling relationship independently of changes in central TRP or 
5-HT. This parallels preliminary findings of an uncoupling of flow from 
metabolism in unipolar depressed patients compared to bipolar patients and 
healthy controls (Dunn et al., 2005). Although controversy exists about the 
exact location and direction of the neurophysiological abnormalities in 
depressive subjects (Drevets, 2000; Soares and Mann, 1997), depressive illness 
is generally characterized by decreases in cerebral blood flow and glucose 
metabolism in limbic and prefrontal cortex structures. However, it seems 
unlikely that a decrease in 5-HT alone accounts for the specific decreases in 
haemodynamic regulation. In addition, low CBF most likely increases the 
interaction between the albumin-bound TRP complex and the glycocalyx of the 
BBB, thereby causing more TRP to dissociate from albumin (Pardridge and 
Fierer, 1990; Smith et al., 1987). This might provide an explanation for the fact 
that ATD-induced peripheral depletion of total TRP levels does not result in 
significant decreases in brain TRP availability. Although it remains unclear how 
changes in peripheral TRP concentrations can interfere with the dynamic 
regulation of cerebral blood flow, the findings support the notion that the 
underlying mechanisms of ATD might go beyond a straightforward 5-HT-
mediated mechanism and that depression in general cannot be simplistically 
described as a 5-HT dysfunctional disorder (see also Figure 1). 
 In general, decreased local CBF is best explained by a loss of dilator tone. 
Decreased local CBF has also been reported after direct inhibition of 
endothelial or neuronal NOS (Kelly et al., 1994; Kelly et al., 1995) and, as 
mentioned previously, direct inhibition of NOS in the hippocampus is known 
to impair object memory performance. These findings, together with the ATD-
induced reduction in local CBF independent of central 5-HT changes, support 
the suggestion that the ATD-induced impairments in object memory 
performance of rats is most likely ascribed to a decrease in NO after ATD. The 
involvement of NO can be explained by the ATD-induced changes in brain 
levels of CIT as described earlier. All the findings together suggest that ATD-
induced object memory impairments are most likely caused by a decrease in 
NO which reduces local CBF in hippocampal areas highly implicated in 
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memory processing. Additionally, this is in line with the fact that PDE2 and 
PDE5 inhibition have been found to increase NOS activity in the 
hippocampus, which explains their potential to attenuate object memory 
impairments. In addition, PDE inhibitors increase central cAMP and cGMP 
concentrations, which are both well known vasodilators (Dundore et al., 1993). 
Although no direct effects upon cerebrovascular dynamics have been found 
after PDE2 or PDE5 inhibition (Rutten et al., 2009), their strong vasodilating 
properties might contribute to the improvement of object memory 
performance through attenuation of the ATD-induced cerebrovascular effects.  
Decreased brain-derived neurotrophic factor 
The pivotal role of disrupted BDNF regulation in both depressive 
symptomatology and cognitive dysfunction, as well as the co-regulating 
mechanisms between BDNF and the 5-HT system in general, lead us to explore 
the effects of ATD upon peripheral and central BDNF levels. Highest levels of 
BDNF mRNA have been reported in the dentate gyrus and hippocampal CA3 
and CA2 layers (Ernfors et al., 1990; Smith et al., 1995a) which corresponds 
with areas in which ATD induced decreases in local CBF were observed 
(dentate PO, CA3 and CA2 region of the hippocampus). Regional changes in 
BDNF protein levels have been found after brief cerebrovascular events 
(Kokaia et al., 1996), consistent with the fact that BDNF plays an important 
neuroprotective role (Larsson et al., 1999; Lindvall et al., 1994).  
Neurotrophins also play an important role in neuronal plasticity, including 
long-term potentiation (LTP). As LTP is assumed to be the underlying 
substrate of learning and memory processes (Bliss and Collingridge, 1993), 
BDNF is thought to be a potential mediator of memory formation in general, 
and is known to be required specifically for memory consolidation (Lee et al., 
2004). ATD in human subjects selectively impairs memory consolidation 
(Riedel et al., 1999), which has been suggested to be caused by lower 5-HT in 
hippocampal areas (Riedel, 2004). However, the ATD-induced cerebrovascular 
changes, independent of changes in central 5-HT levels, suggest that decreased 
CBF in brain regions normally high in BDNF levels might underlie BDNF-
mediated alterations in learning and memory processing after ATD. Moreover, 
ATD did not induce direct changes in peripheral or central BDNF levels 
(chapter 5), which has also been reported by others (Cahir et al., 2008).  
Kynurenine metabolites 
TRP not only leaves the plasma by uptake into the brain, but also by catabolism 
in the liver by TRP pyrrolase into kynurenine (KYN) and to a minor extent by 
excretion into the urine. KYN is the major degradation product of TRP and is 
further converted into potentially neuroactive metabolites such as kynurenine 
acid (KYNA) and quinolinic acid (QUINA; Young and Leyton, 2002). 
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Independently of each other, both metabolites exert specific effects upon 
N-methyl-D-aspartate (NMDA) receptors (Stone, 1993), which play an 
important role in LTP and memory formation (Morris et al., 1990; Morris, 
2003). NMDA receptor antagonists have been shown to inhibit LTP and 
selectively impair learning and memory (Morris et al., 1986). Whereas KYNA 
has a neuroprotective, antagonistic effect upon glutamatergic NMDA receptors, 
QUINA depolarises neurons by activating NMDA receptors (Stone and 
Perkins, 1981). As a result, QUINA can induce overstimulation of the NMDA 
receptor, thereby producing neurotoxicity and subsequent neurotoxic damage, 
similar to that found in hypoxia and ischemia (Schwarcz et al., 1983; Stone, 
2001; Stone et al., 2007). Thus, an ATD-induced shift in the balance of KYN 
metabolites could provide an explanation for the observed cerebral oligaemia 
paralleling decreased peripheral TRP levels (chapter 3) and might additionally 
account for the consistently reported memory impairments after ATD, as has 
been suggested by others (Blokland et al., 2004). However, unpublished 
preliminary data do not support this hypothesis, as no changes were observed 
in central KYN levels or its metabolites 4 h after ATD in rats (Lieben, 2004). 
Confounding stress effects 
Together with other monoamine systems, brain 5-HT is critically involved in 
the mediation of the central response to stressors and subsequent behavioural 
adaptation (de Kloet et al., 2005). Acute stressors stimulate the hypothalamic-
pituitary-adrenal (HPA) axis activity, thereby increasing central 5-HT necessary 
for stress coping (van Praag, 2004). Overnight food deprivation, repeated oral 
administrations by gavage, blood sampling and the immobilization necessary 
for applying the former are well-known stressors (Chamas et al., 2004; Curzon 
et al., 1972; Jahng et al., 2007; Nakahara and Nakamura, 1999), yet are 
experimental procedures inevitably implicated in the application of the ATD 
method. Previous studies with human subjects have revealed that stress might 
be a critical factor in mediating alterations in the ratio TRP/ΣLNAA in plasma 
and subsequent changes in behavioural performance (Markus et al., 2000a; 
Markus, 2007, 2008; Markus et al., 2000b). In rats, both acute and repeated 
exposure to stressful stimuli have been shown to increase glucocorticoid levels 
and alter 5-HT turnover and release in both the hippocampus and frontal 
cortex (Chaouloff, 1993). Thus, ATD application-related procedures might 
interfere with normal brain TRP metabolism and subsequent 5-HT synthesis, 
thereby acting as confounding stress factors for the pharmacokinetic and 
behavioural effects of ATD. 
Stress and tryptophan-albumin binding 
Evidence exists that drugs that displace TRP from its albumin binding sites 
increase brain TRP levels. Likewise stress-induced changes in the breakdown of 
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fat stored in fat cells (lipolysis) may alter brain TRP concentrations. In the same 
way that insulin stimulates the uptake of albumin-bound fatty acids by fat cells, 
thereby decreasing the fraction of free TRP in plasma, stress can result in the 
reverse; stress increases lipolysis and thus the amount of plasma free-fatty acids 
(McMenamy, 1965). This increases the affinity of albumin for fatty-acids, 
thereby displacing TRP from its albumin binding sites. The resultant increase in 
the fraction of free TRP in plasma might increase the availability of TRP for 
uptake into the brain. The subsequent acute increase in brain TRP availability 
might be reflected upon the compensatory increase in tryptophan hydroxylase 
(TPH) levels, as has been demonstrated after a single exposure to 
immobilization stress in male Sprague Dawley rats (Chamas et al., 2004). 
Similarly, at a central level the combination of immobilization stress and food 
deprivation has been reported to increase brain TRP levels in rats to a 
considerable greater level than either of the stressors alone (Curzon et al., 
1972). As more 5-HT is needed to be able to cope with the acute stressful 
situation, brain TRP levels rise to maintain adequate 5-HT concentration.  
 These findings strongly support the results reported in the present thesis. In 
C57BL/6 mice, multiple experimental procedures together significantly altered 
the ratio TRP/ΣLNAA in plasma within 20 min (Chapter 2, study 5). Whereas a 
significant decrease was found after food deprivation together with blood 
sampling, oral treatment by gavage after blood sampling and food deprivation 
increased the ratio TRP/ΣLNAA 20 min after treatment. The latter 
combination represents the standard experimental situation and thus suggests 
that a profound depletion of peripheral TRP is more difficult to establish if the 
ratio initially increases due to acute stress of experimental procedures. In 
addition, decreased levels were found in prefrontal BDNF levels after overnight 
food deprivation together with an oral application by gavage compared to a 
group that was not food deprived or exposed to gavage procedures (Chapter 5). 
Moreover, this paralleled the lack of changes in 5-HIAA levels and the ratio 
5-HIAA/5-HT in the prefrontal cortex after ATD, whereas a significant ATD-
induced decrease was found in these parameters in the hippocampus where no 
changes in BDNF were observed. BDNF is known to be extremely stress-
responsive (Smith et al., 1995b), which is supported by studies showing that 
both acute and repeated immobilization stress considerably decreases BDNF 
mRNA even within 1 h (Smith et al., 1995a; Ueyama et al., 1997). Thus, 
experimental stressors might have interfered with 5-HT metabolism through 
adapting BDNF levels, thereby preventing or changing the expected ATD-
induced neurochemical alterations. Stress-induced changes in BDNF are not 
only glucocorticoid-mediated (Prickaerts et al., 2006), but might be additionally 
regulated by alterations in the activity of specific 5-HT receptors (Vaidya et al., 
1997; Vollmayr et al., 2000). In general, acute stress effects might explain the 
moderate depletion found in the studies of the present thesis, and the failure to 
considerably reduce central 5-HT levels. 
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Figure 2 Potential confounding stress effects of acute tryptophan depletion application-related 
procedures 
The method of acute tryptophan depletion (ATD) requires several highly stressful procedures, 
such as overnight food deprivation, repeated blood sampling, oral administrations by gavage and 
immobilization. Acute stress stimulates lipolysis, thereby increasing the amount of free-fatty acids 
in plasma that displace tryptophan (TRP) from its albumin binding sites. The resultant rise in free 
plasma TRP changes the ratio of TRP to the sum of the other large neutral amino acids 
(TRP/ΣLNAA) in favour of TRP, thereby increasing the amount of TRP available for uptake 
into the brain and its subsequent synthesis into 5-HT. Stress stimulates the secretion of 
corticosterone (CORT) that decreases brain-derived neurotrophic factor (BDNF) and 5-HT1A 
receptor binding. Both BDNF and 5-HT1A receptor functioning are highly implicated in learning 
and memory processes. The acute stress of ATD application-related procedures might thus 
explain the failure of ATD to considerably decrease 5-HT metabolism and its negative effect 
upon object memory performance through increased CORT levels. 
 
 
The effects of acute stress, including the ATD-related application procedures, 
upon 5-HT autoreceptor binding might additionally provide an explanation for 
the consistently reported ATD-induced memory dysfunction as indicated by 
object recognition impairment in rats (Jans et al., 2008; Jans et al., 2007; Jans 
and Blokland, 2008; Lieben et al., 2004b; Rutten et al., 2007a; van Donkelaar et 
al., 2008). Moreover, the impairment in object memory performance seems 
even more pronounced in 5-HT transporter (SERT) knockout rats that are 
predisposed of abnormal 5-HT function (Olivier et al., 2008). Repeated 
exposure to food deprivation stress appears to decrease SERT mRNA levels 
(Jahng et al., 2007) and has also been shown to impair object memory 
performance (Beck and Luine, 1999). Several 5-HT receptors, including 
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5-HT1A, are known to be highly involved in memory function (King et al., 
2008) and ATD has been shown to decrease 5-HT1A receptor binding (Cahir et 
al., 2007). Moreover, acute corticosterone administration directly decreases 
5-HT1A autoreceptor functioning (Laaris et al., 1995). Decreased SERT 
function is generally associated with increased stress responsivity (Canli and 
Lesch, 2007), which might explain why SERT knockout rats show impaired 
object recognition even after administration of the TRP+ control mixture 
(Olivier et al., 2008). Yet, untreated SERT knockout rats did not show an 
impairment in object memory performance, which seems to be in line with the 
confounding ATD-application effects revealed in the presents thesis (chapter 2 
and 5). Thus, a more generalized stress effect of ATD application-related 
procedures, possibly linked to a decrease in 5-HT1A receptor function as 
described above, might underlie the ATD-induced impaired object recognition 
performance for which intact 5-HT1A receptor function seems to be crucial (see 
also Figure 2). 
Implications for cognitive and affective processes 
The 5-HT system is highly implicated in a wide range of functional processes. 
After mood lowering, cognitive functioning is the most prominently impaired 
functional process implicated in clinical depression. Whereas mood-lowering 
effects after ATD are only experienced in depression-free subjects predisposed 
to genetic 5-HT abnormalities, altered cognitive processing after ATD is 
observed in both healthy and genetically vulnerable subjects. Moreover, ATD-
induced impaired object memory performance as measured by the object 
recognition task is consistently reported in rats (Jans et al., 2008; Jans et al., 
2007; Jans and Blokland, 2008; Lieben et al., 2004b; Olivier et al., 2008) even 
after only moderate peripheral TRP depletion (Rutten et al., 2007a) or a single 
administration (van Donkelaar et al., 2008). For adequate cognitive processing, 
the 5-HT system interacts highly with other neurophysiological systems that 
might all be interrupted after ATD, as confirmed by the findings reported in 
the present thesis. This further supports the notion that an acute decrease in 
peripheral TRP levels directly interferes with mechanisms implicated in 
cognitive processing that presumably depend less upon 5-HT functioning per 
se. The potential alternative mechanisms underlying ATD effects might 
therefore provide an explanation for the consistently reported ATD-induced 
cognitive deficits across species.  
 Chronic exposure to stressful situations is one of the main contributing 
factors to the onset of depressive illness (van Praag, 2004) and an intact 5-HT 
system is critical for mediating an adequate neurophysiological stress response 
and subsequent behavioural adaptation (de Kloet et al., 2005). At the level of 
somatodendritic 5-HT autoreceptors, adaptations to stress might be reflected 
by a reduction of these receptors, thereby reducing serotonergic feedback in 
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dorsal raphe projection areas in an attempt to counteract an ATD-induced 
decrease in central 5-HT (Cahir et al., 2007). Such an adaptive mechanism to an 
acute stressor might be less efficient in subjects predisposed to 5-HT 
dysfunction, which might account for the mood-lowering effects after ATD in 
these subjects.  
 Both 5-HT1A and 5-HT2A receptors are highly implicated in the mechanism 
of action of many antidepressants (Cryan and Leonard, 2000). One of the most 
remarkable effects of ATD in human subjects is that it only induces a 
depressive relapse in medication-free, remitted, depressed patients with a 
positive treatment history of serotonergic antidepressants. Antidepressant 
treatment with either selective serotonin re-uptake inhibitors (SSRIs) or MAO 
inhibitors (MAO-Is) are generally associated with a decrease in 5-HT2 receptors 
(Cryan and Leonard, 2000; Landen and Thase, 2006), whereas depression has 
been associated with an up-regulation of these 5-HT receptors. Thus, in 
general, the change in postsynaptic 5-HT2 receptors (density or binding sites), 
caused either by a decrease in 5-HT release or representing stress-induced 
adaptations, could be responsible for a subject’s experience of depressive 
symptoms. Although, ATD does not significantly decrease 5-HT2A receptor 
binding in adult male rats, a positron emission tomography (PET) study in 
humans has revealed decreased 5-HT2 binding in female subjects (Yatham et al., 
2001). This might be in line with sex-specific changes in the number of binding 
sites that have been reported in rats and might link sex differences in peripheral 
hormonal secretion with higher emotional disturbances in female gender 
(Fischette et al., 1983). Likewise, lower 5-HT synthesis rates have been 
observed after ATD in female as compared with male human subjects 
(Nishizawa et al., 1997). In general, these specific effects of ATD upon 5-HT 
receptor types might provide an explanation for the lack of ATD-induced 
mood-lowering effects in healthy subjects without genetic predisposition to 
5-HT dysfunction, and for the fact that these effects in remitted depressed 
patients depend upon the type of antidepressant treatment.  
 Since corticosteroid modulation of 5-HT function plays a central role in 
mood disorders, and cognitive functioning is highly impaired in clinical 
depression, the ATD findings reported in the present thesis might have 
important implications regarding the mechanisms of adaptation to stress, and 
the implication of the 5-HT system in cognitive processing. As the 5-HT 
system is primarily modulatory, it is not surprising that in the clinical situation, 
most 5-HT-based treatments result in only a partial symptomatic improvement. 
The present findings support new insights for alternative treatment strategies 
along other pathways that interact highly with the 5-HT system. Up-regulation 
of the cAMP and BDNF systems has already resulted in a novel model for the 
mechanism of action of antidepressants and new targets for the development of 
therapeutic targets (Duman, 1998) 
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In Conclusion 
Depression is characterized by sustained sadness along with psychological, 
behavioural and physical symptoms. On average, about 800.000 people commit 
suicide every year, of which more than half are aged between 15 and 44 years 
old. It is ranked as the seventh most important cause of disease burden in low- 
and middle-income countries, as it tends to be disabling, recurring or long-
lasting, and often remains untreated. The ATD method seems important in the 
investigation of 5-HT-related vulnerability factors implicated in the onset of 
depression and previously the monoamine systems were considered to be 
primarily responsible for the onset of depressive disorders. However, the lack 
of mood-lowering effects after ATD in healthy subjects does not support a 
direct causal relationship between acute decreased 5-HT metabolism and major 
depressive disorder. Moreover, the findings of the present thesis support the 
notion that ATD possibly exerts its neurochemical and behavioural effects 
through other mechanisms that might go beyond a straightforward decrease in 
5-HT metabolism. These mechanisms should be taken into account for an 
adequate interpretation of data resulting from application of the method in 
both clinical and preclinical settings. Abnormal physiological conditions, 
including ATD-application related confounding stressors possibly interfere 
with the high number of cellular processes that are involved in 5-HT synthesis 
and metabolism, and might trigger other neurophysiological systems that 
generally interact with the 5-HT system. This possibly also reflects the 
heterogeneity of major depressive disorder in general, as all these 
neurophysiological processes might eventually be altered in clinical conditions 
and thus potentially be treated along different pharmacological pathways. In 
general, the findings of this thesis support the fact that depression may not be 
caused solely by an abnormality of 5-HT function, but more likely by a 
dysfunction of other systems or brain regions modulated by 5-HT or 
interacting with its dietary precursor. Likewise, the acute tryptophan depletion 
method does not seem to challenge the 5-HT system per se, but rather triggers 
5-HT-mediated adverse events. A degree of caution should therefore be 
maintained in extrapolating the results of ATD studies to clinical depression. 
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Summary 
The method of acute tryptophan depletion (ATD) currently represents the 
most extensively applied challenge test to investigate the involvement of the 
serotonin (5-hydroxytryptamine; 5-HT) system and 5-HT-related vulnerability 
factors in the pathogenesis and pathophysiology of depression. ATD consists 
of manipulating the availability of the essential amino acid tryptophan (TRP), 
the dietary 5-HT precursor through administration of a TRP-free diet. 
However, the exact mechanism by which ATD exerts its neurophysiological 
effects, and to what extent changes in 5-HT neuronal activity contribute to 
ATD-induced neurochemical and behavioural alterations, is not fully clear. This 
impedes an adequate interpretation of the results arising from application of the 
method in both human and animal studies. The present thesis aimed to explore 
potential alternative mechanisms by which ATD exerts its neurophysiological 
and behavioural effects by administering rodents a gelatin-based protein-
carbohydrate nutritional mixture. 
Chapter 1 introduces the biochemical rationale behind the method of ATD by 
describing the specific features involved in the biosynthesis of the essential 
amino acid TRP from food into the modulating 5-HT neurotransmitter in the 
brain. Functions and characteristics of the 5-HT system are outlined in general 
and with respect to its implication in major depressive disorder. An overview is 
given of the utility of the ATD method in depression research with human 
subjects and preclinical data arisen from applying the method in rats are 
thoroughly reviewed. The basic mechanism behind the induction of peripheral 
TRP depletion by administrating a TRP-free diet is described and the validity of 
parameters used for interpreting the biochemical effects of ATD in the brain is 
critically assessed. Thereafter, the aims of the thesis to explore potential 
alternative mechanisms underlying the ATD method and its potential to induce 
affective and cognitive behavioural changes are introduced. 
Chapter 2 provides an overview of multiple studies in which the 
pharmacokinetic and behavioural effects of different dosing regimes of the 
TRP-free protein-carbohydrate mixture were explored in the Swiss and 
particularly C57BL/6 mice. As pre-existing dysfunctional 5-HT systems are 
nowadays widely modelled in mice, the use of mice in stead of rats for studying 
behaviour in general and the implication of neurotransmitter systems in 
psychiatric disorders in particular has significantly increased. It was, therefore, 
initially aimed to establish the ATD method in the mouse for subsequent 
potential application as 5-HT challenge tool in genetic mice models of 
depression. Peripheral amino acids were measured and central TRP and 5-HT 
concentrations were compared with anxiety and depression-like behaviour in 
the elevated zero-maze (EZM), forced swimming test (FST) and tail suspension 
test (TST). The extent of peripheral TRP depletion highly depended upon the 
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specificity of the dosing volume and the time-frame of the multiple oral 
administrations. While ATD resulted in a 74% reduction of the plasma ratio 
TRP to the sum of other large neutral amino acids (TRP/ΣLNAA) in Swiss 
mice 1h after administration (2x10 ml/kg, 30 min interval), there was only a 
40% reduction in C57BL/6 mice. The latter did not show anxiety in the EZM 
or increased immobility in the FST or TST. A higher dose (2x20 ml/kg) with a 
longer interval (60 min) reduced the ratio with 68% in C57BL/6 mice, lowered 
hippocampal 5-HT turnover, but had no functional effects when tested in the 
EZM and FST. Extreme differences in ATD effects were observed between 
strains and none of the profound peripheral TRP depletions paralleled central 
TRP or 5-HT changes. Yet, interfering ATD application-related stress effects 
were found to confound the ATD-induced effects upon the ratio 
TRP/ΣLNAA in plasma. These findings have important implications for the 
use of ATD in general and in particular for its application in mice. It has been 
postulated that mice with pre-existing 5-HT dysfunction might be more 
vulnerable to ATD, which remains to be elucidated.  
 
Chapter 3 describes the effects of ATD upon local cerebral blood flow (CBF) 
and cerebral metabolic rate of glucose (CMRG) as measured in 43 distinct brain 
regions of adult male Wistar rats by means of [14C]-iodoantipyrine and [14C]-2-
deoxyglucose quantitative autoradiographic imaging, respectively. To gain more 
inside into the potential mechanisms underlying the ATD-induced 
neurochemical and behavioural effects in general, explorative experiments were 
continued in the established rat model of ATD. As the 5-HT neurotransmitter 
possesses important vasoactive properties, an acute decrease in central 5-HT 
concentration could alter CMRG and CBF and the normal relationship 
between them. Such cerebrovascular alterations might contribute to the 
underlying mechanisms of ATD-induced affective behavioural changes and 
cognitive impairments. Whereas the ratio TRP/ΣLNAA decreased with 40%, 
no ATD-induced measurable effects upon TRP and 5-HT levels in the brain 
could be revealed. Nevertheless, ATD significantly reduced local CBF in 11 of 
the 43 brain ROIs measured, while local CMRG remained unchanged. 
Moreover, a downwards resetting of the relationship CBF to CMRG was found 
after ATD compared to the TRP+ control group, indicating a state of relative 
cerebrovascular oligaemia. The ATD-induced decrease in peripheral TRP 
levels, thus, resulted in a decrease of local CBF and an uncoupling of flow from 
metabolism without affecting central TRP or 5-HT levels. Therefore, a more 
additive role for a dysfunctional 5-HT system as an underlying mechanism of 
the ATD method might be implied.  
 
Chapter 4 reveals the cerebrovascular effects of ATD in an animal model of 
acquired 5-HT dysfunction induced by repeated 3,4-methylenedioxymetham-
phetamine (MDMA; ‘ecstasy’) administrations. The neurotoxicity of MDMA is 
known to cause significant 5-HT terminal depletion and an acute decrease in 
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brain 5-HT after ATD is likely to result in disturbed affective behaviour only if 
there is pre-existing vulnerability of the 5-HT system. By using quantitative 
autoradiographic imaging the effects of MDMA pretreatment were measured 
upon local CBF and CMRG under an ATD challenged condition, thereby 
investigating the relationship between cerebrovascular function and 5-HT 
changes in general and MDMA-induced 5-HT dysfunction as a vulnerability 
factor for depression in general and cognitive dysfunction in particular. MDMA 
induced significant 5-HT neurotoxicity and decreased central TRP and 5-HT 
levels considerably. ATD resulted in a mean 40% reduction of the ratio 
TRP/ΣLNAA in plasma without affecting central TRP or 5-HT 
concentrations. A downwards resetting of the relationship of CBF to CMRG 
was only observed after ATD treatment in the drug-naïve control animals. This 
indicates that ATD induced a significant upwards resetting of this relationship 
after MDMA pretreatment compared to controls, thereby inducing a 
potentiation of the MDMA-induced cerebral vascular dysfunction. ATD, thus, 
produces a degree of cerebrovascular hyperperfusion in animals pretreated with 
MDMA which could indicate a predisposition to cerebrovascular accidents, in 
particular haemorrhagic stroke.  
 
Chapter 5 shows the effects of ATD upon peripheral and central 
concentrations of brain-derived neurotrophic factor (BDNF) in the rat while 
controlling for possible confounding stress effects of the specific experimental 
procedures. BDNF is strongly linked to the 5-HT system and, besides being 
extremely stress-responsive, plays an essential role in mood and memory 
processes and might thus contribute to the underlying mechanisms of ATD-
induced behavioural changes. A significant 56% depletion of the ratio 
TRP/ΣLNAA was found after ATD, however, 5-HT metabolism seemed only 
moderately affected in the hippocampus without measurable changes in central 
TRP or 5-HT concentrations. Although no direct effects of ATD upon serum 
or brain BDNF concentrations were found, a stress-mediated decrease in 
BDNF levels was observed in the prefrontal cortex. Moreover, brain TRP 
levels correlated positively with BDNF in both the prefrontal cortex and 
hippocampus. Thus, BDNF-mediated mechanisms due to ATD and/or its 
application stress might underlie ATD-induced neurochemical and behavioural 
alterations. 
 
Chapter 6 examines the ability of phosphodiesterase (PDE) inhibitors to 
reverse an ATD-induced impairment in rat object recognition performance. 
Whereas affective behavioural changes after ATD remain controversial, ATD-
induced memory deficits are consistently reported in humans, but also in rats as 
measured by means of the rat object recognition task. Inhibition of 
phosphodiesterase (PDE) enzymes appears to be a reliable method to improve 
memory processes by increasing the levels of the second messenger molecules 
cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate 
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(cGMP) or both. Exploring the pro-cognitive effects of PDE inhibitors might 
provide more insight into potential interaction between second messenger 
molecules and the 5-HT system as underlying mechanism for ATD-induced 
cognitive dysfunction. ATD significantly decreased the ratio TRP/ΣLNAA in 
plasma and impaired object memory performance considerably. Both the 
PDE5 inhibitor, vardenafil, and the PDE2 inhibitor, BAY 60-7550, that 
increase cGMP and both cAMP and cGMP, respectively, were able to acutely 
improve short-term object recognition performance after an ATD-induced 
deficit.  
 
Chapter 7 summarizes the results of the studies described in this thesis and 
provides a critical discussion concerning potential alternative mechanisms 
underlying the neurochemical and behavioural effects of the method of ATD. 
It is generally concluded that the parameters used to calculate reductions in 
brain TRP availability and 5-HT metabolism may be somewhat inaccurate. 
Therefore, like depression itself, ATD-induced behavioural alterations are not 
easily attributed directly to changes in 5-HT neurotransmission. The findings of 
the present thesis support the contribution of alternative mechanisms such as 
decreased nitric oxide synthase activity and cerebrovascular abnormalities that 
might be implicated in the behavioural effects of ATD and could also explain 
5-HT-mediated clinical depressive symptoms. Moreover, experimental 
procedures related to the application of the ATD method seem highly stressful 
and potentially interfere with TRP metabolism, thereby confounding ATD 
neurochemical and behavioural results in rodents. As the ATD method seems 
important in the investigation of 5-HT-related vulnerability factors implicated 
in the onset of depression, the potential of alternative mechanisms and possible 
confounding factors should be taken into account for an adequate 
interpretation of data resulting from application of the method in both clinical 
and preclinical settings. In general, a degree of caution should be maintained in 
extrapolating the results of ATD studies to clinical depression. 
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Samenvatting 
De acute tryptofaan depletie (ATD) methode is momenteel de meest 
toegepaste challenge test in het onderzoek naar de betrokkenheid van serotonine 
(5-hydroxytryptamine, 5-HT) en 5-HT gerelateerde kwetsbaarheidsfactoren bij 
het ontstaan en het verloop van depressieve stoornissen. ATD is gebaseerd op 
de manipulatie van de beschikbaarheid van het essentiële aminozuur tryptofaan 
(TRP), de 5-HT precursor, door middel van het toedienen van een TRP-vrij dieet. 
Zowel het exacte onderliggende mechanisme van de neurofysiologische 
effecten van ATD als ook de mate waarin de veranderingen in de activiteit van 
5-HT neuronen verantwoordelijk zijn voor de ATD-geïnduceerde 
neurochemische en gedragsveranderingen zijn niet volledig bekend. Dit 
belemmert een adequate interpretatie van de resultaten die verkregen worden 
na toepassing van de methode in humane en dierexperimentele experimenten. 
De studies beschreven in dit proefschrift hadden tot doel potentiële alternatieve 
onderliggende mechanismen van de neurofysiologische en gedragseffecten van 
ATD in ratten en muizen nader te onderzoeken door middel van het toedienen 
van een specifiek voedingsmengsel van eiwitten en koolhydraten op basis van 
gelatine. 
Hoofdstuk 1 introduceert de biochemische principes die de basis vormen van 
de ATD methode door middel van een uiteenzetting van de specifieke 
elementen die kenmerkend zijn voor de biosynthese vanaf het essentiële 
aminozuur TRP in voedsel tot aan de modulerende 5-HT neurotransmitter in 
het brein. Zowel de algemene functies en eigenschappen van het 5-HT systeem 
als ook de specifieke veranderingen die een belangrijke rol spelen en nauw 
betrokken zijn bij de ontwikkeling van depressieve stoornissen worden 
uiteengezet. Er wordt een overzicht gegeven van de bruikbaarheid van de 
methode in depressieonderzoek met proefpersonen en preklinische resultaten 
die tot stand zijn gekomen na toepassing van de methode in ratten worden 
grondig besproken. Het basismechanisme dat ten grondslag ligt aan de inductie 
van perifere TRP depletie door middel van het toedienen van een TRP-vrij 
dieet wordt beschreven en de validiteit van de parameters die gebruikt worden 
voor de interpretatie van de biochemische effecten van ATD in het brein 
worden kritisch geëvalueerd. Vervolgens worden de doelstellingen van het 
proefschrift geïntroduceerd, namelijk het nader onderzoeken van potentiële 
alternatieve onderliggende mechanismen van de ATD methode en de capaciteit 
van de methode om affectieve en cognitieve veranderingen teweeg te brengen. 
Hoofdstuk 2 geeft een overzicht van de meervoudige studies waarbij de 
farmacokinetische en gedragseffecten van diverse doseringsprotocollen van het 
TRP-vrije eiwit-koolhydraatmengsel onderzocht werden in muizen van het 
Swiss type en voornamelijk in C57BL/6 muizen. Gezien het feit dat latent 
aanwezige disfunctionele 5-HT systemen vandaag de dag extensief 
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gemoduleerd worden in muizen, is het gebruik van muizen in plaats van ratten 
voor het bestuderen van gedrag in het algemeen en in het bijzonder de 
betrokkenheid van neurotransmittersystemen in psychiatrische stoornissen 
significant toegenomen. De initiële doelstelling was het opzetten van de ATD 
methode in de muis voor verdere potentiële toepassing als 5-HT challenge model 
in genetische muismodellen voor depressie. Perifere aminozuren werden 
gemeten en centrale TRP en 5-HT concentraties werden vergeleken met angst- 
en depressie-gerelateerde gedrag in de elevated zero-maze (EZM), forced swim test 
(FST) en tail suspension test (TST). De mate van perifere TRP depletie was uiterst 
afhankelijk van de specificiteit van het doseringsvolume en het tijdsbestek van 
de meervoudige orale toedieningen. Terwijl ATD in Swiss muizen resulteerde 
in een afname van 74% van de ratio van TRP tot de som van andere grote 
aminozuren (TRP/ΣLNAA) in plasma 1 uur na toediening (2x10 ml/kg, 30 
min interval), was in C57BL/6 muizen slechts een afname van 40%. Deze 
muizen toonden ook geen angstgerelateerde gedrag in de EZM of een toename 
van immobiliteit in de FST of TST. Een hogere dosering (2x20 ml/kg) met een 
langer interval (60 min) deed de ratio afnemen met 68% in C57BL/6 muizen en 
verlaagde de 5-HT turnover in de hippocampus, maar had geen functionele 
effecten indien getest in de EZM en FST. Extreme verschillen in ATD effecten 
werden geobserveerd tussen de verschillende muizenstammen en geen enkele 
van de diepgaande perifere TRP depleties kwam overeen met centrale TRP of 
5-HT veranderingen. Echter, interfererende stresseffecten gerelateerd aan de 
toepassing van de ATD methode leken de ATD-geïnduceerde effecten op de 
ratio TRP/ΣLNAA in plasma te beïnvloeden. Deze bevindingen hebben 
belangrijke gevolgen voor het gebruik van ATD in het algemeen en in het 
bijzonder voor de toepasbaarheid in muizen. Het wordt verondersteld dat 
muizen met latent aanwezige 5-HT disfunctie mogelijk in hogere mate 
kwetsbaar zijn voor de effecten van ATD, hetgeen nader onderzocht zal 
moeten worden. 
 
Hoofdstuk 3 beschrijft de effecten van ATD op de locale cerebrale 
doorbloeding (cerebral blood flow; CBF) en de mate van cerebraal glucose 
metabolisme (cerebral metabolic rate of glucose; CMRG). Deze werden gemeten in 43 
verschillende hersenstructuren van volwassen mannelijke Wistar ratten aan de 
hand van [14C]-iodoantipyrine en [14C]-2-deoxyglucose kwantitatieve 
autoradiografische imaging. Ter vergroting van het inzicht in de potentiële 
onderliggende mechanismen van ATD-geïnduceerde neurochemische en 
gedragseffecten in het algemeen werden oriënterende experimenten voortgezet 
in het ratmodel van ATD. Gezien het feit dat de 5-HT neurotransmitter 
belangrijke vasoactieve eigenschappen bezit zou een acute afname in centrale 5-
HT concentraties veranderingen teweeg kunnen brengen in de CMRG en CBF 
en hun gewoonlijke onderlinge relatie. Dergelijke cerebrovasculaire 
veranderingen zouden een bijdrage kunnen leveren aan de onderliggende 
mechanismen van ATD-geïnduceerde veranderingen in affectief gedrag en 
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cognitieve beperkingen. Hoewel de ratio TRP/ΣLNAA afnam met 40% 
werden er geen meetbare effecten gevonden van ATD op TRP en 5-HT 
concentraties in het brein. Desondanks reduceerde ATD de locale CBF 
aanzienlijk in 11 van de 43 onderzochte hersenstructuren, terwijl de locale 
CMRG onveranderd bleef. Bovendien werd een neerwaartse resetting van het 
verband tussen CBF en CMRG geobserveerd na ATD vergeleken met de 
TRP+ controlegroep, wijzend op een mate van cerebrovasculaire oligemie. De 
ATD-geïnduceerde afname in perifere TRP concentraties resulteerde dus in een 
verlaagde locale CBF en in een afwijking in het normale verband tussen de 
mate van doorbloeding al naar gelang de mate van metabolisme zonder 
veranderingen in centrale TRP en 5-HT concentraties. Derhalve wordt 
verondersteld dat een disfunctioneel 5-HT systeem eerder slechts een bijrol 
speelt in de onderliggende mechanismen van ATD. 
 
Hoofdstuk 4 onthult de cerebrovasculaire effecten van ATD in een diermodel 
van verworven 5-HT disfunctie geïnduceerd door middel van herhaalde 
toedieningen met 3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’). 
Het is bekend dat de neurotoxiciteit van MDMA significante schade toebrengt 
aan 5-HT neuronen en een acute afname van 5-HT in het brein na ATD 
veroorzaakt mogelijk slechts affectieve gedragsveranderingen als er sprake is 
van een latent aanwezige kwetsbaarheid van het 5-HT systeem. Door middel 
van kwantitatieve autoradiografie imaging werd het effect gemeten van de 
herhaalde voorbehandeling met MDMA samen met een ATD challenge op de 
locale CBF en CMRG. Hierbij werd niet alleen de relatie tussen 
cerebrovasculaire functie en 5-HT veranderingen onderzocht, maar ook de 
MDMA-geïnduceerde 5-HT disfunctie als kwetsbaarheidfactor voor depressie 
in het algemeen en voor cognitive disfunctie in het bijzonder. MDMA 
induceerde significante 5-HT neurotoxiciteit en verlaagde centrale TRP en 5-
HT concentraties aanzienlijk. ATD resulteerde gemiddeld in een afname van 
40% van de ratio TRP/ΣLNAA in plasma zonder de centrale TRP en 5-HT 
concentraties te veranderen. Een neerwaartse resetting van het verband tussen de 
mate van doorbloeding al naar gelang de mate van metabolisme werd alleen 
geobserveerd in de controlegroep die niet aan de drug blootgesteld was. Dit 
geeft aan dat ATD een significante opwaartse resetting van de relatie tussen CBF 
en CMRG veroorzaakt na voorbehandeling met MDMA vergeleken met de 
controlegroep waarbij het de MDMA-geïnduceerde cerebrovasculaire disfunctie 
lijkt te versterken. ATD produceert dus een zekere mate van cerebrovasculaire 
hyperperfusie in dieren die voorbehandeld zijn met MDMA. Dit zou mogelijk 
een kwetsbaarheidsfactor kunnen vormen voor een cerebrovasculair accident 
met in het bijzonder de kans op een hersenbloeding. 
 
Hoofdstuk 5 toont de effecten van ATD op perifere en centrale concentraties 
van brain-derived neurotrophic factor (BDNF) in de rat rekening houdend met 
mogelijke stresseffecten van de specifieke experimentele procedures die de 
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resultaten zouden kunnen beïnvloeden. De productie van BDNF hangt sterk 
samen met het 5-HT systeem en is niet alleen in extreme mate gevoelig voor 
stress, maar speelt ook een belangrijke rol in affectieve en geheugenprocessen 
en zou dus betrokken kunnen zijn bij het onderliggende mechanisme van ATD-
geïnduceerde gedragsveranderingen. Een significante afname van 56% van de 
ratio TRP/ΣLNAA in plasma werd geobserveerd, echter, 5-HT metabolisme 
leek slechts minimaal aangetast te zijn in de hippocampus zonder meetbare 
veranderingen in centrale TRP of 5-HT concentraties. Hoewel geen directe 
effecten van ATD werden gevonden op de BDNF concentraties in serum of 
het brein werd een door stress veroorzaakte afname gevonden in BDNF 
concentraties in de prefrontale cortex. Bovendien correleerden centrale TRP 
concentraties positief met BDNF zowel in de prefrontale cortex als in de 
hippocampus. Veranderingen in BDNF concentraties als gevolg van ATD 
en/of de stress die gerelateerd is aan de toepassing ervan zou derhalve 
betrokken kunnen zijn bij het onderliggende mechanisme van ATD-
geïnduceerde neurochemische en gedragsveranderingen. 
 
Hoofdstuk 6 onderzoekt in hoeverre phosphodiesterase (PDE) remmers in 
staat zijn om een ATD-geïnduceerde verslechtering van de rat object 
herkenningsprestatie op te heffen. Hoewel affectieve gedragsveranderingen na 
ATD controversieel blijken worden ATD-geïnduceerde geheugendeficiënties 
consistent gerapporteerd in mensen, maar ook in ratten zoals gemeten met de 
rat object herkenningstest. Het remmen van PDE enzymen blijkt een 
betrouwbare methode voor het verbeteren van geheugenprocessen door middel 
van het verhogen van de concentraties van de second messenger moleculen cyclic 
adenosine monophosphate (cAMP) en cyclic guanosine monophosphate (cGMP) of 
beiden. Het nader onderzoeken van de pro-cognitieve effecten van PDE 
remmers kan meer inzicht geven in de potentiële interactie tussen second 
messenger moleculen en het 5-HT systeem als onderliggend mechanisme voor 
ATD-geïnduceerde cognitieve disfunctie. ATD verlaagde de ratio 
TRP/ΣLNAA in plasma en veroorzaakte een aanzienlijke verslechtering van de 
object herkenningsprestatie. Zowel de PDE5 remmer, vardenafil, als ook de 
PDE2 remmer, BAY 60-7550, die respectievelijk cGMP en zowel cAMP als 
cGMP verhogen, waren in staat om de object herkenningsprestatie na een 
ATD-geïnduceerde verslechtering acuut te verbeteren.   
 
Hoofdstuk 7 geeft een samenvatting van de resultaten van de studies die 
beschreven worden in dit proefschrift en voorziet in een kritische discussie 
betreffende de potentiële alternatieve onderliggende mechanismen van de 
neurochemische en gedragseffecten van de ATD-methode. Over het algemeen 
wordt geconcludeerd dat de parameters die gebruikt worden om de afname van 
de beschikbaarheid van TRP in het brein en 5-HT metabolisme te berekenen 
niet uiterst nauwkeurig zijn. ATD-geïnduceerde gedragsveranderingen, als ook 
depressie zelf, zijn daarom niet gemakkelijk direct toe te schrijven aan 
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veranderingen in 5-HT neurotransmissie. De bevindingen van dit proefschrift 
wijzen op de bijdrage van alternatieve mechanismen zoals een afname in de 
activiteit van nitric oxide synthase of cerebrovasculaire afwijkingen die betrokken 
zouden kunnen zijn bij de gedragseffecten van ATD en tevens 5-HT-
gemedieerde klinische depressieve symptomen zouden kunnen verklaren. 
Bovendien lijken de experimentele procedures die gerelateerd zijn aan de 
toepassing van de ATD-methode aanzienlijk stressvol en interfereren mogelijk 
met TRP metabolisme, hetgeen de pure neurochemische en gedragseffecten 
van ATD in knaagdieren mogelijk in de war stuurt. Gezien het feit dat de ATD-
methode belangrijk is voor onderzoek naar 5-HT-gerelateerde 
kwetsbaarheidsfactoren die betrokken zijn bij het ontstaan van depressie zou er 
rekening gehouden moeten worden met de potentie van alternatieve 
mechanismen en mogelijke interfererende factoren voor een zorgvuldige 
interpretatie van data die voortkomt uit de toepassing van de methode in zowel 
humane als dierexperimentele studies. In het algemeen lijkt het raadzaam om 
voorzichtig om te gaan met het direct extrapoleren van de resultaten van ATD 
studies naar de klinische symptomen van depressieve stoornissen.  
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Resumen 
La técnica de la depleción aguda de triptófano (ATD por sus siglas en inglés) 
representa hoy en día la prueba de desafío más utilizada para investigar la 
implicación de la serotonina (5-HT), el sistema serotonérgico  así como factores 
de vulnerabilidad relacionados en la patogénesis y la fisiopatología de la 
depresión. La ATD consiste en  la manipulación del triptófano (TRP), un 
amino ácido esencial que es precursor de  la 5-HT, a través de una dieta especial 
carente del mismo. El mecanismo exacto detrás de los efectos 
neurofisiológicos, y el nivel en el que alteraciones en la actividad neuronal de 5-
HT contribuyen a modificaciones neuroquímicas y cambios en el 
comportamiento inducido por ATD no se conocen del todo. Los estudios 
descritos en la presente tesis tuvieron como objetivo explorar mecanismos 
alternativos mediante los cuales ATD ejerce sus efectos neurofisiológicos y de 
comportamiento.  
El capítulo 1 introduce la idea general del uso de la técnica de ATD. Describe 
las características específicas de la biosíntesis del TRP, desde la adquisición del 
mismo a través de la dieta hasta la síntesis de 5-HT, un neurotransmisor 
modulador en el cerebro. Explica las funciones y características generales del 
sistema serotonérgico, así como su implicación en la depresión mayor. Presenta 
un panorama general de la utilidad de la técnica de ATD en la investigación de 
la depresión en humanos y se revisan de manera profunda los datos derivados 
de la aplicación de la técnica. Muestra el mecanismo básico de la depleción del 
TRP periférico mediante la administración de una dieta carente del mismo y se 
evalúa críticamente la validez  de los parámetros que se suelen utilizar para la 
interpretación de los efectos bioquímicos de la depleción de TRP en  el cerebro. 
A continuación se introducen los objetivos de la tesis que consisten en la 
exploración de posibles mecanismos alternativos  subyacentes a la técnica de 
ATD y su potencial para inducir cambios de comportamiento tanto afectivos 
como cognitivos. 
El capítulo 2 presenta un resumen de los múltiples estudios, en los cuales se 
investigaron los efectos farmacocinéticos y conductuales de diferentes dosis del 
compuesto proteico  y de hidratos de carbono sin TRP, en ratones tipo Swiss y 
particularmente en ratones tipo C57BL/6. Hoy en día el sistema serotonergico 
disfuncional es modulado de manera extensa en ratones, por lo que  el uso de 
ratones en vez de ratas para estudiar el comportamiento en general y 
específicamente la implicación de sistemas de neurotransmisores en trastornos 
psiquiátricos, ha incrementado significativamente. El objetivo inicial se basaba 
en el ajuste de la técnica de ATD en el ratón con la posible aplicación de la 
técnica como prueba de desafió de la 5-HT en ratones transgénicos, modelos 
animales de depresión. Los amino ácidos fueron medidos periféricamente y los 
niveles centrales de TRP y de 5-HT fueron comparados con el grado de 
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conducta de ansiedad y depresiva en el laberinto elevado en cero (EZM),  la 
prueba de nado forzado (FST) y el test de suspensión en la cola (TST). El grado 
de depleción de TRP periférico dependía en gran medida de la especificidad del 
volumen de la dosis y del tiempo entre las múltiples administraciones. Mientras 
que en los ratones del tipo Swiss ATD provocó una reducción del 74% de la 
proporción de TRP comparado con la suma de los otros amino ácidos largos 
(TRP/ΣLNAA) una hora después a la administración (2x10 ml/kg; 30 minutos 
de intervalo), en los ratones del tipo C57BL/6 se efectuó una reducción de sólo 
un 40%. Estos últimos no mostraron ansiedad en el EZM o un incremento en 
la inmovilidad en el FST o TST. Una dosis más alta (2x20 ml/kg) con un 
intervalo más largo (60 minutos) redujo la proporción un 68% en los ratones 
del tipo C57BL/6 y disminuyó el recambio  de 5-HT en el hipocampo, pero no 
causo efectos conductuales en el EZM o FST. Se observaron grandes 
diferencias entre los distintos tipos de ratones y las profundas depleciones de 
TRP, las cuales en ningún momento correspondían con cambios en el TRP o 5-
HT cerebral. Sin embargo, se encontró que el estrés relacionado a la aplicación 
del ATD interfiere con los efectos inducidos por ATD respecto a la proporción 
TRP/ΣLNAA en el plasma. Estos resultados tienen una implicación importante 
para el uso de ATD en general y particularmente para su aplicación en ratones. 
Probablemente, ratones con una disfunción de 5-HT  pre-existente podrían ser 
más vulnerables al ATD. 
 
El capítulo 3 describe los efectos de la ATD sobre el flujo sanguíneo cerebral 
(CBF) y la tasa metabólica de glucosa cerebral (CMRG). Ambos parámetros 
fueron medidos en 43 áreas distintas del cerebro de ratas adultas del tipo 
Wistar. Para esto fue utilizada la técnica de imagenología auto radiográfica 
cuantitativa de [14C]-iodoantipirina y [14C]-2-desoxiglucosa, respectivamente. 
Para ampliar la comprensión de los posibles mecanismos responsables de los 
efectos neuroquímicos y conductuales de la ATD se continuó con los 
experimentos de exploración en el modelo establecido de ATD en la rata. El  
neurotransmisor 5-HT posee importantes características vasoactivas, un 
decremento agudo de los niveles de 5-HT podría alterar el CMRG y el CBF y la 
relación que existe entre ambos bajo condiciones fisiológicas normales. Este 
tipo de alteraciones cerebrovasculares podrían contribuir con los mecanismos 
responsables de los cambios conductuales de tipo afectivo y con el déficit 
cognitivo. Mientras que la proporción TRP/ΣLNAA disminuyo un 40%, no se 
pudo observar un efecto perceptible inducido por la ATD sobre los niveles de 
TRP y el de 5-HT en el cerebro. A pesar de ello, la ATD redujo el CBF local 
significativamente en 11 de las 43 áreas de interés, mientras que la CMRG se 
mantuvo similar. Además, se pudo observar que el ATD produjo que la 
relación entre el CBF y la CMRG fue  decreciente en comparación con el grupo 
control, TRP+, indicativo de un estado aparente de oligoemia cerebrovascular. 
Así, el decremento de los niveles periféricos de TRP inducido por la ATD 
resulto en una disminución del CBF local y un desacoplamiento del flujo y 
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metabolismo sin afectar los niveles cerebrales de TRP o 5-HT. Por eso se 
sugiere que un sistema disfuncional de la 5-HT podría ser un mecanismo 
complementario a la ATD. 
 
El capítulo 4 revela los efectos cerebrovasculares de la ATD en un modelo 
animal de disfunción serotonérgica adquirida, inducida por la administración 
repetitiva de 3, 4-metilenedioximetanfetamina (MDMA; ‘extasis’). Se sabe que la 
neurotoxicidad de la MDMA causa una disminución significativa de las 
terminales neuronales serotonergicas  y un decremento agudo de los niveles de 
5-HT. Después de la ATD probablemente exista un trastorno en el 
comportamiento afectivo solamente si se presenta de antemano una 
vulnerabilidad del sistema de 5-HT. Con el propósito de investigar la relación 
entre la función cerebrovascular, los cambios en el sistema serotonérgico y la 
disfunción del sistema 5-HT inducido por el MDMA como factor de 
vulnerabilidad para la depresión en general así como para la disfunción 
cognitiva en particular, se midió el efecto del pre-tratamiento con MDMA 
juntos con la ATD sobre el CBF y el CMRG local. La MDMA provoco una 
neurotoxicidad significativa del sistema 5-HT y disminuyo los niveles cerebrales 
de TRP y de 5-HT considerablemente. ATD resulto en una reducción de un 
40% de la proporción TRP/ΣLNAA plasmática sin afectar los niveles 
cerebrales de TRP o 5-HT. Se observó que solamente el tratamiento con ATD 
en los animales del grupo control (sin el tratamiento farmacológico) hizo que 
decreciera la relación entre CBF y CMRG. Esto indica que, en comparación 
con el grupo control, la ATD per se provoco que esta relación aumentara 
después del pre-tratamiento con MDMA potenciando así la disfunción 
cerebrovascular inducida por el MDMA. Así pues, la ATD produce un grado de 
hiperperfusión cerebrovascular en animales pre-tratados con MDMA lo cual 
podría indicar una predisposición a los accidentes cerebrovasculares, 
particularmente al derrame cerebral.  
 
El capítulo 5 muestra los efectos de la ATD sobre el factor neurotrófico 
derivado del cerebro (brain-derived neurotrophic factor; BDNF), controlando las 
posibles situaciones que en la rata provocan estrés y que posteriormente 
influyen en el análisis de los resultados obtenidos. El  BDNF esta fuertemente 
relacionado con el sistema de 5-HT y no sólo es muy sensible al estrés, si no 
que también tiene un papel esencial en la regulación del ánimo y el 
procesamiento de la memoria, por lo cual podría contribuir con el mecanismo 
que provoca las alteraciones conductuales inducidas por la ATD. Se encontró 
una disminución significativa de un 56% de la proporción TRP/ΣLNAA 
plasmática, no obstante, el metabolismo de 5-HT aparentemente sólo se afectó 
de manera moderada en el hipocampo. Aunque no se encontraron efectos 
directos sobre los niveles de BDNF en el suero o en el cerebro, se detectó un 
decremento en los niveles de BDNF en la corteza frontal producido por el 
estrés. Además, se pudo observar una correlación positiva entre los niveles 
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cerebrales de TRP y los de BDNF tanto en la corteza frontal como en el 
hipocampo. Las alteraciones en los niveles de BDNF causado por la ATD o el 
estrés relacionado con su aplicación podrían entonces ser los responsables de 
las alteraciones neuroquímicas y conductuales inducidas por la ATD.  
 
El capítulo 6 evalúa la capacidad de los inhibidores de la fosfodiesterasa 
(phosphodiesterase; PDE) para revertir el déficit en la ejecución de la tarea de  
reconocimiento de objetos inducido por la ATD. Aunque las alteraciones del 
comportamiento afectivo inducidas por la ATD permanecen controvertibles, el 
déficit de la memoria inducida por la ATD se observa consistentemente tanto 
en humanos como en ratas cuando se mide mediante el test de reconocimiento 
de objetos. La inhibición de las fosfodiasterasas es un método confiable para 
mejorar los procesos de memoria mediante un incremento de los niveles de los 
segundos mensajeros: adenosínmonofosfato cíclico (AMPc) y guanosín 
monofosfato cíclico (CMPc) o ambos. El análisis de los efectos pro-cognitivos 
de inhibidores de PDE podría mejorar la comprensión de la posible interacción 
entre moléculas del tipo segundo mensajero y el sistema 5-HT como 
mecanismo de la disfunción cognitiva inducida por la ATD. La ATD resultó en 
un decremento significativo de la proporción plasmática de TRP/ΣLNAA  y 
afectó la tarea de reconocimiento de objetos considerablemente. Tanto el 
inhibidor de PDE5, vardenafil, y el inhibidor de PDE2, BAY 60-7550, que 
incrementan GMPc y CMPc-AMPc respectivamente tuvieron la capacidad de 
mejorar la ejecución de la memoria a corto plazo después de un déficit inducido 
por la ATD. 
 
El capítulo 7 resume los resultados de los estudios descritos en esta tesis y 
ofrece una discusión crítica con respecto a posibles mecanismos alternativos de 
los efectos neuroquímicos y conductuales de la técnica de la ATD. En general 
se puede concluir que los parámetros utilizados para calcular la disminución de 
la disponibilidad de TRP y el decremento en el metabolismo de 5-HT son poco 
precisos. Por todo esto resulta difícil asociar la depresión, así como las 
alteraciones conductuales inducidas por la ATD directamente con cambios en 
la neurotransmisión de 5-HT. Los resultados de esta tesis apoyan la 
contribución de mecanismos alternativos tales como el decremento en la 
actividad de la enzima oxido nítrico sintasa y las anormalidades 
cerebrovasculares con los efectos conductuales observados  después de la ATD 
y podrían explicar también la sintomatología clínica de depresión mediada por 
5-HT. Los procedimientos relacionados con la aplicación de la técnica de ATD 
resultan muy estresantes  per se y podrían interferir con el metabolismo de TRP 
confundiendo así los resultados neuroquímicos y comportamentales de la ATD 
en roedores. La técnica de ATD parece ser importante para la investigación  de 
los factores de vulnerabilidad relacionados al sistema de la 5-HT implicados con 
el establecimiento de la depresión. Se debe  tener en cuenta la importancia de 
los mecanismos alternativos y los posibles factores de confusión para una 
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interpretación adecuada de los datos obtenidos con la aplicación de la técnica 
en un marco tanto clínico como preclínico. En general, debe tener cierto 
cuidado con la extrapolarización de resultados obtenidos utilizando la técnica 
de ATD a la depresión clínica.   
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